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Abstract 
 
Background: HDLs are heterogeneous particles, and apoA-I is the major 
apolipoprotein in human HDL. CVD is a multifactorial condition, and a various lipids 
and lipoproteins in the plasma are involved in the development of CVD. It has been 
suggested that HDLs have an inverse association with the risk of CVD. A high sugar 
intake (especially fructose and sucrose) was found to associate with a low HDL-C 
level and increased risk of CVD. However, the effect of dietary sugar on HDL kinetics 
is unclear. An insight of HDL subclass kinetics may provide a better understanding of 
the whole dynamic of HDL metabolism. 
 
Methods: Two studies were undertaken: 1) A controlled, randomized crossover 
dietary intervention study was carried out in 6 overweight middle-aged men. Subjects 
underwent two 12-week dietary interventions with high and low non-milk extrinsic 
sugar diets. Total HDL kinetics was measured using a primed constant intravenous 
infusion of [1-13C] leucine for 10 hours. 2) A HDL subclass kinetic study was carried 
out in 6 healthy subjects (3 males and 3 females). An intravenous bolus injection of 
[1-13C] leucine was applied to measure HDL subclass kinetics. Blood samples were 
taken during a 10-hour study and the following 2 weeks. Total HDL, HDL2 and HDL3 
were separated from the plasma by ultracentrifugation, and αHDL and preβHDL were 
isolated by agarose gel electrophoresis. ApoA-I in HDL fractions was separated by 
SDS-PAGE. After purification, hydrolysis and derivatization, the isotopic enrichment 
of apoA-I in HDL was measured by GC-MS and apoA-I fractional catabolic rate 
(FCR) and production rate (PR) was calculated for each subclass and total HDL. 
 
Results: In the dietary intervention study, the FCR of total HDL apoA-I on the high 
and low sugar diet (0.20 ± 0.02 and 0.18 ± 0.02 pools/day) was similar, as was the 
PR (7.33 ± 0.66 and 6.05 ± 0.72 mg/kg/day respectively). In the HDL subclass study, 
the concentration of αHDL apoA-I (0.97 ± 0.05 g/L) was significantly higher than that 
of preβHDL apoA-I (0.15 ± 0.03 g/L) (p<0.001). The FCR of αHDL and preβHDL 
apoA-I was 0.10 ± 0.02 and 0.13 ± 0.04 pools/day, and the PR of αHDL and 
preβHDL apoA-I was 3.94 ± 0.73 and 0.67 ± 0.12 mg/kg/day respectively. The 
concentration of HDL3 apoA-I (0.68 ± 0.04 g/L) was significantly higher than that of 
HDL2 apoA-I (0.23 ± 0.06 g/L) (p=0.002). The FCR of HDL2 and HDL3 apoA-I was 
0.15 ± 0.02 pools/day for both, and PR of HDL2 and HDL3 apoA-I was 1.35 ± 0.35 
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and 3.81 ± 0.51 mg/kg/day respectively. A significant difference was observed 
between αHDL and preβHDL apoA-I PR (p=0.010), and between HDL2 and HDL3 
apoA-I PR (p=0.030) in the whole group. The concentration of HDL2 apoA-I was 
higher in women (0.32 ± 0.08 g/L) than men (0.13 ± 0.02 g/L) though the difference 
was not significant. HDL2 apoA-I PR was significantly higher in women than men 
(p=0.017).  
 
Conclusion: The high and low sugar diet did not affect HDL metabolism in 
overweight men. The higher apoA-I concentration of αHDL and HDL3 might be due to 
the higher apoA-I PR of αHDL and HDL3 compared to preβHDL and HDL2 
respectively in healthy subjects. The higher level of HDL2 apoA-I in female than male 
subjects might be due to the higher PR of HDL2 apoA-I in women. 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 3 
Declaration 
 
This thesis and the work to which it refers are the results of my own efforts. Any 
ideas, data, images or text resulting from the work of others (whether published or 
unpublished) are fully identified as such within the work and attributed to their 
originator in the text, bibliography or in footnotes. This thesis has not been submitted 
in whole or in part for any other academic degree or professional qualification. I 
agree that the University of Surrey has the right to submit my work to the plagiarism 
detection service TurnitinUK for originality checks. Whether or not drafts have been 
so-assessed, the University reserves the right to require an electronic version of the 
final document (as submitted) for assessment as above. The thesis is available for 
library use on the understanding that it is copyright material and that no quotation 
from the thesis may be published without proper acknowledgement or consent. 
 
Some data present in this thesis Chapter 3, including subject characteristics, lipid 
and lipoprotein profile, insulin and glucose, dietary intakes and lipases, were 
measured by Dr. Aryaty Ahmed and Dr. Najlaa Alsini. 
 
 
 
 
 
        Signed:                                                                        Data: 
 
 
 
 
 4 
Acknowledgement 
 
This journey of PhD is a precious experience for me. I wish to take this opportunity to 
express my sincere gratitude to all those who contribute to this work and helped me 
to complete this thesis.  
 
First of all, I would like to thank my principle supervisor Professor Margot Umpleby 
who gave me this opportunity to study in the University of Surrey. I am heartily 
thankful for her invaluable guidance, continuous encouragement and support 
throughout the present research project. I really appreciate for her constructive 
advice, patient explanation and thoughtful consideration during the process of the 
research. She kindly spent her time on reading my thesis, and her comments were 
very helpful. Without her great help I would not have finished this study. 
 
I want to extend my sincere thankfulness to my co-supervisor Dr, Fariba Shojaee-
Moradie for her excellent supervision and generous support in both the clinical study 
and the laboratory work. Thanks you for coming in the early morning and being there 
to help me during the long study day. I am really grateful for her numerous 
contributions, kindness and patience. 
 
I would also like to express my sincere appreciation to Dr. Nicola Jackson for her 
great support in techniques and facilities in the laboratory. I am grateful to Mrs Jo 
Batt who has been kindly helped me in the laboratory and generously shared her 
experience with me. I am also very grateful for the help provided by Dr. Xuefei Li who 
gave me the patient guidance and valuable advice in the laboratory techniques. 
 
I am greatly appreciate the support provided by Dr. John Wright, Dr. Roselle Herring 
and other staffs in the Cedar Centre, Royal Surrey County Hospital who helped me to 
finish all the clinical experiments. I really appreciate for the tremendous contributions 
from Professor Bruce Griffin and Ms. Cheryl Isherwood in the dietary intervention 
study. I would also like to express my sincere appreciation to all the volunteers. 
 
Special thanks to all my friends: Dr. Shaoying Lou, Dr. Najlaa Alsini, Dr. Aryaty 
Ahmed, Mr Andrea Marino. Thank you for giving me so many cheerful and beautiful 
memories throughout this journey. I greatly appreciate for your endless help, support 
and encouragement. 
 5 
I would like to express my heartfelt gratitude to Hejiang Wang and Ciping Zheng of 
being the best parents I could ever wish. Thank you for always being there for me 
with love, care and support. I am very pleased to have this opportunity to express my 
deepest love to them. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
Contents  
Abstract ................................................................................................................... 1 
Declaration .............................................................................................................. 3 
Acknowledgement................................................................................................... 4 
List of Figures ......................................................................................................... 9 
List of Tables ......................................................................................................... 12 
Abbreviations ........................................................................................................ 14 
Chapter 1: Introduction ......................................................................................... 17 
1.1 Lipids and lipoproteins in the human body ............................................... 17 
1.1.1 Lipids................................................................................................................................ 17 
1.1.2 Lipoproteins ................................................................................................................... 17 
1.2 High- density lipoprotein ............................................................................ 23 
1.2.1 HDL structure and composition ............................................................................... 23 
1.2.2 HDL subclasses ........................................................................................................... 24 
1.2.3 HDL apolipoproteins ................................................................................................... 26 
1.2.4 HDL metabolism: Formation of HDL and Reverse Cholesterol Transport . 29 
1.3 Cardiovascular disease ............................................................................... 36 
1.3.1 Definition and prevalence .......................................................................................... 36 
1.3.2 Cardio-metabolic risks ................................................................................................ 37 
1.3.3 Relationship between cardiovascular disease and HDL ................................. 44 
1.3.4 Relationship between cardiovascular disease and diet ................................... 50 
1.4 Application of isotope techniques in lipoprotein metabolic studies ....... 57 
1.4.1 Isotopes techniques .................................................................................................... 57 
1.4.2 Detection of isotope enrichment by GC-MS ........................................................ 60 
1.5 Aims ............................................................................................................. 62 
1.6 Hypothesis ................................................................................................... 62 
Chapter 2: Methodology ....................................................................................... 63 
2.1 Clinical protocol .......................................................................................... 63 
2.1.1 The effect of a low and high extrinsic sugar diet on HDL kinetics ................ 63 
2.1.2 Development of the study design for HDL subclass kinetic study (Pilot    
study) ............................................................................................................................. 67 
2.1.3 HDL subclass kinetics study ..................................................................................... 68 
2.2 Analytical methodology .............................................................................. 71 
2.2.1 Materials ......................................................................................................................... 71 
2.2.2 Summary of laboratory processes to measure leucine enrichment in total 
HDL, and HDL2 and HDL3 apoA-I ......................................................................... 72 
2.2.3 Two-Dimensional Electrophoresis .......................................................................... 77 
2.2.4 Separation of apoA-I by SDS-PAGE ..................................................................... 81 
 7 
2.2.5 Hydrolysis of apoA-I .................................................................................................... 83 
2.2.6 Ion exchange chromatography ................................................................................ 83 
2.2.7 Derivatization ................................................................................................................ 84 
2.2.8 Determination of leucine isotope enrichment by GC-MS ................................ 85 
2.2.9 Determination of α-KIC isotope enrichment ........................................................ 87 
2.2.10 Measurement of triglyceride, cholesterol and HDL concentration ............. 89 
2.2.11 Measurement of glucose and insulin concentration, and HOMA ............... 90 
2.2.12 Determination of the lipase activity in plasma .................................................. 91 
2.2.13 Measurement of apoA-I concentration in plasma and HDL2 and HDL3 
fractions ......................................................................................................................... 91 
2.2.14 Measurement of αHDL and preβ HDL apoA-I concentration: Western 
blotting ........................................................................................................................... 91 
2.2.15 Data analysis .............................................................................................................. 93 
Chapter 3: The effect of a high and low non-milk extrinsic sugar diet on HDL 
kinetics ................................................................................................................... 98 
3.1 Introduction ................................................................................................. 98 
3.2 Results ......................................................................................................... 99 
3.2.1 Subjects characteristics and lipid profile............................................................... 99 
3.2.2 Energy and macronutrient intakes of the high and low sugar diet ............ 100 
3.2.3 The effect of the high and low sugar diets on body weight, body fat, plasma 
lipids and lipoproteins ............................................................................................ 102 
3.2.4 The effect of the high and low sugar diets on blood glucose, insulin and 
insulin resistance ..................................................................................................... 106 
3.2.5 The effect of the high and low sugar diets on lipases ................................... 106 
3.2.6 Isotopic enrichment, PR and FCR of total HDL apoA-I on the high and low 
sugar diets ................................................................................................................. 108 
3.3 Discussion ................................................................................................. 111 
3.3.1 Effects of high and low sugar diet on HDL-C and HDL kinetics ................. 111 
3.3.2 Effects of high and low sugar diet on body weight and body fat ................ 117 
3.3.3 Effects of high and low sugar diet on plasma lipids, glucose and insulin 119 
3.4 Comparison of subset results with those from whole cohort ................ 122 
3.5 Limitations and further work .................................................................... 122 
Chapter 4: Investigation of HDL subclass kinetics using a stable isotope 
technique ............................................................................................................. 124 
4.1 Introduction ............................................................................................... 124 
4.2 Method summary ....................................................................................... 124 
4.3 Results ....................................................................................................... 126 
4.3.1 Optimising the laboratory method – SDS-PAGE ............................................ 126 
4.3.2 Pilot study – Development of the blood sampling protocol .......................... 127 
 8 
4.3.3 HDL subclass kinetic study .................................................................................... 130 
4.4 Discussion ................................................................................................. 146 
4.4.1 The metabolism of αHDL and preβHDL in healthy subjects ....................... 146 
4.4.2 The metabolism of HDL2 and HDL3 in healthy subjects ............................... 152 
Chapter 5: General discussion ........................................................................... 157 
References: ......................................................................................................... 162 
Appdendices………………………………................................................................178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 9 
List of Figures  
Figure 1: Exogenous and Endogenous pathways of lipoprotein metabolism ........... 20 
Figure 2: The structure of spherical HDL ................................................................. 23 
Figure 3: Heterogeneity of human HDL ................................................................... 24 
Figure 4: The process of HDL maturation ................................................................ 30 
Figure 5: The process of HDL remodelling .............................................................. 31 
Figure 6: Factors contributing to global cardiovascular risk. .................................... 38 
Figure 7: Biological activities of normal functional HDL ........................................... 47 
Figure 8: Principles of gas chromatography-mass spectrometry ............................. 60 
Figure 9: Study design of low and high sugar diet intervention study ....................... 66 
Figure 10: Clinical study protocol and sampling time points ..................................... 70 
Figure 11: Laboratory processes to separate and measure leucine enrichment in total 
HDL, HDL2 and HDL3 apoA-I ................................................................... 72 
Figure 12: Laboratory processes to separate and measure leucine enrichment in      
αHDL and preβHDL apoA-I ..................................................................... 77 
Figure 13 A: Separation of αHDL and preβHDL by agarose gel electrophoresis with 
albumin as a standard ............................................................................. 78 
Figure 13 B:Separation of αHDL and preβHDL by agarose gel electrophoresis with 
apoA-I (from human plasma) as a standard .......................................... 79 
Figure 14: Separation of total HDL apoA-I on SDS-PAGE ....................................... 81 
Figure 15: Separation of HDL2 and HDL3 apoA-I on SDS-PAGE. (A: HDL2 apoA-I 
bands separation for five different time points; B: HDL3 apoA-I bands 
separation for six different time points) .................................................... 82 
Figure 16: Separation of αHDL and preβHDL apoA-I on SDS-PAGE. (A: αHDL apoA-
I bands separation for five different time points; B: preβHDL apoA-I bands 
separation for five different time points) ................................................... 82 
Figure 17: Chemical structure of leucine and the oxazolinone derivative ................. 85 
Figure 18: Leucine standard curve  (n=6). (Results are presented as mean ± SEM) 86 
Figure 19: KIC standard curve (n=6). (Results are presented as mean ± SEM) ...... 89 
Figure 20: Western blotting: Measurement of the percentage of αHDL and preβHDL
 ................................................................................................................ 93 
Figure 21: An example of the determination of FCR (pools/h) from the slope of a line 
of best fit ................................................................................................. 95 
Figure 22: The model structure for αHDL and preβHDL (k = rate constant) ............. 96 
Figure 23: The model structure for HDL2 and HDL3 (m = rate constant) .................. 96 
 10 
Figure 24: Correlations between plasma HDL-C and fraction HDL-C on the high and 
low sugar diet ........................................................................................ 104 
Figure 25: Correlations between plasma TG and fraction HDL-TG on the high and 
low sugar diet ........................................................................................ 105 
Figure 26: Correlation between plasma HDL-C and HDL apoA-I on the high and low 
sugar diet .............................................................................................. 105 
Figure 27: Correlation between HL and HDL fraction triglyceride on the high and low 
sugar diet .............................................................................................. 107 
Figure 28: Leucine enrichment of total HDL apoA-I on high and low sugar diets for 
each individual ...................................................................................... 108 
Figure 29: Leucine enrichment of total HDL apoA-I on high and low sugar diets 
among all subjects (n=6) ....................................................................... 109 
Figure 30: Fractional clearance rate (FCR) and production rate (PR) of total HDL for 
individual subjects on the high and low sugar diet. ................................ 110 
Figure 31: Optimizing the laboratory methods: SDS-PAGE. .................................. 126 
Figure 32: Leucine enrichment of αHDL and preβHDL apoA-I during 10h study and 
following 5 days in Pilot study 1 ............................................................. 127 
Figure 33: Leucine enrichment of αHDL and preβHDL apoA-I during 10h study and 
following 6 days in Pilot study 2 ............................................................. 128 
Figure 34: Leucine enrichment of αHDL and preβHDL apoA-I during 10h study and 
following 10 days in Pilot study 3 ........................................................... 128 
Figure 35: Leucine enrichment of HDL2 and HDL3 apoA-I during 10h study and 
following 6 days in Pilot study 2 ............................................................. 129 
Figure 36: Leucine enrichment of HDL2 and HDL3 apoA-I during 10h study and 
following 10 days in Pilot study 3 ........................................................... 129 
Figure 37: α-KIC enrichment during the first 10 hour in HDL subclass kinetic study of 
all subjects (n=6). (mean ± SEM) .......................................................... 134 
Figure 38: Leucine enrichment of αHDL & preβHDL apoA-I during the first 10 hours 
in the HDL kinetic study of all subjects (n=6). (mean ± SEM) ................ 135 
Figure 39: Leucine enrichment of αHDL & preβHDL apoA-I during the first 10 hours 
in the HDL kinetic study of the females (n=3). (mean ± SEM) ................ 135 
Figure 40: Leucine enrichment of αHDL & preβHDL apoA-I during the first 10 hours 
in the HDL kinetic study of the males (n=3). (mean ± SEM) ................... 136 
Figure 41: Leucine enrichment of αHDL & preβHDL apoA-I during the 14 day HDL 
kinetic study of all subjects (n=6) (mean ± SEM) ................................... 137 
Figure 42: Leucine enrichment of αHDL & preβHDL apoA-I during the 14 day HDL 
kinetic study of the females (n=3) (mean ± SEM) .................................. 137 
 11 
Figure 43: Leucine enrichment of αHDL & preβHDL apoA-I during the 14 day HDL 
kinetic study of the males (n=3) (mean ± SEM) ..................................... 138 
Figure 44: Leucine enrichment of HDL2 and HDL3 apoA-I during the first 10 hours in 
the HDL kinetic study of all subjects (n=6). (mean ± SEM) .................... 139 
Figure 45: Leucine enrichment of HDL2 and HDL3 apoA-I during the first 10 hours in 
the HDL kinetic study of the females (n=3). (mean ± SEM) ................... 139 
Figure 46: Leucine enrichment of HDL2 and HDL3 apoA-I during the first 10 hours in 
the HDL kinetic study of the males (n=3). (mean ± SEM) ...................... 140 
Figure 47: Leucine enrichment of HDL2 and HDL3 apoA-I during the 14 day HDL 
kinetic study of all subjects (n=6) ........................................................... 141 
Figure 48: Leucine enrichment of HDL2 and HDL3 apoA-I during the 14 day HDL 
kinetic study of the females (n=3) .......................................................... 141 
Figure 49: Leucine enrichment of HDL2 and HDL3 apoA-I during the 14 days HDL 
kinetic study of the males (n=3) ............................................................. 142  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 12 
List of Tables 
Table 1: Functions of the major apolipoproteins ...................................................... 19 
Table 2: Classification and characteristics of lipoproteins ........................................ 20 
Table 3: Functions of human plasma lipoproteins .................................................... 22 
Table 4: Criteria for clinical diagnosis of the metabolic syndrome ............................ 40 
Table 5: Classification of dietary carbohydrates based on molecular size ............... 53 
Table 6: Preparation of leucine standard curve (n=6) .............................................. 86 
Table 7: Preparation of KIC standard curve (n=6) ................................................... 88 
Table 8: Subject characteristics at screening (n=6) ................................................. 99 
Table 9: Intakes of energy and composition of macronutrients of the high and low 
sugar diet .............................................................................................. 100 
Table 10: Body weight, body fat and the concentrations of lipids and lipoproteins in 
plasma and total HDL fractions on the high and low sugar diets ............ 103 
Table 11: Glucose, insulin and insulin sensitivity on the high and low sugar diets . 106 
Table 12: Total lipase, lipoprotein lipase and hepatic lipase on the high and low sugar 
diets ...................................................................................................... 107 
Table 13: Fractional clearance rate (FCR) and production rate (PR) of total HDL on 
high sugar and low sugar diet ................................................................ 110 
Table 14: Summary of data on total HDL apoA-I kinetic parameters obtained with 
stable isotopes in the previous studies .................................................. 112 
Table 15: The kinetics data of VLDL1-TG and VLDL1-apoB on the high and low sugar 
diet ........................................................................................................ 117 
Table 16: Subject characteristics of HDL subclasses kinetic study (n=6) ............... 130 
Table 17:  Lipid profile and apoA-I concentration of the subjects in HDL subclasses 
kinetic study .......................................................................................... 133 
Table 18: Fractional clearance rate and production rate of αHDL and preβHDL for all 
subjects ................................................................................................. 143 
Table 19: Comparison of fractional clearance rate and production rate of αHDL and 
preβHDL between female and male subjects ........................................ 144 
Table 20: Fractional clearance rate and production rate of HDL2 and HDL3 for all 
subjects ................................................................................................. 145 
Table 21: Comparison of fractional clearance rate and production rate of HDL2 and 
HDL3 between female and male subjects .............................................. 145 
Table 22: Summary of data on preβHDL and αHDL apoA-I kinetic parameters 
obtained with stable isotopes in the previous studies ............................ 147 
 13 
Table 23: Recalculated results of APR of preβ1HDL and αHDL in healthy subjects in 
the study by Chetiveaux et al., 2004 ...................................................... 149 
Table 24: Summary of data on HDL2 and HDL3 apoA-I kinetic parameters obtained 
with stable isotopes in the previous study by Li (2009) .......................... 153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
Abbreviations  
ABCA1                              ATP-binding cassette transporter A1 
AHA                                   The American Heart Association 
αHDL                                 Alpha-migrating high density lipoprotein 
AP                                      Alkaline phosphatase 
APR  Absolute production rate 
APE  Atom percent excess 
Apo  Apolipoprotein 
apoA-I  Apolipoprotein A-I 
apoA-II  Apolipoprotein A-II 
ATP III  Adult Treatment Panel III 
AUC  The area under the curve 
BMI  Body mass index 
BW  Body weight 
CETP   Cholesteryl ester transfer protein 
CE  Cholesterol ester 
CM                     Chylomicron 
CHD  Coronary heart disease 
CHO  Carbohydrate 
Chol  Cholesterol 
CI  Chemical ionization 
CO  Cholesterol oxidase 
CV  Coefficient of variation 
CVD  Cardiovascular disease 
2-DE  2-dimensional electrophoresis 
DNL  de novo lipogenesis 
DP  The degree of polymerization 
EDHF  Endothelium-derived hyperpolarizing factor 
EI                                        Electron ionization 
EL  Endothelial lipase 
FC  Free cholesterol 
FCR  Fractional clearance rate 
FFM  Fat free mass 
FPLC  Fast protein liquid chromatography 
FSR  Fractional secretion rate 
GC-MS  Gas chromatography mass spectrometry 
 15 
GI  Glycaemic index 
GL  Glycaemic load 
HCl  Hydrochloric acid 
HDL  High density lipoprotein 
HDL-C  High density lipoprotein-cholesterol 
HL  Hepatic lipase 
HOMA                                The homeostasis model assessment 
HOMA2-IR   The homeostasis model assessment 2-Insulin resistance 
HTGL                                  Hepatic triglyceride lipase 
IDF                                      The International Diabetes Federation 
IDL  Intermediate density lipoproteins 
IEC  Ion exchange chromatography 
IHD  Ischemic heart disease 
KIC  ketoisocaproic acid 
LCAT  Lecithin:cholesterol acyltransferase 
LDL  Low density lipoprotein 
LPL  Lipoprotein lipase 
MI  Myocardial infarction  
MRS  The magnetic resonance spectroscopy 
MTBSTFA  N-Methyl-N-(tertbutyldimethylsilyl) trifluoroacetamide 
NAFLD  Nonalcoholic fatty liver disease 
NASH  Non-alcoholic steatohepatitis 
NCI                                     Negative chemical ionization 
NDNS  The National Diet and Nutrition Survey 
NH4OH  Ammonium hydroxide 
NO  Nitric oxide 
PBST  Phosphate buffered saline containing 0.05% Tween 20 
PCI  Positive chemical ionization 
PL  Phospholipid 
PLTP  Phospholipid transfer protein 
PON1  Paraoxonase 1 
PR  Production rate 
PreβHDL  Prebeta-migration high density lipoprotein 
PV  Plasma volume 
PLTP  Phospholipid transfer protein 
QC  Quality control 
RCT  Reverse cholesterol transport 
 16 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide electrophoresis 
SEM  Standard error of mean 
SR-BI  Scavenger receptor B type I 
T2D  Type 2 diabetes 
TFA  Trifluoroacetic acid 
TFAA   Trifluoroacetic anhydride 
TG Triglyceride 
VA-HIT The Veterans Affairs HDL Intervention Trial 
VLDL  Very low density lipoprotein 
WHO  World Health Organization 
γHDL Gamma high density lipoprotein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
Chapter 1: Introduction 
1.1 Lipids and lipoproteins in the human body 
1.1.1 Lipids 
Lipids as a major source of energy can be utilized immediately by the body or stored 
as adipose tissue for later utilization when food intake is reduced. They perform a 
variety of essential functions including the maintenance of the structural and 
functional integrity of cell membranes, and are involved in hormone- like activities 
and cell signalling. The lipids circulating in the plasma are mainly fatty acids, 
triglycerides, cholesterol and phospholipids (Marshall, Bangert and Lapsley, 2012).  
 
Due to the water insoluble property of lipids, they require specialized transport 
mechanisms associated with proteins. Free fatty acids are carried by albumin, and 
the other lipids circulate bound to complexes known as lipoproteins (Marshall, 
Bangert and Lapsley, 2012). 
 
1.1.2 Lipoproteins 
1.1.2.1 Lipoprotein structure 
Lipoproteins are macromolecular complexes comprised of both lipids and proteins. 
They have a hydrophobic interior and a relatively hydrophilic external. A typical 
lipoprotein particle consists of a core of neutral lipid of triacylglycerol and cholesterol 
ester surrounded by a surface monolayer of polar lipid of phospholipid and free 
cholesterol. Phospholipid and cholesterol have amphipathic properties. Their 
hydrophobic (neutral) ends face the core and the hydrophilic (polar) ends face 
outward. These structures make the lipoprotein particles able to interact with the 
aqueous environment of the blood, and transport the water insoluble lipids from the 
intestine and the liver to the peripheral tissues, or from the peripheral tissues back to 
the liver (Frayn, 2010). 
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The components exposed on the outer surface of lipoproteins also include specific 
amphipathic proteins called apolipoproteins. Similarly, the hydrophobic domains of 
these proteins that attach to lipoprotein particles dip into its core, and the hydrophilic 
domains are exposed at the surface (Frayn, 2010). Apolipoproteins involved in 
lipoprotein metabolism are usually identified as five principle groups including: 
apolipoprotein A (apoA-I, apoA-II, ApoA-IV), apolipoprotein B (apoB-48, apoB-100), 
apolipoprotein C (apoC-I, apoC-II, apoC-III), apolipoprotein D and apolipoprotein E 
(Frayn, 2010). Apolipoproteins play the vital roles in determining the functions of the 
lipoproteins (Mann and Skeaff, 2007) (Table 1). They are indispensable for 
maintaining the structure and the solubility of the lipoproteins. Apolipoproteins are 
involved in the delivery and redistribution of lipids among specific cells and tissues. 
They paly a role mediating the recognition between specific lipoproteins and cell 
surface lipoprotein receptors. Apolipoproteins also have function as cofactors for 
specific enzymes involved in lipid metabolism (Mahley et al., 1984). 
 
Table 1: Functions of the major apolipoproteins  
 
Apolipoprotein Function 
A-I activates lecithin-cholesterol acyl transferase (LCAT); 
structural (in High density lipoprotein (HDL)) 
A-II inhibits hepatic triglyceride lipase (HTGL) at high concentration; 
structural (in HDL) 
B-100 structural (in very low density lipoprotein(VLDL) and low density 
lipoprotein (LDL)); 
receptor binding 
B-48 structural (in chylomicrons) 
C-II activator of lipoprotein lipase (LPL) 
C-III inhibits LPL; 
inhibits clearance of chylomicrons and VLDL remnant particles 
E Binding to LDL and remnant receptors 
Adapted from Marshall, Bangert and Lapsley (2012). 
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1.1.2.2 Classification and composition 
Lipoproteins are a group of heterogeneous particles that differ in size, density, lipid 
and protein composition. They have been traditionally separated on the basis of 
either their electrophoretic mobility or flotation in an ultracentrifuge. The latter method 
has been used more commonly for classification (Frayn, 2010). Lipoproteins are 
divided into five major fractions based on their density, which include chylomicrons 
(CM), very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), 
low density lipoproteins (LDL) and high density lipoproteins (HDL) (Table 2). The 
density increases from CM through VLDL, IDL and LDL to HDL. HDL can be further 
divided into two subclasses, HDL2 and HDL3. Based on the content of lipid and 
protein, CMs and VLDL particles contain a relatively high amount of triglyceride, and 
are usually referred to as triglyceride-rich lipoproteins. IDL and LDL are cholesterol-
rich particles, while HDL contains a high proportion of protein. According to their 
apolipoprotein (apo) composition, lipoproteins can be classified into two groups, 
apoA containing lipoproteins including HDL and apoB containing lipoproteins 
including CMs, VLDL, IDL and LDL. 
 
Table 2: Classification and characteristics of lipoproteins  
 
Lipoprotein Density  
(g/ml) 
Mean 
diameter 
(nm) 
Composition (weight%) Major 
lipoproteins Protein TG Chol PL 
CM <0.95 500 1 90 5 4 B48, AI, AIV, C, E 
VLDL 0.95-1.006 43 5 65 20 10 B100, C, E 
IDL 1.006-1.019 27 15 30 35 20 B100, E 
LDL 1.019-1.063 22 20 10 50 20 B100 
HDL 1.063-1.210 8 55 5 15 25 AI, AII, C, E 
TG: triglyceride, Chol: cholesterol, PL: phospholipids.  
Adapted from Mann and Skeaff (2007); Marshall, Bangert and Lapsley (2012). 
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1.1.2.3 General metabolic pathways of lipoproteins 
There are two separate pathways in lipoprotein metabolism, the exogenous (dietary) 
pathway and the endogenous (hepatic) pathway (Figure 1). Both pathways similarly 
break down the large lipid-rich lipoproteins that are released from the intestine or 
liver, into smaller lipoproteins or remnants, which supply lipid to the peripheral tissue 
or liver (Davis and Wagganer, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LPL: lipoprotein lipase; FFA: free fatty acids; LDL-R: low-density lipoprotein receptor; LRP: 
low-density lipoprotein receptor-related protein; HL: hepatic lipase. 
 
1.1.2.3.1 Exogenous pathway 
The major function of CMs is to transport the lipids which originated from the diet 
from the intestine to peripheral tissues and liver (Table 3). Therefore the metabolism 
of CMs is often considered as the exogenous pathway of lipoprotein metabolism 
(Davis and Wagganer, 2006). CMs are formed in the small intestine. After the 
absorption and re-esterification of the triacylglycerol and cholesterol in the cells of the 
intestine wall, CMs are secreted into the circulation via the lymphatics. The newly 
Figure 1: Exogenous and Endogenous pathways of lipoprotein metabolism (Davis 
and Wagganer, 2006). 
 21 
synthesized CM particles have a core of triacylglycerol and cholesterol ester 
surrounded by a surface of unesterified cholesterol, phospholipid, and apoB 48, AI 
and AIV. CMs then obtain apoC-II, which is essential for the reaction between CMs 
and enzyme lipoprotein lipase (LPL). Triacylglycerol in CMs are hydrolyzed by LPL, 
and the particle becomes smaller. The free fatty acids are distributed to either the 
muscle or heart tissue for energy utilization or the adipose tissues for energy storage. 
CM remnants are catabolized by the liver.  
 
1.1.2.3.2 Endogenous pathway 
In contrast to the exogenous pathway, the endogenous pathway involves the 
transport of cholesterol and triacylglycerol released from the liver. This pathway 
consists of the metabolism of VLDL and LDL (Davis and Wagganer, 2006) (Table 3). 
VLDL particles are synthesized by the liver. The newly secreted VLDL is composed 
of triacylglycerol, cholesterol ester, apoB 100 and a small amount of apoE and C. 
Like CMs, triacylglycerol in VLDL particles are hydrolyzed by LPL and the free fatty 
acids are then distributed to the peripheral tissues. VLDL remnants are relatively 
cholesterol ester-rich particles known as IDL. IDLs are subsequently hydrolyzed by 
LPL and hepatic lipase (HL). They lose all surface components except the layer of 
phospholipids, free cholesterol and apoB 100. They have a cholesterol ester-rich 
core and become LDL particles. LDLs are the smaller and denser particles. ApoB 
100 on the surface of LDL particles is recognized by the LDL-receptor. Cholesterol 
esters in LDL are hydrolyzed to free cholesterol, which is then delivered to the 
tissues. 
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Table 3: Functions of human plasma lipoproteins 
 
Lipoprotein Function 
CM Transport dietary lipids from intestine to peripheral tissue and liver 
VLDL Transport lipids from liver to peripheral tissues 
IDL Precursor of LDL 
LDL Transport cholesterol to peripheral tissues and liver 
HDL Removes cholesterol from tissues and transfer it to the liver or 
other lipoproteins 
Adapted from Mann and Skeaff (2007). 
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1.2 High- density lipoprotein 
1.2.1 HDL structure and composition 
HDLs are the smallest (diameter 7.4-12 nm) and densest (1.063<d<1.21 g/ml) 
plasma lipoproteins (Barter, 2002). They comprise the largest amount of protein, 
approximately 50% and smallest amount of lipid compared with other lipoproteins 
(Barter and Rye, 2005; Davis and Wagganer, 2006). The mature form of HDL has a 
similar structure to the other plasma lipoproteins. They are mostly spherical particles 
with a hydrophobic core mainly consisting of cholesterol ester and a small quantity of 
triacylglycerol, and the outer surface contains unesterified cholesterol, phospholipids 
and apolipoproteins (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The predominant apolipoproteins in human HDL are apoA-I and apoA-II, which 
account for 70% and 20% of total HDL proteins respectively. There are also some 
minor apolipoproteins contained in HDL particles including apoA-IV, apoA-V, apoC-I, 
apoC-II, apoC-III, apoD, apoE, apoJ and apoL (Barter and Rye, 2005). 
 
 
Figure 2: The structure of spherical HDL (HDL forum, 2011) 
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1.2.2 HDL subclasses 
HDLs are a group of heterogeneous particles that vary in shape, size, density, 
apolipoprotein composition and electrophoretic mobility (Figure 3). 
 
Figure 3: Heterogeneity of human HDL (Barter, 2002) 
 
Shape: In normal plasma, there are most spherical HDLs. However, there is a minor 
population of HDLs, which are the discoidal particles. Discoidal HDLs are the nascent 
forms of HDL, and they comprise only surface constituents and exist as a molecular 
bi-layer of unesterified cholesterol and phospholipids surrounded by apolipoproteins 
(Barter and Rye, 2005). Discoidal HDLs normally have a very low concentration since 
they only exist transiently and convert into spherical HDLs rapidly (Barter and Rye, 
2005).  
 
Size and density: HDL can be isolated as two major subclasses based on density 
by ultracentrifugation: HDL2 (1.063<d<1.125 g/ml) and HDL3 (1.125<d<1.21 g/ml) 
(Barter, 2002). These two subclasses can be further separated into five distinct 
subfractions based on particle size by non-denaturing polyacrylamide gradient gel 
electrophoresis. Two distinct subfractions HDL2b (mean diameter 10.6 nm) and HDL2a 
(9.2 nm) are included in the HDL2 density range, and the other three sufractions 
 25 
HDL3a (8.4 nm), HDL3b (8.0\\ nm) and HDL3c (7.6 nm) are within the HDL3 density 
range (Blanche et al., 1981).  
 
Apolipoprotein composition: HDLs can be divided into two predominant 
subpopulations on the basis of their two major apolipoproteins: apoA-I and apoA-II. 
One subpopulation involves HDL particles containing only apoA-I without apoA-II (A-I 
HDL), while another subpopulation comprise HDL particles consisting of both apoA-I 
and apoA-II (A-I/A-II HDL) (Cheung and Alberts, 1984). ApoA-I is distributed 
approximately equally between A-I HDLs and A-I/A-II HDLs in most human subjects, 
while almost all apoA-II exists in A-I/A-II HDLs (Cheung and Alberts, 1984; Bekaert et 
al., 1992). Most A-I/A-II HDLs are found in the HDL3 density range, while A-I HDLs 
are the predominant components of both HDL2 and HDL3 (Cheung and Alberts, 
1982). There is also a minor HDL subpopulation containing apoA-II but no apoA-I (A-
II HDL), which had been separated from human plasma by using sequential 
immunoaffinity chromatography (Bekaert et al., 1992). Most of A-II HDL particles 
contain apoA-II as its sole apolipoprotein while a minority of A-II HDLs may also 
contain apoD and other minor apolipoproteins. 
 
Electrophoretic mobility: HDL particles also vary in surface charge. HDL can have 
either prealpha (preα), alpha (α), prebeta (preβ) or gamma (γ) migration when 
separated by agarose gel electrophoresis (Asztalos et al., 1993; Huang et al., 1994). 
The α-migrating HDLs that exist as spherical particles account for the predominant 
proportion of HDL in plasma. As the mature forms of HDL, α-migrating HDLs 
comprise HDL2 and HDL3 subclasses, and also A-I HDL and A-I/A-II HDL subclasses 
(Rye and Barter, 2004). Preβ-migrating HDL exist as either lipid-poor apoA-I or 
discoidal particles consisting of two or three molecules of apoA-I, phospholipids and 
possibly a small quantity of unesterified cholesterol. The γ-migrating HDLs exist as 
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discoidal particles. They contain apoE and phospholipids but no apoA-I (Huang et al., 
1994). 
 
1.2.3 HDL apolipoproteins  
1.2.3.1 Major apolipoproteins of HDL 
1.2.3.1.1 Apolipoprotein A-I 
Human apoA-I circulates in plasma predominantly as a component of HDL. There is 
also a small amount of apoA-I found in chylomicrons or their remnants, VLDL or their 
remnants, or LDL (Mahley et al., 1984).  The concentration of plasma apoA-I is about 
1.0-1.5 mg/ml. ApoA-I is mainly synthesized in two sites: the liver and small intestine. 
The intestinal apoA-I secreted into the circulation is associated with chylomicrons 
and then is rapidly transferred to HDL particles via lipoprotein lipase hydrolysis of 
chylomicrons (Mahley et al., 1984). The hepatic apoA-I secreted into the circulation is 
related to nascent HDL particles that contain little or no core of cholesterol ester.  
 
Apolipoprotein A-I was one of the first apolipoproteins to be identified and 
characterized. Human apoA-I is synthesized initially as a 267-amino acid pre-pro-
apoA-I (Brewer et al., 1983; Chau et al., 2006). This undergoes proteolytic 
processing to form the mature apoA-I, a single polypeptide of 243 amino acids with a 
molecular weight of 28.1 KD (Brewer et al., 1978; Mahley et al., 1984). Mature apoA-I 
is composed of a series of repeated 22- and 11-amino acid sequences in the primary 
structure, and amphipathic α-helices with hydrophobic and hydrophilic faces in the 
secondary structure (Frank and Marcel, 2000). The amphipathic properties of α-
helices enables apoA-I to strongly bind with various lipids such as phospholipids and 
cholesterol via the hydrophobic faces, and interact with the aqueous phase through 
the hydrophilic faces (Davidson and Thompson, 2007; Frayn, 2010). Therefore, this 
property may play a crucial role in enhancing the stability of apoA-I particles, 
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enabling the interaction between apoA-I and the cell membrane, and enabling apoA-I 
to collect the cholesterol from the cells. ApoA-I has been found to be a self-
associating system in aqueous medium, which may help to stabilize the lipid-free 
form of apoA-I (Frank and Marcel, 2000; Vitello and Scanu, 1976).  
 
ApoA-I presents in various conformations with metabolic interconversion between 
forms (Ajees et al., 2006). It can exist in lipid free/poor, partially lipidated, and fully 
lipidated states. A series of reactions are involved in the cycling of apoA-I between 
lipid-poor and lipid-bound forms (Barter, 2002).  
 
It has been indicated that human apoA-I has a protective effect against 
cardiovascular disease (Saito et al., 2004). As the principle protein component of 
HDL, apoA-I plays a crucial role in the anti-atherogenic function of HDL. The 
protective action of apoA-I is attributed to its major functions in the reverse 
cholesterol transport pathway (see below) (Saito et al., 2004; Narayanaswami and 
Ryan, 2000). ApoA-I acts as an acceptor of collecting cholesterol from the cell 
membrane and transporting cholesterol to the liver for excretion. It also functions as a 
key activator for the plasma enzyme Lecithin:cholesterol acyltransferase (LCAT).  
 
1.2.3.1.2 Apolipoprotein A-II 
Human apoA-II occurs as a second primary protein component of HDL. It may be 
also associated, in a smaller quantity, with other lipoproteins, such as chylomicrons 
and VLDL (Blanco-Vaca et al., 2001). The plasma concentration of human apoA-II is 
around 0.3-0.35 mg/ml (Mahley et al., 1984). Human apoA-II is initially synthesized in 
the liver as a 100 amino acid precursor pre-pro-apoA-II (Tailleux et al., 2002). Pre-
pro-apoA-II is then converted to pro-apoA-II by removal of an 18 amino acid 
sequence and released to the plasma. It is subsequently converted to the mature 
apoA-II with a molecular weight of 17.4 KD after removal of another 5 amino acid 
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sequence (Irshad and Dubey, 2005; Mahley et al., 1984). The majority of human 
apoA-II in the plasma appears as a dimer of two identical 77-amino acid polypeptide 
chains linked by a disulphide bond at residue 6 (Blanco-Vaca et al., 2001; Schaefer 
et al., 1982).  
 
There are also other species present in plasma, the apoA-II/apoE dimer, the apoA-
II/apoD dimer and the apoA-II monomer (Blanco-Vaca et al., 2001). Like apoA-I, 
apoA-II can bind well to lipid due to the amphipathic property of its secondary 
structure (Mahley et al., 1984; Saito et al., 2004). Each apoA-II monomer contains 
three long α-helices. ApoA-II has a higher affinity to lipoprotein surfaces (including 
HDL) than apoA-I, and this is possibly because apoA-II is more hydrophobic. 
Consistent with the higher binding affinity, apoA-II is known to displace apoA-I from 
HDL (Mahley et al., 1984; Eisenberg, 1984).  
 
1.2.3.2 Minor apolipoproteins of HDL  
1.2.3.2.1 Apolipoprotein E 
Apolipoprotein E (apoE) was first recognized in human VLDL in the early 1970s 
(Shore and Shore, 1973). Human apoE in plasma is a single polypeptide consisting 
of 299 amino acids with a molecular weight of 34.2 KD (Zannis et al., 1984; Rye et 
al., 2006). It can be synthesized in many tissues such as the kidney and adrenal 
gland, however the predominant source of apoE in the plasma is probably the liver 
(Zannis et al., 1984; Frayn, 2010). ApoE not only exists in triglyceride-rich particles 
but also has been found in HDL particles. It has been discovered that apoE is 
present in various subclasses of HDL based on electrophoretic mobility, which 
includes γHDL, preβHDL and αHDL (Krimbou et al., 1997). As a constituent of 
subclasses of HDL, apoE has a function that affects cholesterol efflux from the cells 
(Mahley and Rall, 2000). In the reverse cholesterol transport pathway, apoE acts as 
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a receptor ligand and assists the delivery of cellular cholesterol to the liver. It has 
also been indicated that apoE involves the inhibition of platelet aggregation 
(Higashihara et al., 1991; Riddell et al., 1997). 
  
1.2.3.2.2 Apolipoprotein M 
Apolipoprotein M (apoM) is a recently identified human apolipoprotein. The majority 
of apoM in the plasma is associated with HDL, but there is also a minor proportion 
present in triglyceride-rich lipoprotein and LDL (Xu and Dahlback, 1999; Xu et al., 
2004). ApoM is principally synthesized in the liver and kidney. It exists as a 188-
amino acid residue long protein with the molecular weight of 26 KD (Xu and 
Dahlback, 1999). ApoM is indispensable in HDL metabolism. A study in mice 
deficient in apoM suggested that apoM play a crucial role in the formation of preβ 
HDL (Wolfrum et al., 2005). ApoM also has the ability to modulate cholesterol efflux 
from macrophages to HDL, which may contribute to the anti-atherogenic effect of 
HDL. Anti-oxidation and anti-inflammation effects of apoM also contribute to the anti-
atherogenic effect of HDL (Christoffersen et al., 2008; Huang et al., 2007). 
 
1.2.4 HDL metabolism: Formation of HDL and Reverse Cholesterol Transport 
Excessive accumulation of cholesterol in the artery walls can result in the 
development of atherosclerosis. The metabolism of HDL has been indicated to have 
an inverse relationship with the risk of atherosclerotic cardiovascular disease. It 
involves a complex interaction of factors that modulate the synthesis, remodelling 
and catabolism of HDL. HDL is considered to play a key role in the reverse 
cholesterol transport (RCT) pathway, in which the excess cholesterol can be 
transported by HDL from peripheral tissues back to the liver and subsequently 
excreted in the bile (Lewis and Rader, 2005).  
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The formation of HDL begins with the secretion of lipid-poor apoA-I from the liver and 
intestine (Figure 4). Once released in plasma, apoA-I rapidly acquires free 
cholesterol and phospholipids from the liver via the receptor ATP-binding cassette 
transport A1 (ABCA1), and obtains cholesterol and phospholipids from chylomicrons 
and VLDL via lipoprotein lipase (LPL) to form the discoidal, prebeta-migrating 
nascent HDL particles. The nascent preβHDL particles acquire additional free 
cholesterol and phospholipids from peripheral tissues mediated by ABCA1 and 
generate the more cholesterol-rich preβHDL particles. The enzyme LCAT which is 
carried by HDL esterifies the free cholesterol to form cholesterol ester. Esterified 
cholesterol then moves into the centre of HDL particles as a hydrophobic core, 
altering the discoidal preβHDL to form small spherical, alpha-migrating HDL particles 
(HDL3). Further esterification of free cholesterol by the reaction of LCAT leads to the 
conversion of HDL3 to larger spherical alpha-migrating HDL2. This process leads to 
the further changes in composition and size of HDL particles (Frayn, 2010; Lewis and 
Rader, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABCA1: ATP-binding casstte A1; PL: phospholipids; FC: free cholesterol; LCAT: lethin-
cholesterol acyltransferase; CE: cholesterol ester; LPL: lipoprotein lipase. 
Figure 4: The process of HDL maturation (Lewis and Rader, 2005) 
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The subsequent process of HDL remodelling can be achieved by either the direct or 
indirect pathway (Figure 5). In the direct pathway, cholesterol esters in spheroidal 
HDL particles interact with a specific receptor – the scavenger receptor B type I (SR-
BI), and then are taken up by the liver for excretion in the bile. The indirect pathway 
involves the transport of cholesterol esters to the apoB-containing lipoproteins. By 
the action of cholesterol ester transfer protein (CETP) which is mainly bound to HDL, 
cholesterol ester in mature HDL particles exchange with triglyceride in chylomicron 
and VLDL. This exchange leads to cholesterol ester depletion and triglyceride 
enrichment in HDL particles. In addition, phospholipid transfer protein (PLTP) 
mediates the migration of phospholipid from triglyceride-rich lipoprotein to HDL. 
Hepatic lipase (HL) modification of triglyceride-rich HDL particles releases lipid-poor 
apoA-I and HDL remnants and leads to the reduction in HDL size. Lipid poor apoA-I 
can be degraded in the kidney (Frayn, 2010; Lewis and Rader, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SR-B1: scavenger receptor class-B1; HL: hepatic lipase; CEPT: cholesterol ester transfer 
protein; PLTP: phospholipase transfer protein; TG: triglyceride; CE: cholesterol ester; PL: 
phospholipids. 
 
Figure 5: The process of HDL remodelling (Lewis and Rader, 2005) 
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1.2.4.1 Factors involved in HDL metabolism 
1.2.4.1.1 ATP-binding cassette transporter A1 (ABCA1)   
ABCA1 is a cell membrane transport protein that uses ATP as an energy source to 
transport a wide variety of substrates across the membrane (Segrest et al., 2000). It 
largely occurs in the liver, macrophages, brain and various other tissues (Zannis et 
al., 2006). ABCA1 promotes the efflux of cholesterol and phospholipids from cell 
membranes to lipid-poor apoA-I in the extracellular region, which leads to the 
formation of discoidal apoA-I-containing HDL (Barter, 2002). Although several 
models have been proposed, the mechanism of ABCA1-mediated delivery of 
cholesterol to apoA-I remains elusive (Zannis et al., 2006). Patients with Tangier 
disease (caused by a mutation in ABCA1) have been reported to have a very small 
amount of plasma cholesterol and fail to synthesize the discoidal and spherical HDL, 
which leads to almost complete absence of HDL in plasma (Orso et al., 2000; Zannis 
et al., 2006).  Therefore, ABCA1 is an important factor in lipidation of apoA-I and HDL 
formation in HDL metabolism. 
 
1.2.4.1.2 Lecithin:cholesterol acyltransferase (LCAT) 
LCAT is a 416-amino acid long protein that is released from the liver and circulates in 
the plasma. It is present in plasma in a lipid-free form or is bound the surface of HDL 
particles (Zannis et al., 2006; Barter, 2002). LCAT plays an important role in the 
conversion of nascent discoidal HDL to mature spherical HDL by delivery of 
cholesterol from peripheral tissues to HDL particles. LCAT facilitates the esterification 
of cholesterol to form cholesterol ester (Lewis and Rader, 2005). ApoA-I carried on 
HDL particles is the primary activator of LCAT (Frayn, 2010). Mutations in LCAT can 
cause classical LCAT deficiency. Classical LCAT deficiency can prevent the 
esterification of cholesterol in HDL and can lead to the accumulation of discoidal HDL 
particles in plasma (McIntyre, 1988; Zannis et al., 2006). Deficiency of LCAT is 
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associated with fish eye disease which is characterized by the impaired esterification 
of cholesterol in HDL but not in LDL and VLDL, and this can lead to a low level of 
HDL-cholesterol in plasma (McIntyre, 1988).  
 
1.2.4.1.3 Scavenger receptor Class B type I (SR-BI) 
SR-BI is a member of the scavenger receptor proteins. It is a 509-amino acid 
membrane glycoprotein with a molecular weight of 82KD (Wang and Briggs, 2004). 
SR-BI is mainly present in the liver and adrenal glands, but also can be found in 
other tissues and cells including the brain, the intestine, the testis, macrophages, 
endothelial cells and astrocytes (Zannis et al., 2006; Wang and Briggs, 2004). SR-BI 
can bind to various ligands including HDL, LDL and VLDL. As the first discovered 
HDL receptor, SR-BI has the function of facilitating the selective uptake of HDL 
cholesterol. SR-BI expression can increase cholesterol uptake mediated by HDL in 
culture cells (Ji et al., 1997). It has been found that deficiency of SR-BI in mice can 
lead to a great reduction in the clearance of HDL cholesterol from the circulation (Out 
et al., 2004). An inverse relationship has been shown between SR-BI expression and 
the levels of HDL cholesterol and apoA-I in studies using the SR-BI transgenic mice 
(Wang et al., 1998; Ueda et al., 1999). It has been suggested that increased SR-BI 
expression in the liver of SR-BI transgenic mice is associated with a decrease in HDL 
cholesterol and apoA-I levels (Wang et al., 1998; Uedua et al., 1999).  
 
1.2.4.1.4 Cholesterol ester transfer protein (CETP) 
CETP is a hydrophobic glycoprotein primarily bound to HDL (Barter, 2002). CETP is 
mainly present in the liver, the spleen and adipose tissue but is also present at low 
levels in the small intestine, adrenal gland, skeletal muscle, kidney and heart (Wang 
and Briggs, 2004). CETP promotes the redistribution of cholesterol ester and 
triglyceride between HDL and the apoB-containing lipoproteins (LDL, IDL, VLDL, 
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chylomicrons and remnants), and is thus important in reverse cholesterol transport. 
The net effect of its action is that the cholesterol esters in HDL produced by the 
LCAT reaction are transferred to triglyceride-rich lipoproteins, and triglycerides are 
transported in the reverse direction, from chylomicrons and VLDL to HDL (Rye et al., 
1999). CETP mutations in humans are associated with increased HDL levels (Inazu 
et al., 1990). The level of CETP can be raised in dyslipidaemic state including type 2 
diabetes mellitus and hypercholesterolaemia which are associated with low HDL 
concentrations in plasma (Bagdade et al., 1993). 
 
1.2.4.1.5 Phospholipid transfer protein (PLTP) 
PLTP is a plasma glycoprotein with a molecular weight of 81 KD (Wang and Briggs, 
2004). PLTP activity is associated with larger HDL and moderates the transport of 
phospholipid from triglyceride-rich lipoproteins to HDL (Colhoun et al., 2002; Lewis 
and Rader, 2005). PLTP is able to promote extensive remodelling of HDL particles 
into larger HDL particles by particle combination, with the accompanying release of 
lipid-poor apoA-I (Huuskonen et al., 2001). In a study using human PLTP transgenic 
mice, the enhanced activity of PLTP was shown to be related to increased levels of 
apoA-I in preβ-migrating HDL (Jiang et al., 1996).  
 
1.2.4.1.6 Hepatic lipase (HL) 
HL is considered to be an endothelial enzyme, and a member of the triglyceride 
lipase family, that is involved in HDL metabolism (Wang and Briggs, 2004). HL is a 
467-amino acid protein secreted from the liver. It has been shown that HL is bound to 
the surface of hepatocytes and hepatic endothelial cells. HL has the ability to 
hydrolyse a variety of lipids not only triglyceride and phospholipids but also 
cholesterol ester, monoglycerides and diglycerides (Wang and Briggs, 2004). It can 
hydrolyse the triglycerides and phospholipids of all lipoprotein fractions although the 
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preferred substrate is HDL triglyceride (Barter, 2002). A study that investigated HDL 
metabolism showed that HL can increase the uptake of HDL cholesterol ester by SR-
BI (Lambert et al., 1999). Patients with HL deficiency have been found to have an 
increased level of HDL in plasma (Breckenridge et al., 1982).  
 
1.2.4.1.7 Lipoprotein lipase (LPL) 
LPL is the enzyme found predominantly in adipose tissue, skeletal muscle and heart 
muscle (Frayn, 2010; Wang and Briggs, 2004). It is a triglyceride lipase and it is 
located on the surface of endothelial cells in most tissues (Barter and Rye, 2005). 
The major activity of LPL is to promote the hydrolysis of triglyceride with a minor 
activity as a phospholipase (Lewis and Rader, 2005). LPL is the primary enzyme 
associated with the hydrolysis of triglycerides in chylomicrons and VLDL and the 
subsequent release of free fatty acids, in which the large triglyceride-rich particle is 
transformed into smaller triglyceride-depleted particles (Barter, 2002). This 
triglyceride hydrolysis process leads to the reduction of particle size as well as a 
redundancy of surface constituents such as phsopholipids and apolipoproteins, which 
may be transported to HDL particles. Consequently, the hydrolysis can be a 
significant factor contributing to the plasma concentration of HDL cholesterol and 
HDL-associated apoA-I  (Barter, 2002; Lewis and Rader, 2005).  
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1.3 Cardiovascular disease 
1.3.1 Definition and prevalence 
Cardiovascular disease (CVD) refers to a group of disorders occurring in the heart 
and the blood vessels that supply blood to the heart muscle, the brain and the 
peripheral regions of the body (World Health Organization (WHO), 2013a). Generally, 
it includes coronary heart disease (CHD), which is also known as coronary artery 
disease, ischaemic heart disease, cerebrovascular disease, peripheral arterial 
disease, rheumatic arterial disease, congenital heart disease, and deep vein 
thrombosis and pulmonary embolism. Coronary heart disease (angina and 
myocardial infarction) and cerebrovascular disease (stroke) are the most prevalent 
forms of CVD. Myocardial infarction and stroke are primarily caused by a blockage 
that inhibits the blood flowing to the heart or brain. Stroke can also be caused by 
bleeding from the blood vessels in the brain (WHO, 2013a).  
 
CVD is the major cause of death in both the developing and developed countries 
(WHO, 2013a). It has been estimated that 17.3 million people died from CVD in 
2008, accounting for 30% of all global deaths. Approximately 7.3 million of these 
deaths were caused by CHD and about 6.2 million were due to stroke.  Compared 
with high-income countries, low- and middle-income countries are more exposed to 
CVD risk factors such as tobacco use, unhealthy diet and physical inactivity. It has 
been reported that over 80% of CVD deaths occur in low- and middle-income 
countries, and it distributes almost equally in men and women. Moreover, death from 
CVD in low- and middle-income countries is in younger people, usually in their most 
productive years. WHO predicts that by the year 2030, the number of people who 
died from CVD, mainly CHO and stroke, will be increased to 23.3 million. 
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The death rate from CVD in the UK has been dropping since the early 1970s (British 
Heart Foundation, 2012). In the past ten years, the death rate has fallen by 44% 
among people aged under 75 years. Compared with a younger age group, the death 
rate from CHD has decreased more dramatically in those aged 55 and over in recent 
years (British Heart Foundation, 2012). From the 2000 to 2010, there was a decrease 
of 43% in the CHD death rate among men aged between 55 and 64 in the UK, 
compared to the decrease of 21% among men aged 35 to 44 years. For women, the 
death rate in those aged 55 to 64 declined by 52% while the rate in those aged 
between 35 and 44 years was barely changed. Although the mortality of CVD has 
been falling, CVD is still the most common cause of death in the UK, which 
accounted for approximately one in three of all deaths, almost 180,000 deaths in 
2010 (British Heart Foundation, 2012). 
 
1.3.2 Cardio-metabolic risks 
Cardio-metabolic risk refers to a cluster of CVD risk factors which forms the 
diagnosis of the metabolic syndrome, the traditional risk factors and other unknown 
risk factors (Figure 6) (Despres and Lemieux, 2006). 
 
CVD is a multifactorial condition, and there are various risk factors contributing to the 
likelihood of developing CVD. These risk factors are composed of the untreatable 
factors such as age and gender, and potentially modifiable risk factors including 
smoking, physical inactivity, hypertension, increased LDL cholesterol and a group of 
interrelated metabolic risk factors (British Heart Foundation, 2012; Cannon, 2007). 
The efforts of preventing and treating CVD risk factors during last several decades 
have significantly reduced the rates of CVD-related mortality. However, there are still 
a lot of patients who do not have appropriate control of their CVD risk factors 
although these factors have been recognized. The increased prevalence of obesity 
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and type 2 diabetes has been reported to be associated with the weakening 
improvements in CVD. Therefore, the focus has shifted to the assessment of cardio-
metabolic risk, which may present the greatest potential origins of CVD risk (Cannon, 
2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2.1 Metabolic syndrome 
Metabolic syndrome is a cluster of metabolic disorders that are associated with an 
increased risk of CVD and type 2 diabetes mellitus (Alberti et al., 2009). The concept 
of metabolic syndrome was first described by Kylin, a Swedish physician, as a series 
of abnormalities characterized by hypertension, hyperglycaemia and gout in 1923 
(Kylin, 1923; Eckel et al., 2005). Two decades later, in 1974, upper body adiposity 
(android or male-type obesity) had been suggested as the most common type of 
obesity related to metabolic abnormalities which occurred in patients with CVD and 
type 2 diabetes (Vague, 1974; Eckel et al., 2005). In 1988, Reaven introduced the 
term “Syndrome X” and postulated that insulin resistance could be the key underlying 
cause of hypertension, hyperlipidaemia, type 2 diabetes and CVD (Reaven, 1988; 
Figure 6: Factors contributing to global cardiovascular risk (Despres and 
Lemieux, 2006). 
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Kahn et al., 2005). Following Reaven’s publication, various terms have arisen to 
describe the clustering of insulin resistance and related metabolic disorders which 
result in increased risk of CVD, such as syndrome X, insulin resistance syndrome 
and metabolic syndrome (Kahn et al., 2005). 
 
Various criteria for clinical diagnosis of metabolic syndrome have been proposed by 
different organizations during the past decade. The first formalized definition of 
metabolic syndrome was introduced by a consultation group on the definition of 
diabetes for the WHO in 1998 (Alberti and Zimmet, 1998). This diagnostic criteria by 
WHO was built based on several markers of insulin resistance (impaired glucose 
tolerance or diabetes) combined with another two risk factors including obesity, 
hypertension, high plasma triglyceride level, reduced HDL cholesterol level or 
microalbuminuria. Another definition was proposed by the National Cholesterol 
Education Program Adult Treatment Panel III (ATP III) in 2002. ATP III criteria did not 
include insulin resistance but required the occurrence of 3 of the following 5 factors 
for diagnosis - abdominal obesity, elevated triglyceride, reduced HDL cholesterol, 
increased blood pressure and increased fasting glucose. The criteria of diagnosis for 
metabolic syndrome developed by the International Diabetes Federation (IDF) in 
2005 had greater emphasis on abdominal obesity and particularly focused on waist 
circumference (Alberti et al., 2005). The rest of the criteria are essentially identical to 
the criteria provided by ATP III. More recently, in 2009, six major organizations tried 
to unify the criteria of metabolic syndrome. This included the International Diabetes 
Federation Task Force on Epidemiology and Prevention, National Heart, Lung and 
Blood Institute, American Heart Association, World Heart Federation, International 
Atherosclerosis Society, and International Association for the Study of Obesity. They 
presented a statement of common criteria for the clinical diagnosis for metabolic 
syndrome (Table 4) (Alberti et al., 2009). It was agreed that the risk related to waist 
measurement will differ in different populations.  
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Table 4: Criteria for clinical diagnosis of the metabolic syndrome 
 
Measure Categorical Cut Points 
Elevated waist circumference Population- and country-specific definitions 
Elevated triglycerides ≥150 mg/dL (1.7 mmol/L) 
Reduced HDL-Cholesterol <40 mg/dL (1.0 mmol/L) in male; 
<50 mg/dL (1.3 mmol/L) in females 
Elevated blood pressure Systolic ≥130 and/or diastolic ≥85 mm Hg 
Elevated fasting glucose ≥100 mg/dl (5.6 mmol/L) 
 Adapted from Alberti et al. (2009). 
 
The prevalence of metabolic syndrome has increased with the rise in glucose 
intolerance and type 2 diabetes worldwide (Ogbera, 2010). It has been demonstrated 
that the prevalence of metabolic syndrome in the general population is about 17% to 
25%. Metabolic syndrome is a risk factor of CVD. Patients with metabolic syndrome 
have twice the likelihood of developing CVD during the next 5 to 10 years compared 
to those do not have metabolic syndrome (Alberti et al., 2009). Moreover, people with 
metabolic syndrome have a five times higher risk in developing type 2 diabetes 
mellitus.  
 
1.3.2.2 Abdominal obesity 
Obesity can be briefly described as the condition of abnormal or excessive fat 
accumulation in the body, which may be harmful for health (WHO, 2013b). It 
develops when energy intake exceeds energy expenditure for a period of time 
(Wilding, 2006). Obesity now is the most common nutritional disorder in the world, 
and it is associated with the increased intake of energy-dense foods that are high in 
fat and the increased tendency of physical inactivity. Obesity is often defined by body 
mass index (BMI), which is calculated as weight in kilograms divided by the square of 
height in meters (kg/m2) (Omari and Caterson, 2007). BMI is a simple and easy 
approach to assess overweight and obesity in both individual level and population 
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level. Adults with BMI ≥25 kg/m2 are classified as overweight, BMI between 30-34.9 
kg/m2 are categorized as obese class I, BMI from 35 to 39.9 kg/m2 are obese class II, 
and BMI ≥40 are obese class III with very high risk of comorbidities. Obesity is the 
dominant contributor to the metabolic disturbance related to lipid and glucose 
(Redinger, 2007). It has been indicated that obesity is the key factor in the 
pathophysiology of insulin resistance, diabetes mellitus, hypertension, dyslipidemia 
and atherosclerosis.  
 
The cases of obesity have been nearly doubled in the world since 1980 (WHO, 
2013b). In 2008, 35% of adults, aged 20 and over in the world (approximately 1.4 
billion), were overweight or obese. Of these, there were over 200 million males and 
about 300 million females who were obese, in total accounting for about 11% of 
world’s adult population. Overweight and obesity have become the fifth leading risk of 
global death (WHO, 2013b).  They contribute to 44% of diabetes burden, 23% of 
CHD burden and 7% to 41% of certain cancer burdens. Every year at least 2.8 
million people die as the result of being overweight or obese.  Thirty years ago, the 
major health issue of childhood in developing countries was focused on malnutrition. 
However today, attention has been drawn to the new pandemic of obesity and its 
accompanying noncommunicable diseases (Prentice, 2006). In 2011, more than 40 
million children under five years old were overweight (WHO, 2013b). The prevalence 
of overweight and obesity in children living in low- and middle-income counties is 
higher, compared to high-income countries. There are over 30 million children in the 
developing countries that are overweight and 10 million in the developed countries.  
 
The site of where the adipose tissue accumulates is known to be crucial for 
identifying the risk of obesity-related disease (Omari and Caterson, 2007). Abdominal 
obesity, a vital component of obesity, is particularly associated with the increase risk 
of CVD and type 2 diabetes (Westphal, 2008). Waist circumference, which has been 
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indicated to be a strong marker of obesity-related health risk, is used to assess 
abdominal obesity. The measurement >102 cm in Caucasian men and >88 cm in 
Caucasian women suggests the greater risk of developing metabolic disease (Omari 
and Caterson, 2007). It has been demonstrated that a combination of BMI and waist 
circumference would be a better predictor of health risk than using BMI alone 
(Janssen et al., 2004). 
 
1.3.2.3 Insulin resistance  
Insulin is a crucial metabolic hormone that stimulates glucose uptake in different 
organs, especially muscle and adipose tissue, and inhibits glucose production in the 
liver. It also inhibits lipolysis in adipose tissue (Greenfield and Campbell, 2004). 
Insulin resistance or a reduced biological response to insulin is known as a key 
component of metabolic syndrome, and is linked to type 2 diabetes and obesity. It 
has been suggested that insulin resistance is a strong predictor of the development 
of type 2 diabetes in adults (Greenfield and Campbell, 2004). Studies in obese 
children have also demonstrated this relationship (Lee et al., 2006). Insulin 
resistance is particularly associated with central obesity or abdominal obesity 
(Greenfield and Campbell, 2004). It has been suggested that the accumulation of fat 
in the abdominal area of the body can be a crucial determinant of whole-body insulin 
resistance. The increased level of FFAs, which can expand adipose mass, is 
commonly shown in obesity (Westphal, 2008). Visceral fat is less sensitive to the 
effect of insulin against lipolysis than subcutaneous fat, and the increased release of 
FFAs from visceral fat which goes directly to the liver can promote gluconeogenesis 
and hepatic insulin resistance.  
 
Insulin resistance may be involved in the pathogenesis of nonalcoholic fatty liver 
disease (NAFLD) and most likely progression could be as follows: (i) Peripheral 
insulin resistance, which leads to the insufficient suppression of lipolysis and reactive 
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hyperinsulinemia; (ii) Increased fatty acid influx to the liver, which could lead to the 
increased level of hepatic triglycerides; (iii) Hepatic insulin resistance superimposed 
on peripheral resistance (Bugianesi et al., 2005). Insulin resistance has also been 
associated with an atherogenic plasma lipid profile (DeFronzo and Ferrannini, 1991). 
Insulin resistance can enhance the hepatic synthesis of VLDL and contribute to the 
increased plasma level of triglyceride. Resistance to the action of insulin on 
lipoprotein lipase can also cause hypertrglyceridaemia in patients with obesity and 
diabetes. It has been suggested that the latter process may facilitate the progressive 
elimination of lipid and apolipoproteins from VLDL particles and lead to the elevated 
production of IDL and LDL, which are both known to be atherogenic (DeFronzo and 
Ferrannini, 1991). 
 
1.3.2.4 Fatty liver disease 
The problem of fatty injury to the liver has arisen due to the globally increased 
prevalence of obesity (Preiss and Sattar, 2008). NAFLD can be defined as the 
accumulation of fat in the liver exceeding 5-10% by weight but in the absence of 
alcohol consumption (Hsiao et al., 2007). NAFLD is one of the most common liver 
disorders. It has been estimated that about 20-30% of the adult population in the 
developed countries are affected by NAFLD (Bellentani et al., 2010). Approximately 
2-3% of the same population will have non-alcoholic steatohepatitis (NASH). The 
prevalence of NAFLD is also increasing in children. Paediatric NAFLD has increased 
from about 3% in 2000 age to 5% in 2010 (Bellentani et al., 2010).  
 
There are several stages involved in the progression of NAFLD (Preiss and Sattar, 
2008). Steatosis, which is the initial recognized stage, represents fat accumulation in 
liver tissue without inflammation. The subsequent stage in some cases is NASH, 
which is characterized by steatosis accompanying with hepatocellular injury, and 
inflammation with or without fibrosis. People who have developed NASH can be at 
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very high risk of CVD and progression to the severe stage of NAFLD, cirrhosis, which 
increases the risk of hepatocellular carcinoma. NAFLD is positively associated with 
obesity and BMI (Angulo, 2002). The prevalence of steatosis in obese individuals 
with BMI > 30kg/m2 and BMI > 35 kg/m2 is estimated at 65-75% and 85-90% 
respectively. As mentioned before, NAFLD is also associated with peripheral and 
hepatic insulin resistance. The content of liver fat is significantly increased in people 
with metabolic syndrome (Kotronen et al., 2007). In addition, the presence of severe 
fatty liver in the US population is greatly associated with the prevalence of 
hypertension, abnormal metabolism of glucose and triglyceride (Hsiao et al., 2007). 
 
1.3.3 Relationship between cardiovascular disease and HDL  
1.3.3.1 Pathogenesis of CVD 
Atherosclerosis, which is caused by the development of fatty deposits in the arterial 
walls, is considered to be the most frequent cause underlying CVD (Frayn, 2010; 
Falk, 2006).  Atherosclerosis is a chronic immunoinflammatory, fibroproliferative 
disease that affects the medium and lager-sized arteries (Falk, 2006). In CHD, the 
most common form of CVD, atherosclerosis can cause the partial or complete 
blockage in one or more coronary arteries that provide blood to the muscular walls of 
the heart.  
 
The development of the fatty deposits, which is known as atherosclerotic plaque, is a 
very complicated and slow progressive process, and it is related to various types of 
cells and lipids (Frayn, 2010; Singh et al., 2002). Accumulation of lipid (mainly 
cholesterol), infiltration of macrophages, proliferation of smooth muscles and 
connective tissue are involved in the development of atherosclerosis. Cholesterol 
from LDL particles is considered to be the principle lipid of the atherosclerotic plaque 
(Santos-Gallego et al., 2008). In brief, LDL particles from the circulation migrate into 
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the arterial intima following endothelial dysfunction. After undergoing an oxidation 
process, the oxidized LDLs become very toxic. As part of the mechanism of defense, 
the oxidized LDLs are taken up by macrophages. The macrophages engulf large 
quantities of lipid and become foam cells. Foam cells then accumulate in the arterial 
walls and lead to the first visible lesion in the atherosclerosis, which is called the fatty 
streak. Moreover, monocytes move into the intima as well. They exist in the 
subendothelial area distinguished from the macrophages and engulf further lipids. 
Advanced lesions, fibrous atheromas, may be formed via the migration and 
proliferation of smooth muscle cells and increasing synthesis of connective tissue 
(collagen fibrils). Therefore, excessive cholesterol accumulation in the arterial walls is 
the initial and pivotal phenomenon in the development of atherosclerosis (Santos-
Gallego et al., 2008).  
 
1.3.3.2 Effect of HDL on CVD 
HDLs are atheroprotective and have an inverse correlation with cardiovascular 
disease risk (Kontush and Chapman, 2006).  Low concentration of HDL cholesterol 
has been revealed as an independent predictive risk factor for premature CHD. It has 
been suggested that the plasma concentration of HDL cholesterol could be a more 
powerful predictor of CHD compared with plasma total cholesterol or LDL cholesterol 
(Barter and Rye, 1996).  
 
Numerous studies have investigated the relationship between HDL cholesterol and 
CHD. The Framingham Heart Study indicated that HDL cholesterol was significantly 
inversely associated with the incidence of CHD in both men and women aged 49-82, 
and it was the predominant potent lipid risk factor (Gordon et al., 1977). Since the 
results of the Framingham study were published, several other studies have also 
found a strong inverse association between HDL cholesterol and the risk of CHD 
(Gordon et al., 1989). It has been shown that a 1 mg/dL increase in HDL cholesterol 
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can lead to a 2% decrease of CHD risk in men and 3% in women, and it can also 
result in a significant reduction of CVD mortality rates, about 3.7% in men and 4.7% 
in women. The Helsinki Heart Study, which was a primary prevention trial in 
asymptomatic middle-aged men (40-55 years old) with dyslipidaemia found a 
reduction of 34% in the incidence of CHD after 5-year treatment of gemfibrozil, which 
is a member of fibrates used to increase the concentration of HDL cholesterol (Frick 
et al., 1987). In addition, this risk reduction was independently correlated to the 11% 
increase of plasma HDL cholesterol concentration and 11% decrease in LDL 
cholesterol (Frick et al., 1987). The Veterans Affairs HDL Intervention Trial (VA-HIT) 
also involved treatment with gemfibrozil (Boden, 2000 & Robins, 2001). After 1-year 
of gemfibrozil treatment in men with known CHD (with low HDL cholesterol and low 
LDL cholesterol levels), there was a significant increase in HDL cholesterol (6%) and 
a decrease in triglyceride (31%) and total cholesterol (4%). However, there was no 
change in LDL cholesterol. Moreover, the treatment of gemfibrozil also leaded to a 
notable reduction, about 22%, in incidence of death from CHD. 
 
The protective effect of HDL against CVD is complex, and the understanding of the 
mechanism is still incomplete. The role of HDL in RCT promoting cholesterol efflux 
from cells has been most recognized to contribute to its protective effects. However, 
there are also many other properties of HDL which have been demonstrated to be 
antiatherogenic including inhibition of foam cell formation, inhibition of LDL oxidation, 
inhibition of endothelial cell dysfunction, anti-inflammation, antiapoptotic activity, 
antithrombotic activity, anti-infectious and vasodilatory activity (Figure 7) (Kontush 
and Chapman, 2006). 
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FC: free cholesterol; PL: phospholipid; AI: apolipoprotein AI; CE: cholesterol ester; HDL: high 
density lipoprotein; PON1: paraoconase; ABCA1: ATP-binding cassette transporter A1; 
LCAT: lecithin:cholesterol acyltransferase; HL: hepatic lipase; EL: endothelial lipase; CETP: 
cholesteryl ester transfer protein; PLTP: phospholipid transfer protein; SR-BI: scavenger 
receptor type BI. 
 
 
Macrophages, RCT and inhibition of foam cell formation 
The association between RCT and atherosclerosis was first reported by Ross and 
Glomset in 1973. After several decades of investigation, the relationship of RCT to 
atherosclerosis is still a hypothesis rather than an established fact (Cuchel and 
Rader, 2006). It has been clearly shown that the physiological process of RCT exists 
in all peripheral tissues. However in atherosclerotic lesions, the macrophage is the 
major cell that is overloaded with cholesterol (Cuchel and Rader, 2006).  
Macrophages are part of the body’s defence system and are involved in the immune 
response (Wang and Briggs, 2004). Macrophages also interact with T cells in the 
inflammatory response. These functions could contribute to the mechanism of the 
development of atherosclerosis associated with macrophages. As mentioned before, 
Figure 7: Biological activities of normal functional HDL  (Kontush and Chapman, 2006) 
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atherosclerosis originates by the accumulation and subsequent oxidation of LDL in 
the arterial intima. Macrophages take up the oxidized LDL and accumulate 
cholesterol, which leads to the formation of foam cells, the hallmark cell of 
atherosclerosis (Barter et al., 2004).  
 
HDL-mediated cholesterol efflux from cholesterol-loaded macrophages is one of the 
well-established antiatherogenic functions of HDL (Brewer, 2004). HDL particles 
(both HDL2 and HDL3) can promote the removal of cholesterol from macrophages by 
interaction with the SR-BI receptor, by binding to the ABCA1 transporter, or by 
passive diffusion that involves exchange of free cholesterol between mature 
spherical αHDL and the cell membrane. After obtaining the excessive cellular 
cholesterol from the arterial macrophages, HDL delivers the excess cholesterol to the 
liver, where it is excreted as bile acids.  
 
Antioxidation 
HDL can reduce atherosclerosis by protecting LDL from oxidation (Brewer, 2004). 
The antioxidative function of HDLs is determined by the antioxidative properties of 
the apolipoproteins and enzymes they carry (Kontush et al., 2003). Binding and 
removing oxidative molecules could be one of the mechanisms. The major 
apolipoprotein of HDL, apoA-I, plays an important role in inhibiting LDL oxidation by 
removing LDL-derived oxidized phospholipids and LDL lipid hydroperoxides from 
LDL and/or from artery wall cells (Navab et al., 2001; Navab et al., 2004). HDLs are 
the principle carriers of plasma lipid hydroperoxides in animal models of 
atherosclerosis and in humans (Barter et al., 2004). They are also the carriers of 
antioxidant enzymes including paraoxonase and platelet-activating factor 
acetylhydrolase (Wang and Briggs, 2004). These enzymes can degrade the harmful 
oxidized phospholipids from LDL and inhibit the oxidation of LDL. The antioxidative 
effect of HDL subclasses is mainly correlated to the inactivation of LDL lipid 
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hydroperoxides, and the heterogeneity of HDL results in a different contribution of 
distinct HDL subfractions in antiatherogenic activities (Kontush et al., 2003). It has 
been demonstrated that smaller and denser HDL3 particles perform more efficient 
inhibition of LDL oxidation than larger and lighter HDL2 particles. This could be due to 
their different cholesterol efflux capacity. HDL3 was indicated to have higher capacity 
to accept oxidized lipids than HDL2.  
 
Anti-inflammation 
An early stage of inflammatory process in atherogenesis is the adhesion of 
monocytes to endothelial cells that have been damaged or stimulated in a way to 
express adhesion proteins (Barter et al., 2004). These adhesion proteins are known 
to be expressed in the arteries that may develop atherosclerosis. The anti-
inflammatory properties of HDL are demonstrated by the inhibition of the expression 
of adhesion proteins in endothelial cells, and reduction in the recruitment of 
monocytes into the artery wall in the early stage of atherosclerosis (Barter et al., 
2004). It has been shown that smaller HDL3 has a stronger ability to inhibit to 
adhesion protein expression in the endothelial cells compared with larger HDL2 
particles (Kontush et al., 2003).  
 
Inhibition of Endothelial Dysfunction 
The protective function of HDL against atherosclerosis also includes the inhibition of 
endothelial cell dysfunction (Wang and Briggs, 2004). HDL can facilitate the 
production and release of several atheroprotective factors in the endothelial cells 
such as nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). 
The impairment of endothelium-dependent vasodilations, which is one the risk factors 
of atherosclerosis, can affect both the NO- and EDHF-mediated response. It has 
been shown that HDL can facilitate the normalization of endothelium-dependent 
vasodilation by enhancing the bioavailability of NO. This protective effect of HDL 
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associated with endothelium-dependent vasodilation can be partially attributed to the 
stimulation of expression of endothelial NO synthase by HDL (Wang and Briggs, 
2004).  
 
1.3.4 Relationship between cardiovascular disease and diet 
It has been well established that there are a variety of lipids and lipoproteins in the 
plasma that are involved in the development of CVD (Posta et al., 2006). Dietary 
factors can either enhance or reduce the risk of CVD by altering the lipid and 
lipoprotein profile. 
 
1.3.4.1 Influence of fat intake on CVD risk 
Naturally occurring dietary lipids are derived from a variety of animal and plant 
sources including animal adipose tissue (the visible fat on meat, lard and suet), milk 
and products derived from it (cream, butter, cheese and yoghurt), vegetable seeds, 
nuts, oils and products from them, eggs, fish oil and plant leaves (Mann and Skeaff, 
2007). Triglycerides account for approximately 95% of dietary lipids. Most foods 
contain a range of different fatty acids including saturated fatty acids, 
monounsaturated and polyunsaturated fatty acids (Mann and Skeaff, 2007). Trans 
fatty acids are less naturally occurring in dairy and meat products, but largely present 
in some margarines, commercially baked products and deep-fried foods as the result 
of human processing such as hydrogenation (Erkkila et al., 2008; Willett, 2006).  
 
Numerous studies have investigated the relationship between dietary fat intake and 
CVD. In brief, trans fatty acids, saturated fatty acids and cholesterol can be inversely 
associated with CVD, whereas unsaturated fatty acids including monounsaturated 
fatty acids and polyunsaturated fatty acids may have favorable effects (Posta et al., 
2006).  
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1.3.4.2 Influence of carbohydrate intake on CVD  
Carbohydrates are an important dietary source of energy (Cummings and Mann, 
2007). Carbohydrates are predominantly derived from cereals such as rich, wheat, 
maize, barley, rye, oats, millet and sorghum. They are also found in root crops like 
potatoes, sweet potatoes, cassava, yams and taro, sugar cane and beet, pulses, 
vegetables, fruits and milk products. Carbohydrates are mainly synthesized by plants 
from water and carbon dioxide by utilizing the sun’s energy and have a general 
formula (CH2O)N. There is also a minority synthesized by animals such as lactose in 
milk. In humans, carbohydrates can be stored in muscle and liver as glycogen for 
energy. Carbohydrate-containing foods can supply about 40% to 80% total energy 
intake in the diet, which varies according to culture and economic status (Cummings 
and Mann, 2007). Carbohydrate-containing foods are also crucial sources of protein, 
vitamins and minerals. Carbohydrates are substances with diverse chemical and 
physiological properties. The primary classification of dietary carbohydrates is based 
on molecular size, which is characterized by the degree of polymerization (DP), the 
type of linkage (α or non-α), and the individual monomers (Table 5) (Cummings and 
Mann, 2007). 
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Table 5: Classification of dietary carbohydrates based on molecular size 
 
Class (DP) Subgroup Principal components 
Sugars (1-2) Monosaccharides Glucose, fructose, galactose 
Disaccharides Sucrose, lactose, maltose, trehalose 
Polyols (sugar alcohols) Sorbitol, mannitol, lactitol, xylitol, 
erythritol 
Oligosaccharides 
(3-9) (short-chain 
carbohydrates) 
Malto-oligosaccharides 
(α-glucans) 
Maltodextrins 
Non α-glucans 
oligosaccharides 
Raffinose, stachyose, fructo- and 
galacto- oligosaccharides, 
polydextrose, inulin 
Polysaccharides 
(≥10) 
Starch (α-glucans) Amylose, amylopectin, modified 
starches 
Non-starch 
Polysaccharides 
Cellulose, hemicellulose, pectin, 
arabinoxylans, glucomannans, plant 
gums and mucilages, hydrocolloids 
Adapted from Cummings and Mann (2007). 
 
 
Monosaccharides and disaccharides are usually referred to as sugars. The major 
monosaccharides include glucose, fructose and galactose. Free glucose and fructose 
exist naturally in honey and fruits, and fructose is the sweetest among all 
carbohydrate-containing foods (Cummings and Mann, 2007). The major 
disaccharides include sucrose and lactose. Sucrose widely occurs in fruits, berries 
and vegetables and can be extracted from sugar cane or beet. Lactose is the 
principal sugar in the milk. Based on the physical location in the foods, sugar can 
also be subdivided into intrinsic and extrinsic sugars (Stephen et al., 1995). Intrinsic 
sugars refer to the sugar located inside the cell walls of plants, while extrinsic sugars 
refer to those located outside the cell walls and are added to the foods. Intrinsic 
sugars are found in fruits and vegetables as glucose, fructose and sucrose, and 
extrinsic sugars are found in processed foods like fruit juices. Lactose in milk does 
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not exist within the cell walls, however milk has important nutritional properties. 
Therefore, the term non-milk extrinsic sugar, which was firstly introduced in the UK, 
has been used to distinguish the group of sugars other than intrinsic and milk sugars 
that should be restricted in the diet (Stephen et al., 1995). Starch is the major 
constituent of carbohydrates and is composed of two different types of glucan 
polymers, amylose and amylopectin (Lafiandra et al., 2014). They occur in staple 
foods such as rice, bread, cereal and potatoes. Non-starch polysaccharides are 
considered as the carbohydrate component of dietary fibre. There are also some 
other terms have been used to describe carbohydrates, including complex 
carbohydrate, dietary fibre and glycaemic carbohydrate, which are based on their 
physiological properties with different effects on health.  
 
The association between dietary carbohydrate intake and risk of CVD has been 
examined in a dietary survey among Korean adults. High consumption of 
carbohydrate, > 70% of energy, is associated with higher levels of BMI, blood 
pressure, fasting glucose, plasma triglyceride and LDL cholesterol in Korean women 
aged 20-69 years (Park et al., 2010). Moreover, high carbohydrate intake was 
significantly correlated with a low level of HDL cholesterol and type 2 diabetes in 
women. However in men, high carbohydrate intake was only inversely associated 
with total cholesterol in plasma. Glycaemic index (GI) is a measurement of glucose 
and insulin response after eating, which is related to the rate of digestion and 
absorption. Cabohydrates that are absorbed rapidly and induce a high postprandial 
glucose and insulin response are considered to be high GI carbohydrates. Glycaemic 
load (GL), which is calculated from GI and carbohydrate content, presents both 
quantity and quality of carbohydrate of a specific food. The relationship between GI, 
GL and risk of CVD has also been investigated. The results from a cohort 
prospective study has shown that the consumption of diets with high GL and high GI 
could increase the risk of CVD in middle-aged Dutch women, particularly in those 
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who were overweight (Beulens et al., 2007). It has also been found that higher 
dietary GL and GI were associated with a higher likelihood of developing obesity in 
Korean women but not in men (Youn et al., 2012).  
 
Restriction of dietary carbohydrate has been found to induce a beneficial effect on 
reducing CVD risks by improving hepatic, intravascular and peripheral processing of 
lipoproteins, altering fatty acid composition and reducing inflammation (Volek et al., 
2008). A six-week dietary carbohydrate restriction study was carried out in statin 
users (Ballard et al., 2013). At the end of the intervention, carbohydrate intake was 
reduced nearly 5 times compared to baseline, which accompanied with reduced 
energy intake. Body weight was reduced by 4% in 6 weeks, representing an average 
of 3.6 kg. Both systolic and diastolic blood pressure was decreased after 6-week 
carbohydrate restriction. The levels of serum triglyceride and insulin were also 
decreased. It was suggested that among people on statin therapy, 6 weeks dietary 
carbohydrate restriction could achieve additional improvements in metabolic and 
improved vascular health, such as increased insulin sensitivity and resistance vessel 
endothelial function, and decreased blood pressure and plasma triglycerides. 
Additionally, increased dietary fibre intake has been reported to have the beneficial 
effects on prevention of metabolic and cardiovascular diseases (Liu et al., 2002). It 
has been suggested that people who had higher dietary fibre intake by consuming 
three or more portions of whole grain cereals and their products per day had a lower 
risk of developing obesity, type 2 diabetes and CVD (Lafiandra et al., 2014). 
 
Apart from its role as a source of energy, carbohydrate has an important function in 
regulating lipid metabolism (Volek et al., 2008). Dietary carbohydrate can affect 
insulin secretion and the availability of energy substrates like free fatty acids and 
glycogen. Dietary carbohydrate is usually digested and absorbed as glucose and 
fructose, and fructose is considered to be more lipogenic (Volek et al., 2008). Recent 
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data has suggested that fructose consumption is related to increased risk of CVD 
and type 2 diabetes including visceral obesity, insulin resistance and lipid dysfunction 
(Stanhope and Havel, 2010; Basciano et al., 2005). A high flux of fructose in the liver 
can cause the disturbance of glucose metabolism, and lead to a greatly increased 
synthesis of de novo lipogenesis (DNL) and TG by the enhanced flux of glycerol and 
acyl portions from fructose catabolism (Basciano et al., 2005). The effect of fructose 
on risk factors of CVD has been investigated by comparing the influence of 
consuming glucose, and fructose high fructose corn syrup (Stanhope et al., 2011). 
Men and women aged 18-40 years with BMI 18-35 kg/m2 consumed usual al libitum 
diets along with 3 servings per day of glucose, fructose or high-fructose corn syrup 
sweetened beverages, which accounted for 25% of energy requirement. After 2 
weeks intervention, the consumption of fructose and high-fructose corn syrup 
sweetened beverages increased postprandial triglycerides, LDL cholesterol and 
apolipoprotein B concentration. However, these effects were not found in the group 
who consumed glucose.  
 
The dietary intervention study presented in this thesis was a part of a BBSRC funded 
trial, in which two iso-energetic diets with high and low non-milk extrinsic sugar 
content were designed and implemented in middle-aged Caucasian men who were at 
risk of metabolic syndrome with low or moderately increased liver fat. As mentioned, 
dietary carbohydrate intake can influence the secretion of insulin, DNL, and the 
plasma levels of triglyceride, LDL cholesterol and apoB, and is related to the risks of 
CVD. Moreover, it has been suggested that controlling the quality of dietary 
carbohydrate via reducing extrinsic sugar, such as fructose and sucrose, and 
increasing non-starch polysaccharides (dietary fibre), may have a beneficial 
improvement on CVD risks. Therefore, the whole trial aimed to determine the 
influence of the quality of dietary carbohydrate on lipoprotein metabolism including 
the formation of high and low risk lipoprotein phenotypes, VLDL kinetics (the 
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synthesis of VLDL-TG and VLDL apoB) and LDL kinetics (the production of small 
dense LDL). It also aimed to determine the effect of the quality of dietary 
carbohydrate on the sources of liver fat, whether VLDL-TG is derived from increased 
DNL and /or systemically derived NEFA (adipose tissue and peripheral lipolysis). The 
lipoprotein kinetics, DNL and systemic NEFA kinetics were measured by using stable 
isotope techniques. Furthermore, the whole trial also aimed to evaluate the effect of 
the high and low non-milk sugar diets on several cardio-metabolic risks including 
body weight, fasting plasma lipids, glucose and insulin. In the whole trial, it was 
hypothesized that compared to a low non-milk extrinsic sugar diet, a diet with high 
non-milk extrinsic sugar would increase plasma TG level and the production of LDL 
in subjects at risk of metabolic syndrome and a moderate increase in liver fat, and 
that the changes in plasma TG and lipoproteins would be due to increased VLDL-TG 
and/or VLDL apoB, and increased DNL and/or systemically derived NEFA. I was not 
involved in this BBSRC funded trial except for the analysis of the HDL samples. The 
study presented in this thesis was specifically focused on the effect of the high and 
low non-milk extrinsic sugar diets on total HDL kinetics which was measured by using 
a stable isotope technique in a small group of subjects (n=6) from the whole cohort 
(n=25). Some of the results presented in Chapter 3, including subject’s 
characteristics, lipid and lipoprotein profile, insulin and glucose, dietary intakes and 
lipase activities, were measured by Dr. Aryaty Ahmed and Dr. Najlaa Alsini. 
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1.4 Application of isotope techniques in lipoprotein metabolic studies 
1.4.1 Isotopes techniques 
Isotopes refer to the atoms of a chemical element with the same atomic number and 
similar chemical properties but different atomic weights and physical properties, such 
as 11C, 12C, 13C and 14C (Wong and Abrams, 2003). Some isotopes are radioactive 
(unstable), like 11C and 14C while others are non-radioactive (stable), like 13C and 12C 
(Sunehag and Haymond, 2003). In most cases, only the stable isotopes of the 
elements exist in natural environment (Wong and Abrams, 2003). The most widely 
used stable isotopes in metabolic tracer studies are 2H (hydrogen), 13C (carbon), 15N 
(nitrogen) and 18O (oxygen), and their natural abundances are 0.015%, 1.11%, 
0.36% and 0.204% respectively (Chan et al., 2004; Sunehag and Haymond, 2003).  
 
Lipoproteins are in a state of constant flux. Measurements of the plasma 
concentration of lipids and lipoproteins are traditionally applied to define the 
abnormalities of lipoprotein metabolism. However, lipoprotein metabolism is complex 
and abnormal plasma concentrations can be due to elevated or reduced production 
and/or catabolism rates of different lipoprotein particles. Therefore, static 
determinations of lipid and lipoprotein concentrations are unable to provide the 
information underlying the pathogenic mechanisms. The technique utilizing either 
radioactive or stable isotope tracers in kinetic studies is well established, and 
provides an insight for understanding lipoprotein metabolism and mechanisms of 
metabolic disorders in vivo (Chan et al., 2004).  
 
In research that investigated lipoprotein kinetics in human, such as HDL, both 
exogenous and endogenous labelling methods have been used (Ooi et al., 2006). 
Radioactive isotopes have been commonly used for exogenous labelling, which are 
less used now, whereas endogenous labelling can be performed with either 
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radioactive isotopes or stable isotopes. Radioactive isotopes have the advantage that 
they can be easily detectable in blood, urine or faeces. However, they are a potential 
hazard due to the internal radiation exposure. Hence, radioactive isotopes are not 
suitable for use in the vulnerable groups, such as infants and pregnant women 
(Sandstrom, 1996).  
 
The methodology of using stable isotopes as tracers to label amino acids has been 
established for more than two decades, and now it is widely used for endogenous 
labelling of proteins in lipoprotein metabolism studies (Chan et al., 2004). Compared 
to radioactive isotopes, the application of stable isotopes as endogenous tracers to 
investigate the metabolism of lipoprotein in vivo has several advantages. Firstly, it is 
safer and can be used in individuals of all ages, and is especially useful in studies 
among infants, pregnant and lactating women. Secondly, stable isotopes do not 
decay, so they can be detected in tissues and blood for longer periods of time. By 
using endogenous labelling, there are no worries about lipoprotein modification 
during the isolation and labelling process. Furthermore, it is possible to measure the 
production rate of several different proteins at the same time since all newly 
synthesized proteins will be labelled (Dwyer et al., 2002; Sandstrom, 1996).  
 
The principle of the endogenous stable isotope labelling technique is to introduce the 
tracer into the biological system, such as the whole body or organ. The tracer is 
incorporated into a macromolecule and the ratio of tracer to tracee in the 
macromolecule is measured (Chan et al., 2004). Tracer refers to the labelled 
substance, such as stable isotopically labelled leucine, which is incorporated into the 
macromolecule under investigation. Tracee refers to the unlabelled substance. Since 
lipoproteins can be labeled in their lipid and/or protein components, stable isotopic 
labelled amino acids have been predominantly used as tracers to label 
apolipoproteins in studies of lipoprotein metabolism. The tracer can be introduced 
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into the circulation through intravenous infusion, bolus injection and oral 
administration. Ideally, a tracer needs: 1) to have properties identical to the tracee in 
terms of physical, chemical and biological characteristics; 2) to be quantitatively 
detected by the investigators; 3) does not disturb the system under study (Chan et 
al., 2004). L-[5,5,52H3] leucine, L-[1-13C] leucine and [13C6] phenylalanine are the 
stable isotopes that are most commonly used for endogenous labeling in the 
assessment of HDL apoA-I kinetics (Ooi et al., 2006; Rashid et al., 2006). When 
leucine is used as a tracer, the synthesis rate of protein can be determined if α-
ketoisocaproate (KIC), which provides an estimate of the precursor pool, is 
measured. 
 
Fisher et al., (1995) investigated the kinetics of apoA-I isolated from HDL by using 
three different clinical protocols: bolus intravenous injection of [3H] leucine; bolus 
injection of [2H] leucine; and primed dose followed by 12 hours constant intravenous 
infusion of [2H] leucine. Both healthy subjects and subjects with familial 
hypercholesterolaemia were studied. Blood samples were taken over two weeks. 
Fisher et al. proposed that there were two apoA-I pools, a rapid turnover pool with a 
residence time of less than 1 day and a slow turnover pool which tracer enters after a 
delay of less than half day. The slowly turning-over pool contained the predominant 
mass of apoA-I and was the major determinant of the residence time of apoA-I. A 
larger quantity of apoA-I transported through the fast pathway. However, the mass of 
fast pool was relatively lower than the slow pool due to its rapid turnover. Fisher et 
al., (1995) suggested that apoA-I entered into both fast and slowly turning-over pools 
in plasma. Therefore, the kinetic data can be analysed by assuming either input 
pathways to each pools are separated or the fast pool is the precursor to the slow 
pool. 
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1.4.2 Detection of isotope enrichment by GC-MS 
A GC-MS instrument consists of two components: the gas chromatograph (GC) and 
mass spectrometer (MS) (Sunehag and Haymond, 2003). The tracer: tracee ratios 
are measured by GC-MS. Mixtures of amino acids from a protein hydrolysate are 
isolated as individual amino acids by GC, which are subsequently identified and 
quantified by MS (Figure 8).  
 
 
To detect the isotopic enrichment by GC-MS, amino acids under analysis need to 
undergo a process called derivatization to produce complex molecules, which are 
more volatile (Sunehag and Haymond, 2003). The derivatized amino acids are 
vapourised at high temperature in the injector of the GC, and subsequently they are 
carried through the capillary column by the inert gas under pressure. The carrier gas 
can be helium, hydrogen, nitrogen or methane. The amino acids that need to be 
analysed are separated from other constituents of the sample in the column based 
on their volatility. The separation is achieved by the temperature-regulated interaction 
between the amino acids in the mobile phase (the carrier gas) and the stationary 
phase coating the inner surface of column.   
Figure 8: Principles of gas chromatography-mass spectrometry (Sunehag and Haymond, 
2003) 
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After the separation, the samples move to the ion source in the MS, where they are 
ionized. Different ionization methods can be applied to identify and quantify the 
substance of interest, including electron ionization mode (EI) and chemical ionization 
mode (CI) (Sunehag and Haymond, 2003). In both modes, the electrons are released 
from the heated filament and adhere to the positive charged plate – the anode. In the 
EI mode, the ionization of the molecule is achieved by direct bombardment with 
electrons. In the process of EI, the molecule is broken into fragments when excess 
energy is applied. In the CI mode, different gases, such as methane, ammonia and 
isobutane, can be introduced to the ion source as the reagent gas. In the present 
study, the ionization of the molecule is achieved by reaction with methane ions. In the 
process of CI, methane molecules are hit by electrons and generate different 
methane ions. Methane ions react with sample molecules and ionize them. Since 
positive and negative ions can be produced in the reactions, CI mode is divided into 
two different types, positive chemical ionization (PCI) and negative chemical 
ionization (NCI). Compared with the EI mode, the CI mode is a lower energy process, 
and it can result in larger fragments of the analyte.  
 
Following ionization, the ions that need to be analyzed move to the focusing lenses, 
which accelerate the ions for transporting to the mass analyzer. The ions are filtered 
by mass analyzer according to their mass. The quantity of an ion with specific mass 
is then detected and recorded by a computer (Sunehag and Haymond, 2003).  
 
In this project, stable isotopic techniques will be used to measure HDL apoA-I 
kinetics. The most widely used method for this measurement, a primed continuous 
infusion will be used to investigate the effect of dietary sugar intake on total HDL 
apoA-I metabolism. Since HDL has a long half-life (5 days), measuring HDL apoA-I 
kinetics on a single day may not provide an accurate measurement. In addition, since 
HDLs are heterogenous particles, measuring total HDL apoA-I does not provide a 
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true measure of HDL metabolism. This project will attempt to address these two 
issues by measuring HDL subclass kinetics, using an intravenous injection of 13C 
leucine and measuring leucine enrichment over several days. An optimal sampling 
protocol will be developed and then this will be applied to measure preβHDL and 
αHDL kinetics, and HDL2 and HDL3 kinetics in a small group of subjects. 
 
1.5 Aims 
There are several aims of this project are: 
1) To investigate the effect of a high sugar and low sugar diet on total HDL apoA-I 
metabolism in men at risk of metabolic syndrome. 
2) To develop an optimal blood sampling protocol to measure HDL2, HDL3, preβHDL 
and αHDL flux in vivo in humans. 
3) To measure apoA-I synthesis and clearance rates of HDL subclasses, including 
HDL2, HDL3, preβHDL and αHDL, in healthy men and women using stable isotope 
techniques. 
 
1.6 Hypothesis 
1) HDL cholesterol and apoA-I will be lower and HDL apoA-I FCR will be higher after 
a high sugar diet than a low sugar diet. 
2) A two-week blood sampling protocol will be a feasible method to measure HDL2, 
HDL3, preβHDL and αHDL kinetics. 
3) The FCR and PR of HDL2 apoA-I will be higher than the FCR and PR of HDL3 
apoA-I. 
4) The FCR of preβHDL apoA-I will be higher than the FCR of αHDL apoA-I, and the 
PR of preβHDL apoA-I will be lower than PR of αHDL apoA-I. 
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Chapter 2: Methodology 
2.1 Clinical protocol 
2.1.1 The effect of a low and high extrinsic sugar diet on HDL kinetics 
2.1.1.1. Subjects 
Ethical approval for the study was obtained from the Surrey NHS Research Ethics 
Committee, and University of Surrey Ethics Committee.  
 
Caucasian men aged 40-65 with BMI 26 – 32 kg/m2 were recruited in a dietary 
intervention study. Different approaches were applied in the recruitment. The major 
approach was through an existing Clinical Research Network with GP surgeries in 
the Surrey, which provided a valuable pre-screening tool including BMI, plasma 
lipids, blood glucose, blood pressure, current health, medication and socio-
demographic status. The other approaches were through direct contact with local 
authorities, companies, schools and colleges by letters and email, distributing leaflets 
in the offices, shops and local residential areas, and displaying posters on local 
community notice boards. Men who expressed an interest were sent a participant 
information sheet (Appendix 1). 
 
Subjects had two screening visits.  At the first screening visit, subjects were asked to 
come to the CEDAR Centre, Royal Surrey County Hospital (RSCH) after an 
overnight fast. Subjects’ general health information including age, medical history, 
current medication, smoker/non smoker, were recorded. Weight, height and blood 
pressure were measured, and blood samples were taken to measure the 
haematology (haemoglobin, white blood cell count, platelet count), plasma 
triglyceride, total cholesterol and blood glucose. Subjects who had type 2 diabetes, 
renal disease, hepatic disease (except non-alcoholic fatty liver disease), unstable 
body weight in the past three months, and alcohol consumption more than 2 
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units/day were excluded. Subjects who were taking medication that lowered blood 
lipids, had any metal implants or claustrophobia were also excluded from the study. 
Participants who fulfilled the inclusion criteria then attended the second screening at 
Hammersmith Hospital in London for the magnetic resonance spectroscopy (MRS) 
examination to determine their percentage of liver fat. Subjects who had either low 
liver fat < 5% or high liver fat 7.5% - 30% were recruited. 
 
2.1.1.2. Study protocol 
The study was a controlled, randomized crossover trial with two 12 week dietary 
interventions, which were low and high sugar diets. The two diets had the same 
carbohydrate content in weight and total percentage energy but differed in the 
content of non-milk extrinsic sugars, high non-milk extrinsic sugar vs. low non-milk 
extrinsic sugar diet. The total carbohydrate content in the diets was set to 50%. 
 
Before commencing the first dietary intervention, participants underwent a 4 week 
run-in diet. They were asked to maintain their habitual diet and level of physical 
activity. At the end of the 4 weeks, subjects came to the Cedar Centre for a fasting 
blood sample and subsequently they were allocated randomly to either the high or 
low non-milk extrinsic sugar diet for 12 weeks. Two-thirds of the participants’ habitual 
total CHO intake was replaced by the study foods (≈ 180 g/day), and the remaining 
one-third of total CHO was derived from the subjects’ habitual diet. Foods with sugar 
content ≥ 40% of total CHO per portion were classified as high sugar foods, while 
foods with ≤ 10% total CHO was classified as low sugar foods. Foods with sugar 
content between 10-40% of total CHO per portion were excluded from study food list. 
Dietetic counseling was given to individuals before the run-in diet and at two weekly 
intervals during the study. Participants were asked to fill in 3-day diet diaries (2 on 
weekdays and 1 on weekend) at 0, 6 and 12 week. Some instructions for helping 
participants to fill in the diet diaries, such as reference food portion size photos, 
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examples of describing type and amount of food, and how to find information on food 
labels, were provided in the diet diary. An example of a completed diet diary was 
given as well, and participants were required to provide as much detail as possible 
about the foods they consumed. Subjects were asked to maintain their habitual level 
of physical activity throughout the study.  
 
At the end of the first 12 week intervention, participants were asked to come to the 
Cedar Centre at 7:30 am after an overnight fast, for a 10 hour metabolic study. 
Participants needed to remain fasting during the study and only water was allowed. 
The stable isotope, L-[1-13C] leucine (Cambridge Isotopes, 15mg/ml, 13C enrichment 
99%) was injected intravenously as a priming dose (1 mg/kg) following by a constant 
infusion (1 mg/kg/h) for 10 hours with an IVAC 60 pump (IVAC, Hampshire, UK). 
Blood samples were taken at baseline and every hour up to 10 hours for 
measurement of apoA-I enrichment. The time points 0, 5 and 10 hour were used to 
measure the plasma lipid and apoA-I concentration. Blood samples for measuring α-
KIC were taken at intervals during the study (0, 5, 15, 30, 60, 120, 180, 360, 480 and 
600 min).  
 
Subjects were placed on a 4 week wash-out period of their habitual diet before 
crossing over to the alternative diet for another 12 weeks. At the end of the second 
intervention, the metabolic study was repeated at the CEDAR Centre (Figure 9). 
Participants were also sent for magnetic resonance spectroscopy (MRS) at the 
Hammersmith Hospital to assess their percentage of liver fat at the end of each 
intervention.  
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MRS: magnetic resonance spectroscopy; Visit 1, screening visit; Visit 2, liver fat scan; Visit 3/5, start of study; Visit 4/6, kinetic study day  
 
Figure 9: Study design of low and high sugar diet intervention study (Adapted from Ahmad (2012))
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2.1.2 Development of the study design for HDL subclass kinetic study (Pilot 
study) 
Pilot studies aimed to develop an optimal blood sampling protocol to measure HDL2, 
HDL3, preβHDL and αHDL metabolism in vivo were carried out. 
  
Ethical approval for the study was obtained from the Surrey NHS Research Ethics 
Committee, and University of Surrey Ethics Committee. All aspects of the study were 
explained thoroughly to the subjects, and the subjects were given the opportunity to 
ask questions. Subjects were provided with detailed information in a participant 
information sheet (Appendix 2). Consent forms were signed by all the subjects before 
their participation. 
 
Three healthy women aged 18-70 years were recruited. The subjects were asked to 
fill in a short questionnaire about their general health (Appendix 3). This 
questionnaire was for the purpose of confirming that the subjects had stable weight in 
the past three months and did not have a history of heart disease, diabetes, liver 
disease, kidney disease, hormone disorders, eating disorders, drug or alcohol abuse, 
and they did not have any food allergies or intolerances and were not taking any 
medication known to alter lipid and glucose metabolism, body weight or appetite. 
They participated in one clinical study that involved five or six visits to the CEDAR 
Centre, Royal Surrey County Hospital. The first visit lasted for 10 hours, and the 
other visits took about 15 minutes. 
 
Subjects were required to be fasted overnight (approximately 10-12 hours) for each 
visit. At Visit 1 they remained in a fasting state during the 10 hour study while a 
moderate amount of water was allowed. Height and blood pressure were measured. 
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Weight and body fat were measured by a Tanita Body Composition Analyzer BC-418 
MA (Tanita UK Ltd, Yiewsley). 
 
A flexible plastic tube was placed in the antecubital vein in one arm for blood 
sampling. After taking the baseline blood sample, L- [1-13C] leucine (Cambridge 
Isotopes, 15mg/ml prepared by St Thomas’ Hospital Pharmacy, 13C enrichment 99%) 
was injected intravenously into the contralateral antecubital vein over 3 minutes as a 
bolus dose of 5mg/kg (Dwyer et al., 2002). Following the administration of leucine, 
blood samples were taken frequently in the first hours and then at intervals up to 600 
minutes. This visit was identical in all the pilot studies.  
 
A single blood sample was taken in the morning with the subject in a fasted state at 
the following times - 24, 48, 72 and 120 hours (Day1, Day2, Day3 and Day5) (Visit 2, 
3, 4, 5) in the first pilot study for measurement of HDL kinetics. A single blood sample 
was taken at 24, 48, 72 and 144 hours (Day1, Day2, Day3 and Day6) (Visit 2, 3, 4, 5) 
in the second pilot study, and at 24, 48, 72, 144 and 240 hours (Day1, Day2, Day3, 
Day6 and Day10) (Visit 2, 3, 4, 5, 6) in the third pilot study. 
 
2.1.3 HDL subclass kinetics study 
2.1.3.1 Subjects 
Ethical approval for the study was obtained from the Surrey NHS Research Ethics 
Committee and University of Surrey Ethics Committee. People who express an 
interest were sent a participant information sheet (Appendix 4). All aspects of the 
study were explained thoroughly to the subjects, and the subjects were given the 
opportunity to ask questions. A signed consent form was obtained from all subjects 
before their participation (Appendix 5). 
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Six healthy males and females aged 30-45 with a BMI of 18.5 – 25 kg/m2 were 
recruited for this study. The participants were recruited by advertisement through the 
website of the University of Surrey (SurreyNet), local hospitals, public and private 
sector by either poster or email, and through GP Practices. Subjects were asked 
some questions related to their general health in a phone call. The questions were 
similar to those on the questionnaire that was used in the pilot study (Appendix 6). 
Height, weight, blood pressure, waist and hip circumference, and body fat were 
measured at a screening visit. Blood samples were taken to measure serum insulin, 
plasma glucose, triglyceride, total cholesterol and HDL cholesterol levels.   
 
Subjects with cardiovascular or endocrine disease (such as unstable ischaemic heart 
disease), diabetes and diabetic complications, uncontrolled hypertension, hepatic 
and renal disorders, unstable weight in past three month, or taking any medication 
known to affect lipid metabolism, glucose metabolism, body weight or appetite, or 
having hormone therapy were excluded from the study. 
 
2.1.3.2 Study protocol 
The study involved 7 visits in total, and all the visits were in the CEDAR Centre, 
Royal Surrey County Hospital. Subjects were required to be fasted overnight 
(approximately 10-12 hours) before all the visits. On the first visit, weight, height, BMI 
and bioelectrical impedance analysis of body composition were measured, followed 
by a 10 hour study. The dose of L-Leucine [1-13C] leucine (15mg/ml, 13C enrichment 
99%) was 8mg/kg and it was injected intravenously over 3 minutes as a bolus after 
taking a baseline blood sample. Blood samples were taken at 40mins and every hour 
(except 7 hour and 9 hour) up to 10 hours. Six more single fasting blood samples 
were taken in the morning during the next 2 weeks, Day1, Day3, Day7, Day9, Day10 
and Day14 (Visit 2, 3, 4, 5, 6, 7) for further measurements of leucine enrichment 
(Figure 10). Blood samples at five time points (baseline, 10h, Day1, Day7, Day14) 
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were used to measure the concentration of plasma lipids and apoA-I. Blood samples 
for measuring α-ketoisocaproic acid (α-KIC) which provides an estimation of 
intracellular leucine enrichment were taken frequently in the first hour (0, 5, 10, 20, 
30, 40, 60 min), and then at 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h and 10h. Blood 
samples were taken via sterile syringes and collected into the tubes containing 
different anticoagulants. Plasma for HDL subclasses separation was collected with 
EDTA tubes, and plasma for α-KIC was collected with tubes containing heparin and 
serum for insulin was collected in the tubes containing gel for serum. 
 
Participants in both groups did not need to change their diets or other lifestyle 
behaviors. However, they were asked to avoid vigorous exercise in the 48 hours 
before the long study day (Visit 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intravenous bolus 
of 13C Leucine  
(8mg/kg) 
0         1        2        3       4      5      6        8     10h   1    3      7     9    10        14 day 
Baseline 
sample 
Blood  Blood sampling  me points for leucine enrichment 
Sample for a-KIC 
Figure 10: Clinical study protocol and sampling time points 
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2.2 Analytical methodology 
The laboratory procedures for measuring HDL subclass metabolism are according to 
the method developed by Li et al. (2012). 
 
2.2.1 Materials 
The stable isotope L-Leucine [1-13C] (15mg/ml, 13C enrichment 99%) were obtained 
from Cambridge Isotopes (USA) and prepared by the Pharmacy Department, St 
Thomas’ Hospital (UK). The sterile tubes containing different anticoagulants for 
collecting blood samples were purchased from Becton Dickinson UK Limited (Oxford, 
UK). 
 
Chemical reagents used in the lab including hydrochloric acid, acetic acid, diethyl 
ether, acetonitrile (Far UV), toluene, ethyl acetate, ammonia solution S.G.0.88, 
(35%), and sodium dodecyl sulphate were obtained from Fisher Scientific UK Ltd 
(UK). Ethanol (100%) was obtained from Chemistry Store (University of Surrey, UK). 
Methanol (for HPLC) and Tricine (98%, for biochemistry) were purchased from Agros 
Organics (UK). Chemical reagents including 3-Methylbutanol, N,N,N`,N`-
Tetramethylethylene-diamine, agarose (Type VI-A), glycine (for electrophoresis 
≥99%), phosphate buffered saline (pH 7.4), bromphenol blue, trizma base (Primary 
standard and buffer ≥99.9%), sodium chloride, ammonium persulfate, trifluoroacetic 
acid, trifluoroacetic anhyfride, N-tert-butyldimethylsily-N-methyltrifluoroacetiamide 
(>97%) and O-phenylenediamine were obtained from Sigma-Aldrich Ltd (UK). 
Coomassie brilliant (Blue R-250), calcium lactate and tween 20 were purchased from 
BDH, VWR International Ltd (UK). AG 50W-X8 resin, acrylamide (Bis Solution, 40%) 
fixative enhance concentration, development accelerator reagent, silver stain Plus kit 
(sliver complex solution, reduction moderator solution and image development 
reagent), AP conjugate substrate kit were obtained from Bio-Rad Laboratories (USA). 
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2.2.2 Summary of laboratory processes to measure leucine enrichment in total 
HDL, and HDL2 and HDL3 apoA-I 
2.2.2.1 Separation of plasma 
Plasma was separated from blood cells by using centrifugation at 3000 rpm for 10 
minutes at 4qC. Plasma samples for the separation of HDL2 and HDL3 fractions were 
stored in a cold cabinet at 4qC overnight and the separation begun the following 
morning. Plasma samples for the separation of αHDL and preβ HDL, and 
measurements of α-KIC enrichment, lipids and HDL concentration, glucose and 
insulin levels, were stored at -80qC until used. Measurement of leucine enrichment in 
total HDL, HDL2 and HDL3 apoA-I required a series of laboratory processes, which 
are shown in Figure 11. 
 
 
Figure 11: Laboratory processes to separate and measure leucine enrichment in total 
HDL, HDL2 and HDL3 apoA-I 
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2.2.2.2 Removal of VLDL, IDL and LDL 
2.2.2.2.1 Isolation of VLDL 
Three ml plasma from each sample at the different time points was transferred into 
labeled ultraclear ultracentrifugation tubes (U/C) (Beckman Instrument, USA). 
Approximately 1.5 ml of saline containing 0.1% Na2EDTA (d= 1.006 g/ml) was added 
into each tube to make the total volume 4.5 ml. The volume was adjusted to the 
upper line on the tube shoulder. The tubes were capped, mixed well, and loaded in 
the pre-chilled type 50.4 Ti rotor. Samples were spun at 37000 rpm (147425 × g) by 
an Optima LE-80K ultracentrifuge (Beckman Instrument, USA) for at least 16 hours 
at 4qC. After ultracentrifugation, approximately 1.2 ml of the top layer containing 
VLDL was cut by a centrifuge tube cutter (Beckman Instrument, USA) and removed. 
 
2.2.2.2.2 Isolation of IDL and LDL 
After removing VLDL, the remaining samples at the bottom of the cut U/C tubes were 
transferred into the new U/C tubes containing 0.5 ml 1.519 g/ml NaBr solution. The 
total volume was adjusted to the upper line on the tube shoulder by topping up with 
saline containing 0.1% Na2EDTA (d= 1.006 g/ml). The tubes were capped, mixed 
and loaded into the pre-chilled type 50.4 Ti rotor. Samples were spun at 37000 rpm 
for at least 20 hours at 4qC. After centrifugation, approximately 1.2 ml of the top layer 
containing IDL and LDL was cut and removed. 
 
2.2.2.3 Separation of total HDL fraction 
After cutting VLDL, IDL and LDL, the remaining samples at the bottom of the cut U/C 
tubes were transferred into the new U/C tubes containing 1.5 ml 1.504 g/ml NaBr 
solution. The density was adjusted to 1.21 g/ml to make a total volume of 4.5 ml. The 
final volume was adjusted to the upper line on the tube shoulder. The tubes were 
capped, mixed well and then loaded into a pre-chilled U/C rotor. The tubes were 
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placed to make the rotor balanced. The samples were ultracentrifuged at 40000 rpm 
(172301 × g) for at least 24 hours at 4°C.  
 
After the spinning, the top layer that contained the total HDL fraction was cut by the 
centrifuge cutter. The cut part of the U/C tube and the well of the cutter were rinsed 
with saline containing 0.1% Na2EDTA (d=1.006 g/ml). Both the top layer and the 
washing solutions were collected in a clean glass tube and stored at -20°C for further 
analysis. For the samples used to determine the concentration of total HDL fractions, 
the cut samples and the washing solution were transferred to a 2 ml mini-volumetric 
flask to make the total volume to 2 ml, and then collected into the clean glass tubes. 
Samples were kept at -20°C until used. 
 
2.2.2.4 Separation of HDL2 and HDL3 fractions 
2.2.2.4.1 Separation of HDL2 fractions 
After removal of IDL and LDL, the remaining samples at the bottom of the cut U/C 
tubes were transferred to new U/C tubes to which had been added 1.5 ml 1.249 g/ml 
NaBr density solution. The total volume was adjusted to the upper line on the tube 
shoulder. The tubes were capped, mixed, put into a pre-chilled 50.4 Ti rotor and spun 
at 40000 rpm (172301 × g) for at least 48 hours at 4qC. After ultracentrifugation the 
top layer (HDL2 fraction), approximately 1.2 ml, was cut by the centrifuge cutter. The 
cut part of the U/C tube and the well of the cutter were washed with saline containing 
0.1% Na2EDTA (d= 1.006 g/ml). Both the cut samples and the washing solutions 
were collected in duplicate in two clean glass tubes and stored at -20qC until used. 
 
For the samples used to measure the concentration of HDL2 fractions, the top layer 
was collected into a 2 ml mini-volumetric flask (Sigma-Aldrich Ltd, UK) using a plastic 
pipette. The cut part of the U/C tube and the well of the cutter were washed with 
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saline containing 0.1% Na2EDTA (d= 1.006 g/ml). The washing solution was 
transferred to the volumetric flask as well to make the total volume to 2 ml. The 
samples were then mixed well, placed into two new glass tubes and stored at -20qC 
until further analysis. 
 
2.2.2.4.2 Separation of HDL3 fractions 
After removing the HDL2 fraction, the remaining sample at the bottom of the cut U/C 
tube was transferred into a new U/C tube to which had been added 1.5 ml 1.38 g/ml 
NaBr density solution. The volume was adjusted to the upper line on the tube 
shoulder. The tubes were capped, mixed, and then loaded into the rotor, and spun at 
40000 rpm (172301 × g) for at least 48 hours at 4qC. When the centrifugation had 
finished, the top layer containing the HDL3 fraction was cut. The cut part of U/C tube 
and the well of the cutter were rinsed with saline containing 0.1% Na2EDTA (d= 
1.006 g/ml). The top layer and the washing solutions were collected in duplicate in 
new glass tubes. Samples were kept at -20qC for further analysis. 
 
For those samples used to measure the concentration of the HDL3 fraction, the top 
layer was transferred into a 2 ml mini-volumetric flask (Sigma-Aldrich Ltd, UK). After 
rinsing the cut part of the U/C tube and the well of the cutter with saline containing 
0.1% Na2EDTA (d= 1.006 g/ml), all the washing solutions were transferred to the 
volumetric flask to make the total volume to 2 ml. The samples were then mixed well, 
placed in two new glass tubes and stored at -20qC until further laboratory analysis. 
 
2.2.2.5. Delipidation of total HDL, HDL2 and HDL3 fractions  
Methanol and diethyl ether were precooled at 4qC for at least 30 minutes. Four 
hundred Pl HDL fraction was added into 4 ml methanol. Four ml diethyl ether was 
then added into each sample and mixed vigorously. The samples were centrifuged at 
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4000 rpm (3684 × g) for 30 minutes at 1qC. The solvent was decanted gently. 
Another 4 ml diethyl ether was added into each sample and vortexed. Samples were 
centrifuged at 4000 rpm (3684 × g) for 20 minutes at 1qC. The diethyl ether was 
subsequently decanted and the tubes were left upside down to dry the sample at 
room temperature for about 30 minutes. Proteins were dissolved in 70 Pl sample 
buffer (pH6.8) for SDS-PAGE. Samples were stored in the freezer at -20qC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
2.2.3 Two-Dimensional Electrophoresis 
2.2.3.1 Summary of laboratory processes to measure leucine enrichment in 
preβHDL and αHDL apoA-I 
Measurement of leucine enrichment of αHDL and preβHDL apoA-I required a series 
of steps as shown in Figure 12. 
 
Figure 12: Laboratory processes to separate and measure leucine enrichment in αHDL 
and preβHDL apoA-I 
 
 
2.2.3.2 First dimension: Agarose gel electrophoresis 
αHDL and preβHDL in plasma were separated by agarose gel electrophoresis 
(Figure 13A and 13B). Agarose gel at a concentration of 0.6% was prepared. 
Agarose powder (Sigma, UK) was dissolved in tris-tricine buffer (25mM, pH8.6) by 
heating in a microwave. The gel was left to cool down until the temperature was 
approximately 60qC and was then transferred into the flat-bed gel cassette. Two 
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hundred and sixty Pl plasma was diluted with 65Pl tris-tricine sample buffer (125mM, 
pH8.6) (4:1 v:v) (325 Pl in total), and 300 Pl of the mixture (equal to 240 Pl plasma) 
was loaded onto the agarose gel. Albumin (bovine serum ≥96%) (Sigma, USA) and 
apoA-I (from human plasma, ≥85%, 3.25 mg protein/ml) were loaded to identify the 
position of the αHDL and preβ HDL bands. Albumin runs in the same position as 
αHDL while apoA-I is a marker for preβHDL. The gel was run in tris-tricine buffer at 
170 V for 3 hours. The gel was subsequently stained with 0.125% coomassie blue 
R250 staining solution overnight. Excessive dye was removed by destaining with 
methanol/acetic acid/H2O solution (5:1:3 v:v:v).  αHDL and preβ HDL bands 
separated on agarose gel were excised and then dried on the freeze dryer 
(ModulyoD Freeze Dryer, Thermo Fisher Scientific Inc, Waltham, MA, USA) 
overnight. 
 
 
Figure 13 A: Separation of αHDL and preβHDL by agarose gel electrophoresis with 
albumin as a standard 
 
Albumin 
 αHDL 
preβHDL 
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Figure 13 A:Separation of αHDL and preβHDL by agarose gel electrophoresis with 
apoA-I (from human plasma) as a standard 
 
 
2.2.3.3 Extraction of proteins 
Freeze dried gel was incubated in 3 ml 1% SDS solution for 2 hours at room 
temperature. The supernatant solution was collected into a 10 ml round bottom glass 
tube. The gel was repeatedly washed with 3 ml 0.2% SDS solution three times for 
αHDL and twice for preβ HDL. All the washing solution was transferred to the 10 ml 
glass tube and frozen in a freezer at -20qC overnight. Samples were dried on the 
freeze dryer and stored in the freezer at -20qC for further analysis. 
 
2.2.3.4 Precipitation and delipidation  
Ethanol and diethyl ether were precooled on ice for at least 30 minutes. Four ml 
ethanol was added into the HDL sample extracted from agarose gel and mixed well. 
The tubes were kept on ice for 1 hour to precipitate the proteins and then centrifuged 
at 4500 rpm (4662 × g) for 1 hour at 1qC. The blue supernatant containing coomassie 
blue was poured out gently. Four ml diethyl ether was added into each sample and 
then centrifuged at 4500 rpm (4662 × g) for another 1 hour. Diethyl ether was then 
Human apoA-I 
preβHDL 
 αHDL 
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poured out gently. The tubes were left upside down to dry at room temperature for 1 
hour for αHDL and 30 minutes for preβ HDL. Proteins were dissolved in 70 Pl sample 
buffer (pH6.8) for SDS-PAGE and the samples were stored in the freezer at -20qC. 
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2.2.4 Separation of apoA-I by SDS-PAGE 
ApoA-I in the HDL fractions was isolated by Sodium dodecyl sulphate – 
Polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 14, 15 and 16). Two layers 
of discontinuous SDS-PAG were prepared. The resolving gel (10%) was prepared 
using tris base-SDS buffer (tris base 0.75M, SDS 0.2%, pH8.8), and the stacking gel 
(4%) using tris base-SDS buffer (tris base 0.25M, SDS 0.2%, pH6.8). The stacking 
gel has the ability to enhance the resolution of protein separation and sharpen the 
sample bands on the resolving gel. Two gels were cast in a PROTEAN II gel cast 
(Bio-Rad, USA). Samples in sample buffer (containing SDS) were heated at 110qC 
for 5 minutes and subsequently cooled down on ice. SDS in the sample buffer can 
linearise the proteins after heating and give the protein a negative charge. Following 
loading the samples on SDS-PAG, the gel was run at 80v for 16 hours. Known 
molecular weight standards, prestained and unstained standards, and human apoA-I 
standard were loaded to identify the position of the apoA-I bands. Prestained 
standard is able to show the colours without staining, which was used to check 
whether the SDS-PAGE work normally or not after overnight running, while unstained 
standard will be visible only after the staining process. 
 
Figure 14: Separation of total HDL apoA-I on SDS-PAGE 
 Total HDL 
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unstained  
       std 
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Figure 15: Separation of HDL2 and HDL3 apoA-I on SDS-PAGE. (A: HDL2 apoA-I bands 
separation for five different time points; B: HDL3 apoA-I bands separation for six 
different time points) 
 
 
 
 
Figure 16: Separation of αHDL and preβHDL apoA-I on SDS-PAGE. (A: αHDL apoA-I 
bands separation for five different time points; B: preβHDL apoA-I bands separation for 
five different time points) 
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Gels were stained to develop the images by using a silver stain kit. The gel was firstly 
fixed in fixative enhancer solution (methanol, acetic acid, fixative enhancer 
concentration, H2O, 5:1:1:3 v:v:v:v) for 20 minutes. After washing the gel with 
nanopure H2O twice for 20 minutes in total, the silver staining solution was added to 
stain the gel for 10- 20 minutes. Acetic acid (5%) was added for 15 minutes to stop 
the staining reaction when the ideal image had appeared. Nanopure H2O was used 
to eliminate the excessive acetic acid. HDL apoA-I bands were excised for further 
analysis. 
 
2.2.5 Hydrolysis of apoA-I 
The apoA-I bands separated by SDS-PAGE were transferred to round bottom glass 
tubes. One ml 6M HCl was added to each sample, and the tubes were heated on a 
heating block at 120qC for 24 hours to hydrolyse apoA-I to amino acids. 
 
2.2.6 Ion exchange chromatography 
Amino acids from hydrolysed apoA-I were purified by ion exchange chromatography 
(IEC). IEC is based on the ionic interactions between the charged molecules in the 
mobile phase and the charged solid support in the immobile phase. In terms of cation 
exchange chromatography, which was used, positively charged amino acids in 6M 
HCl (at low pH) bind to the negatively charged solid support resin. To elute the amino 
acids, ammonium hydroxide (NH4OH) was added to increase the pH of the mobile 
phase, therefore the ionic interaction between amino acids and the resin were 
weakened.  
 
AG50W – X8 cation exchange resin was weighed (1g/sample) and washed with 
nanopure H2O twice in the beaker. Following washing with 2M NH4OH (1:2 v:v) to 
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remove any possible contamination, resin was rinsed with nanopure H2O until the pH 
of the eluted water was 7. The resin was then washed with 1M HCl (1:1 v:v). 
Nanopure H2O was added to rinse the resin until the pH of the eluted water was 7, 
and the resin was ready for the columns to purify amino acids. Nanopure H2O was 
added to resin (1:1 v:v) and stirred. Two ml of the mixture (containing 1g resin) was 
transferred to polypropylene columns (1 column/sample). Samples from hydrolysis 
were loaded to each column. Each hydrolysis tube was subsequently washed with 5 
ml nanopure H2O, and then the washing solution was transferred to the columns. The 
column was rinsed with 5 ml nanopure H2O 4 times until the pH of the eluted water 
reached 7. Three ml 4M NH4OH was added into each column and the eluted solution 
was collected in a new glass tube. Samples were frozen at -20qC overnight and then 
freeze dried on a freeze dryer. 
 
2.2.7 Derivatization 
Freeze dried samples containing purified amino acids need to be derivatized before 
the determination of 13C leucine enrichment by gas chromatography mass 
spectrometry (GC-MS). Leucine was converted into a volatile and thermally stable 
oxazolinone derivative (Figure 17). The oxazolinone derivative was analysed by 
negative ion chemical ionization GC-MS. Fifty Pl of trifluoroacetic anhydride (TFAA) 
and 50 Pl of trifluoroacetic acid (TFA) (1:1 v:v) was added separately to each sample. 
Samples were capped with Teflon lined caps and heated at 110qC for 5 minutes. Five 
hundred Pl toluene and 1 ml nanopure H2O were added to samples and mixed 
vigorously. Samples were then centrifuged at 2500 rpm (1439 × g) for 10 minutes at 
4qC. The toluene layer at the top was removed and transferred to GC vials for GC-
MS analysis. 
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2.2.8 Determination of leucine isotope enrichment by GC-MS 
2.2.8.1 Leucine standard curve 
It needed to be confirmed that the detector was functioning properly before analyzing 
any samples on the GC-MS. A range of standards with different enrichment was 
prepared to determine the sensitivity and linearity of GC-MS. L-12C-leucine and L- [1-
13C] leucine were used for the preparation of standards. The standards were 
derivatized and analysed by GC-MS.  
 
The preparation of leucine standard curve is shown in Table 6. The standard curve is 
demonstrated as the measured 13C/12C peak area ratio plotted against the theoretical 
enrichment. A linear relationship (R2=0.999) was indicated by a slope approximating 
to unity (1.0004) (Figure 18). 
 
 
 
 
 
 
Figure 17: Chemical structure of leucine and the oxazolinone derivative 
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Table 6: Preparation of leucine standard curve (n=6) 
 
 Concentration of 
13C leucine (µg/µl) 
Concentration of 
12C leucine (µg/µl) 
Theoretical 
13C/12C ratio 
Observed 13C/12C 
ratio (mean ± SEM) 
1 0 4.33 0 0.09159 ± 0.0008 
2 0.004579 4.33 0.0011 0.09248 ± 0.0008 
3 0.009157 4.33 0.0021 0.09402 ± 0.0008 
4 0.018314 4.33 0.0042 0.09577 ± 0.0008 
5 0.027471 4.33 0.0064 0.09807 ± 0.0007 
6     0.036628     4.33     0.0085     0.10017 ± 0.0007 
7 0.045785 4.33 0.0106 0.10240 ± 0.0009 
 13C/12C ratio: the concentration ratio of L-12C-leucine and L- [1-13C] leucine 
 
 
 
Figure 18: Leucine standard curve (n=6). (Results are presented as mean ± SEM) 
 
 
2.2.8.2 Measurement of 13C leucine isotope enrichment 
The samples were analyzed by a GC-MS (7890A GC system, Agilent 5975C inert XL 
EI/CI MSD, Agilent Technologies, Wokingham, Berkshire, UK). Samples were loaded 
in sequential order and injected with an Agilent 7683 autosampler. The GC was 
equipped with a capillary column with 30 meter 0.25 mm inner diameter, 0.25μm 
(J&W Scientific, Inc CA, USA) using helium as the carrier gas. The GC-MS was 
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operated in a negative chemical ionization (NCI) mode using methane as the reagent 
gas. The initial temperature of GC oven was 50°C for 1 minute and the ramp was 
6°C/minute to 90°C, 30°C/minute to 280°C. The oxazolinone derivative of 12C leucine 
and 13C leucine have a molecular mass of 209 and 210 respectively, and the analysis 
of oxazolinone derivative of 12C leucine and 13C leucine would enable to measure 
apoA-I leucine enrichment. 
 
2.2.9 Determination of α-KIC isotope enrichment 
Plasma samples for measuring α-KIC isotope enrichment were kept at -80qC until 
analysis. After thawing, plasma was vortexed and then centrifuged at 2500 rpm 
(1439 × g) for 10 minutes at 4qC to precipitate any proteins. One hundred Pl of the 
plasma was added into a small glass test tube containing 1 ml ethyl alcohol. Samples 
were vortexed and centrifuged at 2500 rpm (1439 × g) for 10 minutes at 4qC. The 
supernatant was transferred to new vials by glass pipettes and dried under oxygen 
free nitrogen (Nitroflow, Parker Filtration and separation, Parker Hannifin Ltd, 
Maidston, UK) at 50qC. The remainder was dissolved in a mixture of 200 Pl H2O and 
100 Pl O-phenylenediamine (2% in 4M HCl), and put on the heating block at 90qC for 
1 hour. Samples were left to cool down to room temperature. One ml of ethyl acetate 
was added to extract the keto-acid. The top layer containing the keto-acid was 
collected. The extraction process was repeated by adding another 1 ml ethyl acetate. 
The extracts were dried over sodium sulphate followed by evaporation under oxygen 
free nitrogen at room temperature. The remainder was derivatized by 100 Pl 
acetonitrile and 100 Pl N-Methyl-N-(tertbutyldimethylsilyl) trifluoroacetamide with 1% 
trimethylcholorsilane (MTBSTFA). Samples were put on a heating block at 120qC for 
45 minutes. The excess derivatising reagent was removed by oxygen free nitrogen at 
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room temperature. One hundred Pl decane was added to the derivative before 
loading to the GC-MS. 
 
The preparation of KIC standard curve is shown in Table 7. The derivative of D1 and 
Do have a molecular mass of 259 and 260 respectively. Therefore, α-KIC isotope 
enrichment (Figure 19) was measured by EI GC-MS by the selected ion monitoring of 
fragments at m/z 259 (m) and 260 (m+1). Chromatographic peaks were determined, 
and area ratio of α-KIC (13C/12C) was calculated. The α-KIC isotope enrichment was 
presented as APE.  
 
Table 7: Preparation of KIC standard curve (n=6) 
 
 Concentration of 
D1 (µg/µl) 
Concentration of 
Do (µg/µl) 
Theoretical 
260/259 ratio 
Observed 260/259 
ratio (mean ± SEM) 
1 0 2.40 0 0.2259 ± 0.0009 
2 0.15 2.40 0.0625 0.2900 ± 0.0012 
3 0.30 2.40 0.1250 0.3571 ± 0.0073 
4 0.45 2.40 0.1875 0.4178 ± 0.0060 
5 0.90 2.40 0.3750 0.6019 ± 0.0042 
6     1.20     2.40     0.5000     0.7213 ± 0.0123 
7 1.60 2.40 0.6667 0.8870 ± 0.0097 
8 1.80 2.40 0.7500 0.9682 ± 0.0108 
259/260 ratio: the concentration ratio of D1 and Do. D1: 4-Methyl-2-Oxopentanoic-1-13C acid 
Sodium Salt; Do: 4-Methyl-2-Oxopentanoic acid Sodium Salt  
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Figure 19: KIC standard curve (n=6). (Results are presented as mean ± SEM) 
 
 
2.2.10 Measurement of triglyceride, cholesterol and HDL concentration  
The concentration of triglyceride (TG) in the plasma were determined by the ABX 
Mira analyzer (Horiba ABX, Northampton, UK). The TG assay kit was used and the 
measurement was based on the enzymatic photometric method. After the enzymatic 
reactions, the colorimetic indicator which was quinoneimine was detected by 
colorimetry. The N (low) and P (high) QCs were 1.23 and 2.29 mmol/L), and CVs 
were 1.98% and 2.23% respectively (n=3). 
 
The concentration of cholesterol in the plasma was measured by the ABX Mira 
analyzer using an enzymatic colorimetric method. A total cholesterol assay kit 
(Horiba ABX, Northampton, UK) was needed for the determination. QCs were 
prepared with N (low) and P (high) concentration (2.28 and 4.81 mmol/L), and CVs 
were 3.53 % and 1.45% respectively (n=3). 
 
Plasma HDL-Cholesterol was measured by the ABX Mira analyzer as well. The 
method is based on accelerating the reaction of cholesterol oxidase (CO) with non-
HDL unesterified cholesterol and dissolving HDL selectively using specific detergent, 
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Accelerator Selective Detergent. Two reagents from Horiba ABX (Northampton, UK), 
which are subject to the enzyme reaction, the solubilization of HDL specifically and to 
develop color for the quantitative determination of HDL-C, were used. QCs were 
prepared with N (low) and P (high) concentration (0.83 and 1.82 mmol/L), and CVs 
were 8.48% and 7.35% respectively (n=3). 
 
2.2.11 Measurement of glucose and insulin concentration, and HOMA 
Plasma glucose concentration was measured by a glucose analyzer (YSI 2300 STAT 
Plus. Analytical @technologies, UK). Each sample was measured twice, and the 
average value was used.  
 
Plasma insulin was measured by using a double antibody radioimmunoassay. Fifty μl 
plasma was incubated with 450 μl of the first antibody, guinea pig anti-insulin serum 
(GP 8) with tracer 125I-A14-tyr-monoiodo-insulin (Amersham Pharmacia Biotech, UK), 
at room temperature overnight. One hundred μl of the second antibody, a solid phase 
sheep-anti-guinea pig serum antibody (Pharmacia Decanting Suspension, UK) was 
added to the sample and incubated for 2 hours. After adding 1 ml of H2O, the 
samples were spun at 1500 rpm for 45 minutes at 4 °C. Then, the supernatant was 
decanted and the precipitate was counted on a gamma counter (Wallac Wizard 1470, 
UK).  
 
The homeostasis model assessment (HOMA) was calculated from fasting glucose 
and insulin concentration by using the HOMA2 calculator, which was downloaded 
from the University of Oxford website: 
(http://www.dtu.ox.ac.uk/homacalculator/download.php). 
 
 
 91 
2.2.12 Determination of the lipase activity in plasma 
The activity of the total and hepatic lipase was analysed by a continuous fluorometric 
lipase test (Conflulip lipase test, Progen, Biotechnik Gubh, Heidleberg, Germany) via 
assessing the capacity of triglyceride hydrolysis in plasma samples. A lipase 
substrate, which is a triglyceride comprised of pyrene fluorescence, is included in the 
test kit. By adding the active lipase, the lipase substrate was hydrolysed and the 
intensity of pyrene fluorescence, which is related to lipase activity in the samples, 
was detected. 
  
2.2.13 Measurement of apoA-I concentration in plasma and HDL2 and HDL3 
fractions 
Apolipoprotein A-I concentrations in plasma, HDL2 and HDL3 fractions were 
measured by an automatic ABX Mira analyzer (Horiba ABX, France) according to an 
immunoturbidimetric method. Reagents, ABX Pentra Apo AI (a fraction of purified 
immunoglobulins from rabbit antiserum) and immunogen (apoA-I from human HDL) 
were needed for the assay. ApoA-I reacts with its specific antibody and generates the 
immune complexes, scattering a beam of light through the sample. The proportion of 
apoA-I concentration in the samples is represented as the intensity of the scattered 
light. The low and high quality controls (QCs) were 1.137 and 2.424 mg/ml, and inter-
assay coefficient of variations (CV) were 7.531% and 3.173% respectively (n=5). 
 
2.2.14 Measurement of αHDL and preβ HDL apoA-I concentration: Western 
blotting 
After separation of αHDL and preβ HDL on agarose gel electrophoresis, the agarose 
gel was covered with a 0.2 Pm nitrocellulose membrane, filter paper and fibre pad to 
make a sandwich. The sandwich was then placed into a plastic cassette filled with 
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transfer buffer (pH8.3). The gel was on the negative polarity and the membrane was 
on the positive polarity. Following 24 hours electrophoretic transfer at a constant 
voltage (30V), the αHDL and preβ HDL bands were transferred to the membrane. 
The membrane was incubated in a blocking buffer containing 5% dried non-fat milk, 
0.12% Tris base, 0.58% NaCl and 0.5% Tween 20 (pH7.5) for 1 hour at room 
temperature. After washing with 100 ml phosphate buffered saline containing 0.05% 
Tween 20 (PBST, pH7.4) three times, each time for 10 minutes, the membrane was 
incubated with the primary antibody (Goat polyclonal antibody to human apoA-I, 
Abcam, UK) at room temperature for 1 hour. The excess primary antibody was 
washed off with 100 ml PBST for 10 minutes three times, and the membrane was 
incubated with the secondary antibody (Donkey polyclonal antibody to goat IgG, 
H&L, Abcam, UK) at room temperature for 1 hour. The excess secondary antibody 
was washed off again with 100 ml PBST for 10 minutes three times. αHDL and preβ 
HDL bands were visualised on the membrane by staining with AP (alkaline 
phosphatase) staining reagent for 1 minute (Figure 20). The reaction was stopped by 
adding nanopure H2O. 
 
The membrane was subsequently put on the Calibrated Imaging Densitometer 
(Model GS-800, Bio-Rad, the United States) and scanned. The scanned image was 
created and analysed using Quantity One (Version 4.5.2, Bio-Rad Laboratories, the 
United States). The bands of αHDL and preβ HDL were selected as a rectangle 
shape on the image, and the volume of each band was quantified as the sum of the 
intensities of the pixels inside the volume boundary multiplied by the area of a single 
pixel (the area of the band) (mm2). The background intensity of each selected band 
was identified by Quantity One automatically, and the adjusted volume (Adj. Vol) 
(volume minus the background volume) was used to calculate the percentage of 
αHDL and preβ HDL in each sample. The formula is as follows: 
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αHDL% = Adj. Vol of αHDL / (Adj. Vol of αHDL + Adj. Vol of preβHDL) 
preβHDL% = 1 - aHDL% 
The concentration of αHDL and preβ HDL was calculated as: 
αHDL concentration = αHDL % × total apoA-I 
preβHDL concentration = preβHDL % × total apoA-I 
 
Figure 20: Western blotting: Measurement of the percentage of αHDL and preβHDL 
 
 
2.2.15 Data analysis  
After all the apoA-I samples had been run on the GC-MS, the area under the m/z 210 
peak and m/z 209 peak were recorded, and the ratio of m/z 210/209 at each time 
point was calculated. The ratio was then converted to atom percent excess (APE), 
which is a measure of isotope enrichment taking into account the baseline isotopic 
enrichment.  
The APE for each time point was calculated by the following equation: 
APE (%) = [(Rt-R0)/(Rt-R0+1)] × 100                                                            Equation 1 
pure apoA-I std 
 αHDL 
preβHDL 
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Where Rt and R0 represent the isotope area ratios of m+1/m (210/209) for sample at 
time t, and baseline sample at time zero (before the injection of the isotope) 
respectively. The KIC APE was calculated using the isotope area ratio of m/z 
260/259. 
 
For the dietary intervention study, which used a primed bolus injection followed by a 
constant infusion of stable isotope (Chapter 3), the fractional secretion rate (FSR) of 
HDL apoA-I was calculated by linear regression as used in a previous study for the 
measurement of HDL apoA-I kinetics (Li et al., 2012). 
FSR (pools/day) 
= (Slope of the apoA-I APE time curve/KICAPE) × 24                               Equation 2 
where plasma α-ketoisocarproate (KICAPE) is the measurement of the precursor pool 
enrichment of hepatic intracellular leucine. In a steady state, the FSR is equal to the 
fractional catabolic rate (FCR). The production rate (PR) was calculated from the 
FSR and the pool size. ApoA-I pool size was calculated from the concentration of 
apoA-I and plasma volume (PV) divided by body weight. PV was calculated as 
shown below: 
PR (mg/kg/day) = FSR × HDL apoA-I pool size                                       Equation 3 
ApoA-I pool size (mg/kg) = HDL apoA-I concentration × PV / BW        Equation 4 
For males, PV (ml)  = 1578 × S                                                                   Equation 5 
For female, PV (ml)  = 1395 × S                                                                  Equation 6 
Where S is surface area (m2) 
S (m2) = BW0.425 × Height0.725 ×0.007184                                             Equation 7 
where BW is body weight (kg), height (cm). 
 
For the HDL subclasses study, which used a bolus injection of stable isotope, the 
apoA-I enrichment (APE) of HDL2, HDL3, αHDL and preβHDL for time points after the 
10-hour study, which are Day1, Day3, Day7, Day9, Day10 and Day 14, was plotted 
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using a natural logarithmic scale. A line of best fit was fitted and the equation for this 
curve fit provided the slope of the curve. The slope is equal to FCR (pools/hour). An 
example is shown in Figure 21. The values of FCR in pools/hour were multiplied by 
24 to express FCR in pools/day for HDL2, HDL3, αHDL and preβHDL. PR for HDL 
subclasses was then calculated by using Equation 3. ApoA-I pool size, plasma 
volume and surface area were calculated by using Equation 4, 5, 6 and 7 
respectively. The area under the curve (AUC) of leucine enrichment data for αHDL, 
preβHDL, HDL2 and HDL3 during the first 10 hour study and the rest of days in the 
following two weeks was calculated automatically by SigmaPlot (Version 12.3, Systat 
Software Inc, USA). 
 
 
 
 
 
 
 
 
 
 
 
It was hoped that a mathematical model developed by the Department of 
Mathematics, University of Surrey, could be used to determine HDL subclass 
kinetics. Two models were developed, one to describe αHDL and preβHDL, and one 
to describe HDL2 and HDL3. The model structures for αHDL and preβHDL, and for 
HDL2 and HDL3 shown in Figure 22 and Figure 23 respectively were based on 
models proposed previously (Fisher et al., 1995). The models were used to fit the 
leucine enrichment curve for αHDL, preβHDL, HDL2 and HDL3. However, the model 
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Figure 21: An example of the determination of FCR (pools/h) from the 
slope of a line of best fit 
 96 
structures did not allow a good fit to all the data, suggesting the model structure 
needed to modification. Therefore, other model structures need to be explored in the 
future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: The model structure for αHDL and preβHDL (k = rate constant) 
Figure 23: The model structure for HDL2 and HDL3 (m = rate constant) 
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Statistics analysis 
The results are presented as mean ± SEM. Microsoft Excel 2003 was used to 
analyze data and create graphs and curves. Statistical analyses were performed by 
using Statistical Package for the Social Sciences (SPSS) version 22 (IBM 
Corporation, New York, USA). A paired two-tailed t-Test was used to analyse the 
differences in HDL subclass variables, and between the high and low sugar diet of all 
variables. An unpaired t-Test was used to compare HDL subclass kinetics between 
genders. The associations between variables were determined by calculating 
Pearson’s correlation. In the all comparisons, P<0.05 was considered statistically 
significant.
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Chapter 3: The effect of a high and low non-milk extrinsic 
sugar diet on HDL kinetics 
3.1 Introduction 
This dietary intervention study was part of a BBSRC funded trial to investigate the 
effects of dietary sugar on lipoprotein kinetics. In this thesis, the association between 
dietary sugar intake and HDL metabolism is investigated. It also addresses the 
influence of dietary sugar consumption on several cardio-metabolic risks, such as 
body weight, fasting plasma lipids, glucose and insulin. 
 
The study was a controlled, randomized crossover trial. Six Caucasian middle-aged 
men were recruited, and they underwent two 12-week dietary interventions with high 
and low sugar diets. The aim was for the macronutrient content of the two diets to be 
the same with the only difference being in the content of non-milk extrinsic sugars, 
high or low non-milk extrinsic sugar. The dietary intake of the subjects was measured 
by 3-day diet diaries. Anthropometrics, fasting plasma lipids and lipoproteins, glucose 
and insulin levels were measured at the end of the interventions. The assessment of 
HDL kinetics using a stable isotope technique was also measured at the end of each 
dietary intervention. L-[1-13C] leucine isotope was given intravenously as a priming 
dose of 1 mg/kg followed by a constant infusion (1 mg/kg/h) for 10 hours. Blood 
samples were taken at intervals during the study. The total HDL fraction was 
separated from plasma by using ultracentrifugation, and apoA-I in the fractions was 
isolated via SDS-PAGE. After the purification and derivatization, the leucine 
enrichment of apoA-I was finally determined by GC-MS (Chapter 2, section 2.2.8). 
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3.2 Results 
3.2.1 Subjects characteristics and lipid profile 
The characteristics of subjects at screening in the study are shown in Table 8. Six 
male subjects were aged between 49 to 65 years old. Subjects 01, 02, 03 and 05 
were overweight, and subjects 04 and 06 were borderline obese. According to the 
categories defined by the American Heart Association (AHA, 2014), only subject 06 
had a normal systolic blood pressure (less than 120 mmHg), while other subjects 
were at the prehypertension levels (120-139 mmHg). The diastolic blood pressure of 
subjects 03, 05 and 06 were in the normal range (less than 80 mmHg), and subjects 
01 and 02 were in the prehypertension range (80-89 mmHg). The diastolic blood 
pressure of subject 04 was in high blood pressure stage 1 category (90-99 mmHg).  
In terms of liver fat, subjects 03 and 04 had low liver fat (<5.0% liver fat) while the 
other subjects had moderately enhanced liver fat. 
 
Table 8: Subject characteristics at screening (n=6) 
 
Subject 01 02 03 04 05 06 Mean ± SEM 
Age (years) 58 49 58 50 65 63 57.2 ± 2.7 
Height (m) 1.78 1.75 1.83 1.75 1.66 1.77 1.76 ± 0.02 
Weight (kg) 86.4 88.1 95.3 92.7 78.7 96.6 89.63 ± 2.72 
BMI (kg/m2) 27.3 28.9 28.3 30.3 28.6 30.8 29.03 ± 0.54 
Systolic BP 
(mmHg) 
127 127 124 135 121 118 125.33 ± 2.40 
Diastolic BP 
(mmHg) 
80 87 76 91 75 76 80.83 ± 2.73 
Liver fat (%) 7.90 10.90 3.67 3.07 16.14 9.96 8.61 ± 1.99 
BP: blood pressure 
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3.2.2 Energy and macronutrient intakes of the high and low sugar diet 
The mean of total energy and macronutrient intakes from the habitual, the high and 
low sugar diets are presented in Table 9. The dietary data of subject 02 was not 
available, so the mean ± SEM values were calculated from the other five subjects. 
No significant differences were found in total energy, carbohydrate, protein, total fat 
and saturated fat intakes between the habitual and high sugar diet, habitual and low 
sugar diet. The differences in fibre intake between the habitual and high sugar diet 
was on the borderline of being significant (p = 0.051), whereas no significant 
difference was found between the habitual and low sugar diet. Sugar consumption 
(g/d) was significantly different between the habitual and low sugar diet (p = 0.006) 
but not between the habitual and high sugar diets. However, there was a significant 
difference in the percentage of energy intake from sugar between the habitual and 
high sugar diet, and the habitual and low sugar diet (p = 0.048 and p = 0.012 
respectively). 
 
Table 9: Intakes of energy and composition of macronutrients of the high and 
low sugar diet 
Nutrient Habitual  
diet 
High sugar  
diet 
Low sugar  
diet 
Paired T-test 
(Low vs. High) 
Energy (MJ/d) 10.3 ± 1.1 10.4 ± 1.2 11.2 ± 1.0 p = 0.548 
CHO (g/d) 270.7 ± 33.0 317.6 ± 26.3 278.7 ± 30.7 p = 0.395 
   % Total energy 44.3 ± 2.3 53.5 ± 5.5 41.6 ± 2.8 p = 0.084 
Sugar (g/d) 115.3 ± 13.9 173.9 ± 14.0 60.2 ± 9.6* p = 0.007 
   % Total energy 19.4 ± 2.7 30.0 ± 4.5* 8.9 ± 1.1* p = 0.012 
Protein (g/d) 88.6 ± 7.1 90.2 ± 13.1 116.0 ± 14.5 p = 0.047 
   % Total energy 14.7 ± 0.8 14.4 ± 0.8 17.5 ± 1.5 p = 0.076 
Fat (g/d) 89.9 ± 12.7 75.8 ± 22.8 104.1 ± 14.9 p = 0.173 
   % Total energy 32.7 ± 1.7 25.9 ± 5.7 34.5 ± 2.6 p = 0.163 
Saturated fat (g/d) 37.6 ± 4.8 33.1 ± 11.1 44.8 ± 9.6 p = 0.211 
Fibre (g/d) 27.7 ± 3.9 20.9 ± 2.6 28.2 ± 4.4 p = 0.132 
Data are presented in mean ± SEM (n=5). CHO: carbohydrate.  
* Significantly different from habitual diet p < 0.05. 
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There were no significant differences in the intakes of total energy, carbohydrate, 
total fat, saturated fat and fibre between the high sugar and low sugar diet. Although 
there was a statistically significant difference in the amount of protein consumption 
(g/d) (p = 0.047), the distribution of protein in total energy was not significantly 
different. The quantity of sugar intake and its percentage of total energy on the high 
and low sugar diet were both statistically different (p = 0.007 and p = 0.012 
respectively). The mean intake of energy on both the high and low sugar diet in the 
present study was slightly higher compared with the mean energy intake in men aged 
50-64 years old from the National Diet and Nutrition Survey (NDNS), which is 9.55 
MJ (Hoare et al., 2004). Energy from carbohydrate in the high sugar diet was 6% 
higher and in the low sugar diet was almost 6% lower than the mean intake of 
middle-aged men from the NDNS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
3.2.3 The effect of the high and low sugar diets on body weight, body fat, 
plasma lipids and lipoproteins 
The individual and the mean values of body weight, body fat, the concentration of 
lipids and lipoproteins in plasma and total HDL fractions on the high and low sugar 
diets are shown in Table 10. Body weight after the high sugar dietary intervention 
was higher than that after the low sugar dietary intervention, and this difference 
between the two diets was statistically significant (p = 0.020). The percentage of 
body fat was higher on the high sugar diet compared to the low sugar diet, and the 
difference between the two diets was also statistically significant (p = 0.014).  
 
The fasting plasma triglyceride for subject 02, 03, 04, 05 was in the normal range 
(<1.7 mmol/L) after the two dietary interventions, while the concentration of 
triglyceride for subject 01 and 06 was higher than the normal level on both diets. The 
fasting levels of plasma cholesterol for subject 01 to 05 was in the normal range (<5 
mmol/L) or just on the borderline after the two dietary interventions, whereas the 
cholesterol levels of subject 06 on both diets was above the normal range. Moreover, 
the values of plasma HDL-C for all subjects on the high sugar diet were below the 
normal level (>1.2 mmol/L). Subject 02 and 04 had a borderline normal fasting HDL-
C concentration on the low sugar diet, however the other subjects had a 
concentration below the normal range. Although the levels of fasting plasma 
triglyceride, cholesterol and HDL-C varied within individuals on the high and low 
sugar diets, there were no significant differences between the two diets. In addition, 
there were no significant differences in the levels of triglyceride, cholesterol and 
apoA-I in total HDL fractions between the diets. 
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Table 10: Body weight, body fat and the concentrations of lipids and 
lipoproteins in plasma and total HDL fractions on the high and low sugar diets 
 
CHOT Diet 01 02 03 04 05 06 Mean ± SEM 
Body 
weight (kg) 
High sugar 89.8 89.1 91.8 92.5 76.6 98.1 89.65 ± 2.91 
Low sugar 89.4 85.8 90.6 92.0 73.5 99.2 87.92 ± 3.20 
Paired 
T-test 
      p = 0.020 
Body fat 
(%) 
High sugar 29.2 30.3 24.0 26.3 26.4 29.5 27.62 ± 0.99 
Low sugar 26.2 27.4 23.9 24.8 22.2 28.0 25.42 ± 0.90 
Paired 
T-test 
      p = 0.014 
Plasma TG 
(mmol/L) 
High sugar 1.75 1.67 1.58 1.52 1.24 3.69 1.91 ± 0.36 
Low sugar 2.74 1.64 1.64 0.93 1.07 3.12 1.86 ± 0.36 
 Paired 
T-test 
      p = 0.835 
Plasma 
CHOL 
(mmol/L) 
 
High sugar 4.15 4.33 4.26 4.61 4.02 7.12 4.75 ± 0.48 
Low sugar 5.02 4.15 3.90 4.34 3.70 6.33 4.57 ± 0.40 
 Paired 
T-test 
      p = 0.474 
Plasma  
HDL-CHOL 
(mmol/L) 
 
High sugar 1.15 1.16 0.79 1.12 0.86 1.10 1.03 ± 0.07 
Low sugar 1.19 1.23 0.62 1.25 0.87 1.01 1.03 ± 0.10 
 Paired 
T-test 
      p = 0.972 
HDL 
fraction -
TG 
(mmol/L) 
High sugar 0.13 0.10 0.13 0.13 0.08 0.16 0.12 ± 0.01 
Low sugar 0.14 0.08 0.16 0.10 0.06 0.14 0.11 ± 0.02 
 Paired 
T-test 
      p = 0.425 
HDL 
fraction-
CHOL 
(mmol/L) 
High sugar 1.18 1.26 0.81 1.00 0.72 1.03 1.00 ± 0.08 
Low sugar 1.24 1.06 1.06 1.09 0.61 0.83 0.98 ± 0.09 
 Paired 
T-test 
      p = 0.815 
HDL  
apoA-I 
(g/L) 
 
High sugar 1.23 1.45 0.83 1.05 0.71 1.02 1.05 ± 0.11 
Low sugar 1.56 1.05 0.90 1.07 0.53 0.65 0.96 ± 0.15 
 Paired 
T-test 
      p = 0.477 
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Plasma HDL-C was significantly correlated to fraction HDL-C on the high sugar diet (r 
= 0.900, p = 0.007) but not on the low sugar diet (r = 0.407, p = 0.212) (Figure 24). 
There was no correlation between body weight and body fat (%) on either the high or 
low sugar diets. There was also no relationship between body weight or body fat (%) 
and the level of plasma triglyceride and cholesterol. A positive correlation was 
observed between plasma concentration of triglyceride and triglyceride in the HDL 
fraction on the high sugar diet (r = 0.753, p = 0.042) (Figure 25) but not on the low 
sugar diet (r = 0.620, p = 0.095). A significant positive association was also observed 
between plasma HDL concentration and HDL apoA-I on the high sugar diet (r = 
0.845, p = 0.017) (Figure 26), but this correlation was not found on the low sugar diet 
(r = 0.529, p = 0.140).  
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Figure 24: Correlations between plasma HDL-C and fraction HDL-C on the high and low sugar diet 
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Figure 25: Correlations between plasma TG and fraction HDL-TG on the high and low sugar diet 
Figure 26: Correlation between plasma HDL-C and HDL apoA-I on the high and low sugar diet 
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3.2.4 The effect of the high and low sugar diets on blood glucose, insulin and 
insulin resistance 
The fasting plasma glucose, insulin and insulin sensitivity of the participants on the 
high and low sugar diets were measured, and the results are summarized in Table 
11. There were no significant differences found in the levels of fasting glucose, 
insulin and HOMA2-IR between two diets.  
 
 
Table 11: Glucose, insulin and insulin sensitivity on the high and low sugar 
diets 
 
CHOT Diet 01 02 03 04 05 06 Mean ± SEM 
Glucose 
(mmol/L) 
High sugar 4.85 5.19 4.80 4.34 4.90 5.49 4.93 ± 0.16 
Low sugar 5.48 4.30 4.47 4.87 5.83 5.50 5.08 ± 0.25 
Paired 
T-test 
      p = 0.620 
Insulin 
(mU/L) 
High sugar 11 8.6 18 24 21 27 18.27 ± 2.96 
Low sugar 15 22 17 16 22 27 19.78 ± 1.84 
 Paired 
T-test 
      p = 0.622 
HOMA2-IR 
 
High sugar 1.4 1.1 2.3 2.9 2.6 3.5 2.30 ± 0.37 
Low sugar 2.0 2.7 2.1 2.0 2.9 3.4 2.52 ± 0.24 
 Paired 
T-test 
      p = 0.558 
 
 
 
 
3.2.5 The effect of the high and low sugar diets on lipases 
The total lipase, lipoprotein lipase (LPL) and hepatic lipase (HL) levels on the two 
dietary interventions are shown in Table 12. The total lipase levels were similar on 
the high and low sugar diet. The levels of LPL were also not statistically different 
between two diets. The HL level was significantly higher on the high sugar diet than 
that on the low sugar diet (p = 0.018). No correlation was observed between total 
lipase and HL. Moreover, there were no associations between HL and plasma or 
fraction HDL-C levels. A significant correlation was observed between HL and 
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plasma triglyceride on both the high and low sugar diet (r = 0.915, p = 0.005 and r = 
0.762, p = 0.039). The association between HL and HDL fraction triglyceride was on 
the border of being significant (r = 0.721, p = 0.053) on the high sugar diet but not on 
the low sugar diet (r = 0.638, p = 0.086) (Figure 27). 
 
Table 12: Total lipase, lipoprotein lipase and hepatic lipase on the high and low 
sugar diets 
 
CHOT Diet 01 02 03 04 05 06 Mean ± SEM 
Total lipase 
(pmol/ml/ 
min) 
High sugar 6.25 2.38 1.99 4.86 2.35 4.01 3.64 ± 0.69 
Low sugar 4.03 2.24 3.31 6.75 2.90 2.92 3.69 ± 0.66 
Paired 
T-test 
      p = 0.937 
Lipoprotein 
lipase 
(LPL) 
(pmol/ml/ 
min) 
High sugar 3.54 1.14 0.03 2.82 0.28 0.87 1.45 ± 0.58 
Low sugar 1.76 1.57 1.49 5.01 1.56 0.66 2.01 ± 0.62 
Paired 
T-test 
      p = 0.377 
Hepatic 
lipase 
(HL) 
(pmol/ml/ 
min) 
High sugar 2.71 1.23 1.96 2.04 2.07 4.88 2.48 ± 0.52 
Low sugar 2.27 0.67 1.82 1.74 1.34 3.58 1.90 ± 0.40 
Paired 
T-test 
      p = 0.018 
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Figure 27: Correlation between HL and HDL fraction triglyceride on the high and low sugar diet 
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3.2.6 Isotopic enrichment, PR and FCR of total HDL apoA-I on the high and low 
sugar diets 
The leucine enrichment of HDL apoA-I during the 10 hour study after the high and 
low sugar diets expressed as APE for each subject is shown in Figure 28 and the 
mean APE is shown in Figure 29. No significant difference was found between the 
two diets. 
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Figure 28: Leucine enrichment of total HDL apoA-I on high and low sugar diets for each individual 
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Figure 29: Leucine enrichment of total HDL apoA-I on high and low sugar diets among 
all subjects (n=6) 
 
 
Table 13 and Figure 30 show the fractional clearance rate (FCR) and production rate 
(PR) of total HDL on the high sugar and low sugar diet. PR was lower in 5 out of the 
6 subjects on the low sugar diet. There was no statistically significant difference in 
either FCR and PR between the two dietary interventions. In addition, no significant 
correlations were found between FCR and plasma or HDL fraction TG levels, and 
there was also no correlation between PR and the concentration of plasma or HDL 
fraction cholesterol.  
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Table 13: Fractional clearance rate (FCR) and production rate (PR) of total HDL 
on high sugar and low sugar diet 
 
Subjuects 
(n=6) 
ApoA-I pool 
size (mg/kg) 
FCR (pools/day) PR (mg/kg/day) 
High sugar 
diet 
Low sugar 
diet 
High sugar 
diet 
Low sugar 
diet 
High sugar 
diet 
Low sugar 
diet 
CHOT 01 45.0 57.2 0.17 0.11 7.85 6.45 
CHOT 02 52.4 38.9 0.16 0.20 8.32 7.70 
CHOT 03 30.6 33.4 0.24 0.25 7.32 8.33 
CHOT 04 37.4 38.1 0.26 0.14 9.53 5.48 
CHOT 05 26.9 20.5 0.21 0.21 5.61 4.33 
CHOT 06 35.3 22.8 0.15 0.18 5.32 4.01 
Mean ± 
SEM 
37.9 ± 3.8 35.2 ± 5.4 0.20 ± 0.02 0.18 ± 0.02 7.33 ± 0.66 6.05 ± 0.72 
Paired T-
test 
p = 0.524 p = 0.533 p = 0.115 
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Figure 30: Fractional clearance rate (FCR) and production rate (PR) of total HDL for individual 
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3.3 Discussion 
In this dietary intervention study, the diet with high non-milk extrinsic sugar induced 
higher body weight and body fat than the low non-milk extrinsic sugar diet among the 
middle-aged men. With respect to the other cardio-metabolic risk factors including 
plasma lipids (triglyceride and cholesterol) and lipoproteins (HDL), glucose, insulin 
and insulin resistance, beneficial effects of the low sugar diet compared to the high 
sugar diet were not observed. An association between plasma TG and HDL-TG, and 
between plasma HDL and HDL apoA-I was only found on the high sugar dietary 
intervention. Moreover, distinct effects of high and low sugar intakes on total HDL 
apoA-I FCR and PR was not shown.  
 
3.3.1 Effects of high and low sugar diet on HDL-C and HDL kinetics 
In two previous studies, HDL apoA-I FCR and PR were measured after 6-week 
consumption of a baseline average US diet (49% carbohydrate, 15% protein, 35% fat 
(14% saturated, 14% monounsaturated, 7% polyunsaturated) and 147mg of 
cholesterol/1000kcal) in men aged >40 or >50 years old (Velez-Carrasco et al., 2000; 
Tilly-Kiesi, 1997). Among healthy men aged >40 years (57±11 years) with HDL-C 
level of 0.97 ± 0.02 mmol/L, the mean values of HDL apoA-I FCR and PR were 0.225 
± 0.062 pools/day and 12.28 ± 3.64 mg/kg/day respectively (Velez-Carrasco et al., 
2000). In another study, among men aged >50 years (58±12 years) who had high 
plasma cholesterol (5.90 ± 1.27 mmol/L) but normal triglyceride concentration (1.40 ± 
0.36 mmol/L) and a HDL-C level of 1.14 ± 0.23 mmol/L, the mean levels of HDL 
apoA-I FCR and PR were 0.14 ± 0.04 pools/day and 8.5 ± 2.7 mg/kg/day respectively 
(Tilly-Kiesi et al., 1997). In the present study, the HDL apoA-I FCR levels for 
individual subjects on both the high and low sugar diet were similar to the data in the 
studies by Velez-Carrasco et al. (2000) and Tilly-Kiesi et al. (1997). The levels of 
HDL apoA-I PR for individuals in the present study were lower than the results in 
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those two previous studies on both diets, except subject 04 on the high sugar diet. 
The mean ages of the male subjects in the studies by Velez-Carrasco et al. (2000) 
and Tilly-Kiesi et al. (1997) were similar to the mean age in the present study. 
However, the kinetic measurements in the previous studies were carried out under 
constant feeding condition (Table 14), while the HDL apoA-I FCR and PR in the 
present study were measured under fasting state. This may account for the lower PR 
in the current study. 
 
Table 14: Summary of data on total HDL apoA-I kinetic parameters obtained 
with stable isotopes in the previous studies 
 
Authors Methodology Subjects Nutritional 
state 
HDL apoA-I 
FCR (pools/d) 
HDL apoA-I 
PR (mg/kg/d) 
Velez-
Carrasco et 
al., 2000 
15h primed-
constant 
infusion of 
[5,5,5-2H3]L-
Leucine 
18 males 
aged >40y 
(57 ± 11y) 
constant-
feeding 
0.225 ± 0.062 12.28 ± 3.64 
Tilly-Kiesi et 
al., 1997 
15h primed-
constant 
infusion of 
[5,5,5-2H3]L-
Leucine 
11 males 
aged >50y 
(58 ± 12y) 
constant-
feeding 
0.14 ± 0.04 8.5 ±2.7 
Velez-
Carrasco et 
al., 1999 
15h primed-
constant 
infusion of 
[5,5,5-2H3]L-
Leucine 
5 males 
aged >40y 
(49 ± 12y) 
constant-
feeding 
0.245 ± 0.029 14.67 ± 2.22 
Frenais et 
al., 1997 
14h primed-
constant 
infusion of 
[5,5,5-2H3]L-
Leucine 
5 males 
aged  
25 ± 3y 
fasting 0.21 ± 0.06 12.0 ± 4.2 
 
 
It has been suggested that various factors including female sex, exercise, alcohol 
consumption, low fat diet, high polyunsaturated fat diet, obesity, and smoking may 
alter plasma HDL levels (Tall, 1990). It has been found that a high carbohydrate diet 
(>57.4% of energy) is associated with a low concentration of HDL-C in men aged 25-
64 years of the non-institutionalized population (Yang et al., 2002), while a 
carbohydrate-restricted diet (10-12% of energy) is associated with increased plasma 
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HDL-C concentration (by 12-13%) in overweight men aged 18-69 years (Wood et al., 
2006; Volek et al., 2009). The proportion of total carbohydrate in the present study 
was about 53% and 41% of total energy on the high and low sugar diet respectively. 
This relatively moderate difference might not be able to achieve a remarkable 
difference in HDL-C concentration.  
 
The relationship between the type of carbohydrate and HDL metabolism has been 
investigated previously. A prospective study indicated that energy from dietary 
sucrose was inversely associated with HDL-C in both cross-sectional (at baseline 
and year 7) and longitudinal analyses (from baseline to year 7) (Archer et al., 1998). 
Moreover, higher consumption of added sugars or soft drinks was also found to 
correlate with lower HDL-C levels (Welsh et al., 2010; Dhingra et al., 2007). It has 
been indicated that increased dietary carbohydrates, especially simple sugars and 
starches with high GI could lead to increased levels of small and dense HDL, which 
was considered to be positively related to atherogenic dyslipidemia (Siri and Krauss, 
2005). Hence, although there was no difference in total HDL levels, changes in HDL 
subclasses might have occurred. Unfortunately, HDL subclasses were not measured 
in the present study.  
 
Weight loss and decreased body fat induced by a carbohydrate-restricted diet with or 
without reduced energy intake has been shown to be associated with increased 
plasma HDL-C concentration (Wood et al., 2006; Volek et al., 2009; Dattilo and Kris-
Etherton, 1992). Body weight was significantly higher in the high sugar diet than that 
in the low sugar diet, although there was considerable variation between individuals. 
This variance of body weight may account for the variance in HDL-C levels, which 
could be one of the possible explanations for the non-significant differences in HDL-C 
levels between two dietary interventions in the current study. Additionally, exercise 
can also increase the levels of HDL-C and apoA-I (Thompson et al., 1997). However, 
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subjects in the present study were asked to maintain their habitual physical activity, 
and the physical activity levels of the subjects during the two dietary interventions 
were not assessed.  
 
The rates of synthesis and/or catabolism of major HDL proteins determine plasma 
HDL concentration, and the variation of HDL and apoA-I between individuals is 
associated with differences in the PR and FCR of apoA-I (Tall, 1990). Blum et al. 
(1977) found that a reduced HDL concentration in normal subjects, which was 
induced by a low fat, high carbohydrate diet, resulted from the increased fractional 
catabolism of plasma apoA-I. The FCR of apoA-I has been considered to be more 
crucial than apoA-I PR in determining plasma HDL levels, and it was found to have a 
strong positive association with triglyceride levels (Brinton et al., 1991). In the present 
study, neither the concentration of HDL apoA-I or the PR and FCR of HDL apoA-I 
were significantly different between the high and low sugar diet. Although HDL apoA-
I PR was not significantly different, surprisingly it was lower in 5 out of 6 subjects on 
the low sugar diet. 
 
Tall (1990) suggested that apoA-I catabolism could be affected by alterations in the 
lipid composition in the HDL core or the HDL size. Increased level of triglyceride or 
triglyceride-rich lipoproteins result in increased exchange of cholesterol ester in HDL 
particles with triglyceride in triglyceride-rich lipoproteins, which may lead to an 
increased level of triglyceride-rich HDL. A positive correlation between HL and 
plasma triglyceride concentration was observed in the present study, which indicates 
that an increased level of plasma triglyceride may also relate to an increased level of 
HL. HL promotes the catabolism of triglyceride-rich HDL, which reduces HDL size 
and these smaller HDL particles may be more rapidly taken up by the liver. The 
reduction in HDL size also leads to a loss of apoA-I which may be cleared by the 
kidney (Tall, 1990). It has been suggested that the adverse relationship between 
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plasma triglyceride level and HDL-C (or apoA-I) might be partly due to the elevated 
exchange of cholesterol ester for triglyceride from HDL to triglyceride lipoproteins, 
which leads to the secondary reduction of apoA-I because of increased catabolism 
(Tall, 1990). Neither triglyceride nor cholesterol levels were significantly different on 
the high and low sugar dietary intervention in the present study, which might be 
explained by the non-significant change in FCR of total HDL as well as PR.  
 
HL is the lipase that is important in reverse cholesterol transport, and its activity is 
inversely associated with HDL levels (Lambert et al., 1999). HL plays an important 
role in converting larger HDL particles, αHDL or HDL2 and HDL3, to smaller HDL 
remnants, preβHDL and lipid-poor apoA-I (Lewis and Rader, 2005). Therefore 
greater activity of HL can lead to an increased level preβHDL and decreased level of 
mature αHDL, the predominant form of HDL. The level of HL on the high sugar diet 
was significantly higher than that on the low sugar diet. This might suggest that high 
sugar diet can induce higher level of preβHDL and lower level of αHDL compared to 
the low sugar diet, even though the concentration of plasma HDL did not change. 
Unfortunately, only total HDL was measured in the present study. 
 
LPL, CETP and PLTP, which are involved in the process of the formation of HDL and 
reverse cholesterol transport, have also been suggested to have effects on HDL 
levels and HDL apolipoprotein metabolism (Tall, 1990; Goldberg et al., 1990; Masson 
et al., 2009). It has been suggested that high consumption of fructose may reduce 
the activity of lipoprotein lipase at the adipocyte (Johnson et al., 2009) resulting in 
increased plasma triglyceride. LPL is also involved in the formation of nascent 
preβHDL. In the present study, LPL was not different on the two diets.  
 
A recent study by Verges et al. (2014) has investigated the associations between the 
kinetics of VLDL subclasses and HDL catabolism among subjects with abdominal 
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obesity by using stable isotopic technique. They found that HDL apoA-I FCR was 
positively associated with VLDL1-triglycerides PR and VLDL1-apoB PR. Verges et al. 
(2014) suggested that apoA-I FCR is independently correlated with the production 
and catabolism of VLDL1-TG. This study was part of BBSRC funded trial, which also 
measured VLDL triglyceride and apoB kinetics. The relationships between HDL 
apoA-I FCR and VLDL subclasses kinetics was therefore examined in the present 
study. The kinetics data of VLDL1-TG and VLDL1-apoB for the subjects in the dietary 
intervention study are shown in Table 15. However, no significant correlations were 
found between apoA-I FCR and VLDL1-triglycerides PR or FCR, and between apoA-I 
FCR and VLDL1-apoB PR or FCR on both the high and low sugar diet. The study 
population in the study by Verges et al. (2014) and in the current study had the 
similar age. However, the subjects in this recent study were abdominal obese and 
had higher BMI compared to the present study. The study by Verges et al. (2014) 
included a relatively larger sample size (n=62) with a mixture of male and female 
subjects. In the current study, only male subjects were involved and the sample size 
was small (n=6), which may not be powerful enough to induce a significant 
association between HDL catabolism and VLDL kinetics. Furthermore, the subjects in 
the current study were on the high and low sugar diet, which may influence the 
metabolism of HDL and VLDL. Therefore, these factors could lead to the difference in 
the results between the study by Verges et al. (2014) and the present study.  
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Table 15: The kinetics data of VLDL1-TG and VLDL1-apoB on the high and low 
sugar diet  
 
Subject VLDL1-TG FCR 
(pool/day) 
VLDL1-TG PR 
(mg/kg/day) 
VLDL1-apoB FCR 
(pool/day) 
VLDL1-apoB PR 
(mg/kg/day) 
High 
sugar 
Low 
sugar 
High 
sugar 
Low 
sugar 
High 
sugar 
Low 
sugar 
High 
sugar 
Low 
sugar 
CHOT 01 10.46 9.94 274.35 319.64 - - - - 
CHOT 02 8.79 9.79 234.86 284.60 - - - - 
CHOT 03 8.73 8.98 177.41 145.62 5.28 5.17 4.54 0.93 
CHOT 04 10.03 9.94 201.59 133.12 7.83 7.08 10.64 7.66 
CHOT 05 5.55 5.95 74.94 80.86 9.26 14.86 2.34 9.39 
CHOT 06 5.03 4.83 207.44 187.65 6.05 5.40 1.94 5.68 
Mean ± 
SEM 
8.10 ± 
0.93 
8.24 ± 
0.92 
195.10 
± 27.57 
191.92 
± 37.80 
7.11 ± 
0.90 
8.13 ± 
2.29 
4.87 ± 
2.01  
5.91 ± 
1.83 
* VLDL1-apoB data for subject CHOT 01 and 02 is not available. 
 
3.3.2 Effects of high and low sugar diet on body weight and body fat 
Although the study aimed to maintain body weight throughout the two dietary 
interventions, body weight on the high sugar diet was higher than that on the low 
sugar diet, and this difference occurred without any statistically significant difference 
in total energy intake. However, the dietary assessment methods may cause an 
underestimation of energy intake. It has been reported that the underreporting of 
energy intake occurred commonly in self-recorded diet diaries (Samaras et al., 1999; 
Bedard et al., 2004; Johansson et al., 2001). Many factors may explain the 
underreporting of energy intake, such as BMI, body fat, age, smoking habits, 
educational level and environment of living (Macdiarmid and Blundell, 1998; Novotny 
et al., 2003; Johansson et al., 2001). Moreover, the dietary assessment tool itself 
could also be a source of error (Bedard et al., 2004). For example, the reference 
portion size photos in the diet diary might be misused by the participants or not used 
at all.  
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The effects of dietary carbohydrate intake on body weight in previous studies are 
inconsistent. A meta-analysis of 30 randomized controlled trials has suggested that 
among the adults consuming ad libitum diets (with no strict control of food intake), a 
decreased dietary sugar intake was associated with reduced body weight and 
increased intake of sugars was correlated with increased body weight (Morenga et al., 
2013). This finding is consistent with the present study. However, some other 
randomized controlled trials found that an isocaloric diet with either a higher content 
of carbohydrate (54-55% energy contribution from carbohydrate) or a lower content 
of carbohydrate (15% or < 40% energy from carbohydrate), could achieve a 
reduction in body weight and body fat (Brehm et al., 2003; Frisch et al., 2009).  
 
It has been suggested that the type of carbohydrate may be associated with a 
variation of body weight and body fat rather than the percentage of energy from 
carbohydrate (Ma et al., 2005). Sugar intake, particularly fructose, has been 
considered to be a risk factor for obesity (Johnson et al., 2007). Several systematic 
reviews and meta-analysis have examined the relationship between sugar-
sweetened beverage, especially soft drinks, and body weight (Malik et al., 2006; 
Vartanian et al., 2007; Gibson, 2008). It found that higher consumption of sugar-
sweetened beverages was positively associated with increased body weight in both 
short-term feeding trials and long-term follow-up prospective cohort studies (Malik et 
al., 2006; Vartanian et al., 2007). Gibson (2008) also reported that there was a 
significant correlation between sugar-sweetened soft drinks and adiposity. 
Consuming fructose-sweetened beverages for 10 weeks significantly increased 
visceral adipose volume (Stanhope et al., 2009). It has been suggested that greater 
intake of sugar-sweetened beverages, especially carbonated soft drinks and fruit 
drinks containing a high quantity of added sugar, might be an predominate 
contribution to the prevalence of overweight and obesity (Malik et al., 2006). 
Furthermore, it has been found that a high consumption of fruit juices such as apple 
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juice, which contained high fructose and sucrose, may also be associated with 
overweight and obesity.  
 
It has been suggested that the potential mechanism of the promotional effect of 
sugar-sweetened beverages on weight gain is the low satiety of liquid carbohydrates, 
which may lead to the incomplete compensation of energy intake at subsequent 
meals (Malik et al., 2006). A crossover study found that the consumption of liquid 
carbohydrate (soda) promoted a higher energy intake and increased body weight 
during a 4 week study period compared with the isoenergetic solid carbohydrate (jelly 
beans) (DiMeglio and Mattes, 2000). Moreover, there were no differences in satiety 
or subsequent energy intake when people consumed isoenergetic beverages which 
contained different types of sugar, either fructose or sucrose (Monsivais et al., 2007; 
Soenen and Westerterp-Plantenga, 2007).  
 
In the present study, carbonated soft drinks and fruit juices were included in the study 
foods in the high sugar diet but not in the low sugar diet, which could be one of the 
possible explanations of the significant difference in body weight on the high and low 
sugar diets. The carbonated soft drinks and fruit juices with low satiety may promote 
higher energy intake on the high sugar diet, inducing higher body weight than the low 
sugar diet. 
 
3.3.3 Effects of high and low sugar diet on plasma lipids, glucose and insulin 
A positive association between carbohydrate consumption and plasma triglyceride 
and cholesterol has been reported in a cross-sectional study (Leise et al., 2007). It 
has been shown that a high carbohydrate diet (>57.4% of energy in men and >59.1% 
in women) was associated with a higher triglyceride concentration compared with a 
low carbohydrate diet (<38.7% in men and <41% in women), though the total energy 
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intake was lower in the high carbohydrate diet (2467 ± 49 kcal in men and 1664 ± 32 
kcal in women) than the low carbohydrate diet (2912 ± 54 kcal in men and 1998 ± 42 
kcal in women) (Yang et al., 2002). A moderated carbohydrate restricted (26% of 
energy), low-saturated fat diet may achieve a decrease in the plasma level of 
triglyceride (Krauss et al., 2006). It was estimated that every 100g higher intake of 
carbohydrate could result in a 7-8 mg/dL increase in total cholesterol level in men 
and 13-17 mg/dL increase in triglyceride level in women (Leise et al., 2007). In 
contrast, another cross-sectional study by Nichols et al. (1976) did not detect any 
significant relationship between carbohydrate intake and plasma levels of triglyceride 
and cholesterol among people who had similar total energy intake. This finding was 
consistent with the results in the present study.  
 
Two cross-sectional studies with large sample size (n>6000) have investigated the 
relationship between sugar intake and plasma triglyceride, and a strong positive 
association was reported (Welsh et al., 2010; Dhingra et al., 2007). It found that 
higher intake of added sugar is associated with increased triglyceride levels in US 
adults, and among middle-aged adults in the Framingham Heart Study. Individuals 
who consumed ≥1 soft drink per day had higher levels of triglyceride than those 
consuming <1 soft drink per day (Dhingra et al., 2007). The effect of different types of 
dietary sugars on plasma lipids has been investigated in the intervention studies, and 
the findings were variable. A short-term study found overfeeding of glucose in parallel 
with a hypercaloric diet for 7 days among 11 healthy young men (24.6 ± 0.6 years) 
had no effect on fasting plasma triglyceride (Sock et al., 2010), whereas 10-week 
consumption of glucose sweetened beverage (providing 25% of energy) in parallel 
with subjects’ usual ad libitum diet and an energy-balanced diet among 15 older 
adults (54 ± 3 years in men and 56 ± 2 years in women) induced about 10% increase 
in fasting plasma triglyceride concentration (Stanhope et al., 2009). Stanhope and 
Havel (2008) also suggested that consuming sucrose-sweetened beverages could 
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increase postprandial triglyceride levels. However, a single meal containing 75 g 
sucrose had no effect on postprandial triglyceride level (Brynes et al., 2002). 
Moreover, in an intermediate-term study, the effect of sucrose on fasting plasma 
triglyceride was not detected by feeding 70 g sucrose per day in parallel with subjects’ 
habitual diet for 30 days among 40 overweight or obese males and females 
(Yaghoobi et al., 2008).  
 
It has been suggested that fructose, which is commonly found in added sugars, may 
mediate the adverse effects of carbohydrate on plasma lipids by increasing both 
postprandial and fasting triglyceride levels (Johnson et al., 2009). The findings from 
the feeding intervention studies suggested that consumption of either fructose or high 
fructose corn syrup-sweetened beverages (25-30% of energy) was associated with 
an increased 24-hour triglyceride area under the curve (Stanhope et al., 2011; Teff et 
al., 2009). However, an increase in fasting plasma triglyceride concentration was not 
found in another study, which involved the consumption of a fructose-sweetened 
beverage (25% of energy) for 10 weeks (Stanhope et al., 2009). It has been 
suggested that a high flux of fructose in the liver, which is the major organ that 
metabolizes this simple carbohydrate, can disturb glucose metabolism and glucose 
uptake and result in a notable increase in de novo lipogenesis in the liver, hepatic 
triglyceride synthesis and decrease in the clearance rate of peripheral triglyceride 
(Johnson et al., 2009; Basciano et al., 2005). 
 
A remarkable association between soft drink consumption and type 2 diabetes has 
been reported (Vartanian et al., 2007). Sustained consumption of ≥1 soft drink per 
day was linked to impaired fasting glucose in a larger cross-sectional study (Dhingra 
et al., 2007). In feeding studies, consumption of fructose-sweetened beverages (25% 
of energy) for 10 weeks was correlated with raised levels of fasting plasma glucose 
and insulin and decreased insulin sensitivity (Stanhope et al., 2009).  
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In the present study, although the duration of dietary interventions were relatively 
long-term, the sample size was small and it may not be powerful enough to induce a 
significant effect of dietary sugars on plasma lipids, glucose, insulin and insulin 
sensitivity. Moreover, it has been suggested that it is only at an abnormally high 
amount (>20% of energy from sucrose and >5% of energy from fructose), that the 
consumption of fructose and sucrose may lead to the increase in plasma triglyceride 
concentration (Frayn and Kingman, 1995; Fried and Rao, 2003). Therefore, it might 
be possible that the quantity of fructose and sucrose consumed in the test diets in the 
present study was not large enough to promote an essential change in plasma 
triglyceride levels. Unfortunately, the respective amount of fructose and sucrose 
contained in the study foods was not assessed in the present study. The non-
significant difference in the levels of plasma triglyceride might also be explained by 
the variability of fasting triglyceride response to dietary fructose within individuals 
(Stanhope et al., 2009).  
 
3.4 Comparison of subset results with those from whole cohort 
The results from 6 subjects that are presented in this chapter are just a small part of 
the whole dietary intervention study. In terms of the whole cohort (n=25), there was a 
significant difference in fasting plasma triglyceride level (1.79 vs. 1.48 mmol/L, high 
sugar vs. low sugar, p < 0.02). The concentration of HDL, glucose and insulin were 
not significantly different in the whole cohort. 
 
3.5 Limitations and further work 
The sample size in the present study was relatively small, and it may not be powerful 
enough to demonstrate any remarkable differences in plasma lipids, glucose and 
insulin levels, and HDL metabolism on the high and low sugar diet. It would be 
interesting to explore if the GI values in the high and low sugar diet had an impact not 
only on plasma glucose and insulin but also plasma lipid level and HDL 
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concentration. Only total HDL fractions were assessed, changes in HDL subclasses 
were not measured. Although total HDL apoA-I was not changed, there may has 
been changes in HDL subclasses. Moreover, the activities of some lipid transfer 
proteins involved in HDL metabolism, such as CETP and PLTP, could also provide 
valuable information. 
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Chapter 4: Investigation of HDL subclass kinetics using a 
stable isotope technique 
4.1 Introduction 
HDL has an atheroprotective effect, and it could be a more powerful predictor of CHD 
than plasma total cholesterol and LDL cholesterol (Kontush and Chapman, 2006; 
Barter and Rye, 1996). HDL is a heterogeneous particle and its metabolism is 
complex due to the bidirectional inter-conversion between HDL subclasses. 
Therefore, only measuring total HDL may not be able to provide enough information 
regarding the biological functions of individual HDL subclasses. In order to have a 
better understanding of HDL metabolism, an investigation of HDL subclass kinetics 
was performed in the present study. 
 
4.2 Method summary 
A pilot study was carried out firstly among three healthy women aged 18-70. Different 
durations of the study (up to 5, 6 and 10 days) were tested to develop an optimal 
blood sampling protocol for measurement of HDL metabolism. Kinetic studies using 
this optimal blood sampling protocol were carried out subsequently to measure HDL2 
and HDL3, αHDL and preβHDL metabolism in healthy subjects.  
 
Six Caucasian males (n=3) and females (n=3) aged 30-45 with BMI 18.5-25 kg/m2 
were recruited. Subjects were required to fast overnight before all the visits in the 
CEDAR Centre, Royal Surrey County Hospital. Anthropometrics were measured 
before the study, and HDL subclasses kinetics was assessed by using a stable 
isotope technique. L[1-13C] leucine isotope was injected intravenously as a bolus with 
dose of 8 mg/kg. Blood samples were taken at baseline and at intervals up to 10 
hours. Six more single blood samples were collected in the morning in a fasted state 
during the following 2 weeks (Day1, 3, 7, 9, 10 and 14) for further measurement of 
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leucine enrichment. Blood samples for measuring the concentration of plasma lipids, 
HDL, apoA-I, glucose and insulin were taken at baseline, 10h, Day1, Day7 and 
Day14, and blood samples for measuring a-KIC were taken frequently during the first 
10 hours at the study. HDL2 and HDL3 fractions were isolated from plasma via 
untracentrifugation, and αHDL and preβHDL fractions were isolated from plasma by 
agarose gel electrophoresis. After delipidation, apoA-I in the fractions was separated 
using SDS-PAGE. The samples were then purified and derivatized, and finally run on 
the GC-MS to determine the leucine enrichment of apoA-I (Chapter 2, section 2.2.8). 
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4.3 Results  
4.3.1 Optimising the laboratory method – SDS-PAGE 
All the laboratory procedures that were to be used were optimised before carrying out 
the HDL kinetic study. In the process of separation of HDL3 apoA-I by using SDS-
PAGE, the amount of sample that was loaded into each well on the gel was 50 μl in a 
previous study by Li (2009). However, it was found that by loading 50 μl sample, 
HDL3 apoA-I might get contaminated with the samples in adjacent lanes since the 
size of the band was quite large (Figure 31A). This could be due to the overloading of 
the sample. Therefore, the amount of samples loaded on the gel was reduced to 25 
μl and tested again. It has been found that HDL3 apoA-I bands were reduced to a 
more optimal size, reducing the risk of contamination between samples (Figure 31B). 
Moreover, the samples with different loading amount on the SDS-PAGE, 50 μl for 
HDL2 and 25 μl for HDL3, were assessed on the GC-MS. The isotopic area of ion 209 
and 210 for both HDL2 and HDL3 samples had the same digital values, which 
indicated that reducing the loading amount to 25 μl for HDL3 did not affect the 
measurement of leucine enrichment. 
 
Figure 31: Optimizing the laboratory methods: SDS-PAGE. 
A: 50 μl of sample was loaded for both HDL2 and HDL3 for separation of apoA-I bands; B: 50 
μl of sample was loaded for HDL2 and 25 μl was loaded for HDL3 for separation of apoA-I. 
apoA-I 
HDL3 (50 µl)   
A 
prestained 
std 
prestained 
std 
apoA-I 
B 
HDL2 (50 µl)   HDL2 (50 µl)   HDL3 (25 µl)   
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4.3.2 Pilot study – Development of the blood sampling protocol 
Because of the relatively slow turnover rate of apoA-I, which has a mean residence 
time of approximately 5 days (Schaefer et al., 1982), a series of pilot studies were 
undertaken of 1-2 week duration to determine an optimal protocol of blood sampling 
for measuring HDL subclass kinetics. Figure 32, 33, 34 show the αHDL and preβHDL 
apoA-I enrichment (APE) that was determined at timed intervals for 10 hours and 
over the following 5, 6 and 10 days in the first, second and third pilot study 
respectively. The isotopic enrichment values of the last time point in three pilot 
studies are shown in the figures. The values of the last time point in the third pilot 
study (Day 10) for both αHDL and preβHDL apoA-I enrichment (APE) were most 
close to the baseline value compared with the first and second study. 
 
 
 
Figure 32: Leucine enrichment of αHDL and preβHDL apoA-I during 10h study and 
following 5 days in Pilot study 1 
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Figure 33: Leucine enrichment of αHDL and preβHDL apoA-I during 10h study and 
following 6 days in Pilot study 2 
 
 
 
Figure 34: Leucine enrichment of αHDL and preβHDL apoA-I during 10h study and 
following 10 days in Pilot study 3 
 
Isotopic enrichment of HDL2 and HDL3 apoA-I were not measured in pilot study 1. 
Figure 35 and 36 show the HDL2 and HDL3 apoA-I enrichment (APE) that was 
determined in a 10 hour study and over the next 6 and 10 days in pilot study 2 and 3 
respectively. The values of isotopic enrichment (APE) at the last time point in the 
second and third pilot study are shown in the figures. The enrichment at last time 
point for HDL2 and HDL3 apoA-I in the second and third pilot study seemed to be 
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similar. The values at Day 10 for αHDL and preβHDL apoA-I enrichment in the third 
pilot study were most close to the baseline, and the duration of the study up to 10 
days seemed to be the most optimal blood sampling protocol among three pilot 
studies. However, the enrichment of HDL2 and HDL3 apoA-I at Day 10 was not as 
close to the baseline as αHDL and preβHDL apoA-I. Therefore, the duration of the 
study was extended to 14 days in the final study design for a better measurement of 
HDL subclass kinetics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Leucine enrichment of HDL2 and HDL3 apoA-I during 10h study and 
following 10 days in Pilot study 3 
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Figure 35: Leucine enrichment of HDL2 and HDL3 apoA-I during 10h 
study and following 6 days in Pilot study 2 
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4.3.3 HDL subclass kinetic study 
4.3.3.1 Subjects characteristics and lipid profile 
The characteristics of subjects are shown in Table 16 Three male and 3 female 
subjects were aged between 34 to 45 years old. The BMI of subjects 01, 02, 03 and 
04 was in the normal range. Whereas subject 05 was borderline overweight, and 
subject 06 was overweight. All subjects had a normal fasting glucose level (3.9-5.5 
mmol/L). The fasting insulin concentration of subject 01, 03, 04, 05 and 06 was in the 
normal range, while subject 02 had a borderline high fasting insulin concentration 
(fasting insulin level 5-15 mU/L is normal) (Wilcox, 2005).   
 
Table 16: Subject characteristics of HDL subclasses kinetic study (n=6) 
 
Subjects 01 02 03 04 05 06 Mean ± SEM 
Age (years) 45 34 34 35 34 34 36 ± 1.81 
Gender 
 
F F F M M M - 
Height (m) 1.72 1.67 1.66 1.79 1.79 1.76 1.73 ± 0.02 
Weight (kg) 68.6 54.6 67.5 74.2 87.0 77.7 71.60 ± 4.46 
Fat mass (kg) 25.7 15.6 24.1 13.7 17.4 15.0 18.58 ± 2.07 
FFM (kg) 42.9 40.5 44.8 60.6 69.3 63.5 53.60 ± 5.02 
BMI (kg/m2) 23.2 19.6 24.5 23.2 25.1 27.2 23.80 ± 1.03 
Glucose (mmol/L) 5.24 5.20 5.30 5.31 4.81 4.83 5.12 ± 0.09 
Insulin (mU/L) 12.3 15.0 9.6 10.9 8.9 7.4 10.68 ± 1.10 
HOMA2-IR  1.60 1.94 1.26 1.43 1.14 0.95 1.39 ± 0.14 
F: female; M: male; FFM: fat free mass; HOMA-IR: The homeostasis model assessment 2 - 
insulin resistance 
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Table 17 presents the plasma lipids, HDL and apoA-I concentration of the six 
subjects. All subjects had a normal fasting plasma triglyceride (<1.7 mmol/L). The 
fasting plasma cholesterol level for female subjects 01 and 02, and male subjects 04 
and 06 were in the normal range (<5 mmol/L), while female subject 03 and male 05 
had slightly higher plasma cholesterol. All female subjects, 01, 02 and 03, had a 
normal plasma HDL-C level (1.2-2.0 mmol/L) (Barter, 1994). Male subjects 04 and 05 
had a normal level of HDL-C (1.1-1.8 mmol/L), while the HDL-C concentration of 
subject 06 was below the normal range. 
 
There were no correlations between body weight and plasma triglyceride, and 
between body weight and plasma cholesterol level. A significant positive association 
was found between plasma HDL-C concentration and plasma apoA-I level (r = 0.954, 
p = 0.002). There was no statistically significant difference found in triglyceride and 
cholesterol levels between HDL2 and HDL3 fractions. No correlations were observed 
between plasma triglyceride concentration and triglyceride level in HDL2 and HDL3 
fractions. No correlation was found between plasma cholesterol and HDL2 
cholesterol (r = -0.039, p = 0.470), while a significant positive association was 
observed between plasma cholesterol concentration and cholesterol level in the 
HDL3 fraction (r = 0.839, p = 0.018).  
 
Plasma HDL-C concentration was significantly correlated with HDL2 cholesterol (r = 
0.903, p = 0.007) but not with HDL3 cholesterol (r = 0.483, p = 0.166). A significant 
difference was observed between HDL2 apoA-I and HDL3 apoA-I (p = 0.002), and 
also between αHDL apoA-I and preβHDL apoA-I concentration (p = 0.000). Moreover, 
plasma HDL-C was significantly correlated with HDL2 apoA-I and αHDL apoA-I (r = 
0.868, p = 0.012 and r = 0.986, p = 0.000) but not with HDL3 apoA-I and preβHDL 
apoA-I (r = 0.134, p = 0.400 and r = 0.594, p = 0.107 respectively). In addition, a 
significant correlation was found between plasma apoA-I concentration and HDL2 
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apoA-I (r = 0.900, p = 0.007) but not HDL3 apoA-I (r = -0.039, p = 0.471), whereas a 
significant positive association was observed between both plasma apoA-I and 
prebHDL apoA-I (r = 0.787, p = 0.032), and plasma apoA-I and aHDL apoA-I levels (r 
= 0.953, p = 0.002). In the whole group, the ratio of cholesterol to TG in HDL2 and 
HDL3 fractions were 7.00 and 7.13 respectively. 
 
With respect to gender differences, there was no significant difference in plasma 
triglyceride and cholesterol levels. There was also no significant difference in plasma 
HDL-C between female and male subjects, whereas a significant difference was 
found in plasma apoA-I concentration (p = 0.036). Moreover, there were no 
statistically significant differences in triglyceride, cholesterol and apoA-I levels in 
HDL2 and HDL3 fractions. The only significant difference in HDL subclass variations 
was observed in aHDL apoA-I between females and males (p = 0.041) but not in 
prebHDL apoA-I.  
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Table 17:  Lipid profile and apoA-I concentration of the subjects in HDL subclasses kinetic study 
 
Subjects Plasma-
TG 
(mmol/L) 
Plasma-
CHOL 
(mmol/L) 
Plasma 
HDL-
CHOL 
(mmol/L) 
HDL2-TG 
(mmol/L) 
HDL3-TG 
(mmol/L) 
HDL2-
CHOL 
(mmol/L) 
HDL3-
CHOL 
(mmol/L) 
Plasma 
apoA-I 
(g/L) 
HDL2 
apoA-I 
(g/L) 
HDL3 
apoA-I 
(g/L) 
αHDL 
apoA-I 
(g/L) 
preβHDL 
apoA-I 
(g/L) 
01 0.89 4.18 1.66 0.07 0.06 0.73 0.47 1.37 0.43 0.53 1.10 0.27 
02 1.12 4.82 1.23 0.06 0.11 0.29 0.58 1.14 0.18 0.73 0.97 0.17 
03 0.77 5.34 1.68 0.06 0.07 0.61 0.75 1.26 0.36 0.80 1.14 0.12 
Female 
mean ± 
SEM 
0.93 ± 
0.10 
4.78 ± 
0.33 
1.52 ± 
0.14 
0.06 ± 
0.00 
0.08 ± 
0.02 
0.54 ± 
0.13 
0.60 ± 
0.08  
1.26 ± 
0.07 
0.32 ± 
0.08 
0.69 ± 
0.08 
1.07 ± 
0.05 
0.19 ± 
0.04 
04 1.07 4.28 1.12 0.07 0.09 0.38 0.55 1.01 0.17 0.71 0.88 0.13 
05 0.49 5.85 1.30 0.06 0.09 0.29 0.64 1.07 0.10 0.75 0.94 0.13 
06 1.03 3.95 0.91 0.05 0.07 0.21 0.45 0.89 0.12 0.58 0.80 0.09 
Male 
mean ± 
SEM 
0.86 ± 
0.19 
4.70 ± 
0.59 
1.11 ± 
0.11 
0.06 ± 
0.01 
0.08 ± 
0.01 
0.29 ± 
0.05 
0.55 ± 
0.06 
0.99 ± 
0.05* 
0.13 ± 
0.02 
0.68 ± 
0.05 
0.87 ± 
0.04* 
0.12 ± 
0.01 
All 
subjects 
mean ± 
SEM 
0.90 ± 
0.10 
4.74 ± 
0.30 
1.32 ± 
0.12 
0.06 ± 
0.00 
0.08 ± 
0.01 
0.42 ± 
0.08 
0.57 ± 
0.05 
1.12 ± 
0.07 
0.23 ± 
0.06 
0.68 ± 
0.04 
0.97 ± 
0.05 
0.15 ± 
0.03 
TG: triglyceride; CHOL: cholesterol; HDL: high density lipoprotein; apoA-I: apolipoprotein A-I 
* Significant difference (p < 0.05) between males and females 
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4.3.3.2 α-KIC enrichment during the first 10 hours in HDL subclass kinetic study 
Figure 37 shows the mean α-KIC enrichment (APE) of 6 subjects in the HDL kinetic 
study. α-KIC enrichment peaked at 5 minutes and then decreased rapidly and returned 
to baseline values at the end of the first 10 hour of the study. 
 
 
Figure 37: α-KIC enrichment during the first 10 hour in HDL subclass kinetic study of all 
subjects (n=6). (mean ± SEM) 
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4.3.3.3 Isotopic enrichment of preβHDL and αHDL 
The mean leucine enrichment of αHDL & preβHDL apoA-I (APE) for all subjects during 
the first 10 hour of the study is shown in Figure 38 and the data for females and males is 
shown in Figure 39 and Figure 40. The enrichments for each subject are shown in 
Appendix 7. Among all subjects, the leucine enrichment of αHDL & preβHDL apoA-I was 
increased similarly in the first 6 hours while the enrichment of preβHDL apoA-I started to 
decrease at 8 hours and the enrichment of αHDL apoA-I started to decrease at 10 hours.  
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Figure 38: Leucine enrichment of αHDL & preβHDL apoA-I during the first 
10 hours in the HDL kinetic study of all subjects (n=6). (mean ± SEM) 
Figure 39: Leucine enrichment of αHDL & preβHDL apoA-I during the first 
10 hours in the HDL kinetic study of the females (n=3). (mean ± SEM) 
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The mean leucine enrichment of αHDL & preβHDL apoA-I (APE) for all subjects during 
the whole 14 day study is shown in Figure 41 and the data for the female and male 
subjects is shown separately in Figure 42 and Figure 43. The enrichments for each 
subject are shown in Appendix 7. Leucine enrichment for both αHDL & preβHDL apoA-I 
continued to decrease after Day 1 and the values on the last day (Day 14) were close to 
the baseline level.  
 
There was no significant difference in the area under the curve (AUC) of leucine 
enrichment between αHDL & preβHDL apoA-I during the first 10 hours of the study and 
the following 14 days among all 6 subjects and within the female and male group. There 
was also no statistically significant difference in the AUC of αHDL & preβHDL apoA-I 
leucine enrichment between female and male subjects. 
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Figure 40: Leucine enrichment of αHDL & preβHDL apoA-I during the first 
10 hours in the HDL kinetic study of the males (n=3). (mean ± SEM) 
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Figure 41: Leucine enrichment of αHDL & preβHDL apoA-I during the 14 
day HDL kinetic study of all subjects (n=6) (mean ± SEM) 
Figure 42: Leucine enrichment of αHDL & preβHDL apoA-I during the 14 
day HDL kinetic study of the females (n=3) (mean ± SEM) 
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Figure 43: Leucine enrichment of αHDL & preβHDL apoA-I during the 14 
day HDL kinetic study of the males (n=3) (mean ± SEM) 
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4.3.3.4 Isotopic enrichment of HDL2 and HDL3 
Figure 44 shows the leucine enrichment of HDL2 and HDL3 apoA-I (APE) during the first 
10 hours of the study for all subjects, and the results for female and male subjects are 
shown in Figure 45 and Figure 46 respectively. The enrichment in each subject is shown 
in Appendix 7. 
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Figure 44: Leucine enrichment of HDL2 and HDL3 apoA-I during the first 10 
hours in the HDL kinetic study of all subjects (n=6). (mean ± SEM) 
Figure 45: Leucine enrichment of HDL2 and HDL3 apoA-I during the first 10 
hours in the HDL kinetic study of the females (n=3). (mean ± SEM) 
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The mean leucine enrichment of HDL2 and HDL3 apoA-I (APE) for all subjects during the 
14 day study is shown in Figure 47, and the data for the female and male subjects is 
shown separately in Figure 48 and Figure 49. The enrichment in each subject is shown 
in Appendix 7. Compared to HDL2 apoA-I, leucine enrichment of HDL3 apoA-I increased 
more rapidly, and the values of HDL3 apoA-I enrichment were higher during the first 10 
hours of the study and the next 14 days.   
 
No significant difference was observed in the AUC of leucine enrichment between HDL2 
and HDL3 apoA-I during the first 10 hours of the study and next two weeks among all 
subjects and within female and male group. However, a statistically significant difference 
was found in the AUC of HDL3 apoA-I leucine enrichment during the first 10 hours 
between female and male subjects (p = 0.024) but not in in the AUC of HDL2 apoA-I 
leucine enrichment (p = 0.593). 
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Figure 46: Leucine enrichment of HDL2 and HDL3 apoA-I during the first 10 
hours in the HDL kinetic study of the males (n=3). (mean ± SEM) 
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Figure 47: Leucine enrichment of HDL2 and HDL3 apoA-I during the 14 day 
HDL kinetic study of all subjects (n=6) (mean ± SEM) 
Figure 48: Leucine enrichment of HDL2 and HDL3 apoA-I during the 14 day 
HDL kinetic study of the females (n=3) (mean ± SEM) 
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Figure 49: Leucine enrichment of HDL2 and HDL3 apoA-I during the 14 days 
HDL kinetic study of the males (n=3) (mean ± SEM) 
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4.3.3.5 Fractional clearance rate and production rate of HDL subclasses 
Table 18 shows the fractional clearance rate (FCR) and production rate (PR) of αHDL 
and preβHDL for all subjects, and Table 19 shows the comparison of the FCR and PR 
(in both mg/kg BW/day and mg/kg FFM/day) of αHDL and preβHDL between female and 
male subjects. There was a statistically significant difference was found between αHDL 
and preβHDL PR for all subjects (p = 0.010) but no significant difference between αHDL 
and preβHDL FCR (p = 0.546). Moreover, no significant differences were observed in 
αHDL and preβHDL FCR and PR between female and male subjects. There was also no 
significant difference in αHDL and preβHDL FCR within female and male groups. The 
αHDL PR and preβHDL PR in mg/kg FFM/day was on the borderline of being significant 
different within female group (p = 0.050) but not within male group (p = 0.093). In 
addition, there was no association between αHDL and preβHDL apoA-I concentration 
and FCR or PR of αHDL and preβHDL. 
 
Table 18: Fractional clearance rate and production rate of αHDL and preβHDL for 
all subjects 
 
Subjects FCR (pools/day) PR (mg/kg BW/day) 
αHDL preβHDL αHDL preβHDL 
01 0.08 0.09 3.28 0.84 
02 0.17 0.03 6.91 0.25 
03 0.11 0.10 4.49 0.44 
04 0.05 0.10 1.89 0.55 
05 0.13 0.19 4.47 0.93 
06 0.08 0.29 2.62 1.01 
Mean ± SEM 0.10 ± 0.02 0.13 ± 0.04 3.94 ± 0.73 0.67 ± 0.12 
Paired T-test p = 0.546 p = 0.010 
BW: body weight 
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Table 19: Comparison of fractional clearance rate and production rate of αHDL 
and preβHDL between female and male subjects  
 
Subjects  
(Mean ± SEM)  
FCR (pools/day) PR (mg/kg BW/day) PR (mg/kg FFM/day) 
αHDL preβHDL αHDL preβHDL αHDL preβHDL 
Females  
(n=3) 
0.12 ± 0.03 0.07 ± 0.02 4.89 ± 1.07 0.51 ± 0.18 7.11 ± 1.19 0.78 ± 0.30* 
Males  
(n=3) 
0.09 ± 0.02 0.19 ± 0.05 3.00 ± 0.77 0.83 ± 0.14 3.71 ± 0.99 1.03 ± 0.18 
Independent 
Samples  
T-test 
p = 0.399 p = 0.130 p = 0.226 p = 0.229 p = 0.094 p = 0.528 
* p = 0.05, the differences between αHDL and preβHDL PR within female group 
BW: body weight; FFM: free fat mass 
 
 
 
 
Table 20 shows the fractional clearance rate (FCR) and production rate (PR) of HDL2 
and HDL3 for all subjects, and Table 21 shows the comparison of FCR and PR (in both 
mg/kg BW/day and mg/kg FFM/day) of HDL2 and HDL3 between female and male 
subjects. There was a significant difference between HDL2 and HDL3 PR for all subjects 
(p = 0.030) but not between HDL2 and HDL3 FCR (p = 0.878). There was a significant 
difference in HDL2 PR in both mg/kg BW/day and mg/kg FFM/day between females and 
males (p = 0.017 and p = 0.028). However, there was no significant difference in HDL2 
FCR, HDL3 FCR and HDL3 PR between female and male subjects. Moreover, within the 
male group a significant difference was observed between HDL2 and HDL3 FCR (p = 
0.023), and between HDL2 and HDL3 PR (p = 0.023 for mg/kg BW/day and p = 0.026 for 
mg/kg FFM/day).  
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Table 20: Fractional clearance rate and production rate of HDL2 and HDL3 for all 
subjects  
 
Subjects FCR (pools/day) PR (mg/kg BW/day) 
HDL2 HDL3 HDL2 HDL3 
01 0.15 0.14 2.40 2.71 
02 0.21 0.10 1.56 2.87 
03 0.18 0.10 2.29 2.98 
04 0.09 0.13 0.62 3.79 
05 0.14 0.21 0.54 5.91 
06 0.14 0.20 0.67 4.61 
Mean ± SEM 0.15 ± 0.02 0.15 ± 0.02 1.35 ± 0.35 3.81 ± 0.51 
Paired T-test p = 0.878 p = 0.030 
BW: body weight 
 
 
Table 21: Comparison of fractional clearance rate and production rate of HDL2 and 
HDL3 between female and male subjects  
 
Subjects 
(Mean ± SEM) 
FCR (pools/day) PR (mg/kg BW/day) PR (mg/kg FFM/day) 
HDL2 HDL3 HDL2 HDL3 HDL2 HDL3 
Females  
(n=3) 
0.18 ± 0.02 0.11 ± 0.01 2.08 ± 0.26 2.86 ± 0.08 3.13 ± 0.52 4.24 ± 0.19 
Male  
(n=3) 
0.13 ± 0.02 0.18 ± 0.03* 0.61 ± 0.04 4.77 ± 0.62*  0.75 ± 0.04 5.90 ± 0.81* 
Independent 
Samples  
T-test 
p = 0.078 p = 0.090 p = 0.017 p = 0.063 p = 0.028 p = 0.145 
* p < 0.05, the differences between HDL2 and HDL3 FCR or PR within male group 
BW: body weight; FFM: free fat mass 
 
 
The mathematical model developed in the present project did not allow a good fit to all 
the leucine enrichment data of αHDL, preβHDL, HDL2 and HDL3. Therefore, the kinetic 
data calculated from the modelling are not present in this thesis. 
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4.4 Discussion 
This study is the first study to measure preβHDL, αHDL, HDL2 and HDL3 over a time 
period which captures the whole dynamics of HDL metabolism. Although this was a 
small study, with 3 men and 3 women, a significant difference in HDL2 kinetics was 
observed between the genders. 
 
4.4.1 The metabolism of αHDL and preβHDL in healthy subjects 
In the present study, a bolus injection of 13C leucine stable isotope was used to measure 
the kinetics of αHDL and preβHDL apoA-I, and a two-dimensional electrophoresis 
technique was applied to separate αHDL and preβHDL fractions from plasma, and apoA-
I from these two fractions. The measurement of αHDL and preβHDL apoA-I kinetics 
used the same laboratory methods described in a previous study by Li et al. (2012). The 
FCR and PR of αHDL and preβHDL apoA-I in this previous study are shown in Table 22, 
and these values were higher than the results in the current study. Moreover, in the 
study by Li et al. (2012), the FCR of preβHDL apoA-I was significantly higher than FCR 
of αHDL apoA-I. In the present study, though the FCR of preβHDL apoA-I was higher 
than FCR of αHDL apoA-I, the difference was not significant. In the current study, the PR 
of preβHDL apoA-I was significantly lower than PR of αHDL apoA-I, as shown in the 
previous study by Li et al. (2012).  
 
In the study by Li et al. (2012), the study population (2 men and 4 women) was similar to 
the current study, whereas the clinical protocol was different. In this previous study, a 
precursor product technique in which 13C leucine stable isotope was given as a priming 
dose followed by a constant infusion for 9 hours was used, and FSR of preβHDL and 
αHDL apoA-I were calculated from the precursor pool enrichment of hepatic intracellular 
 147 
leucine, which is α-KIC, and the slope of the apoA-I enrichment curve for 9 hours. 
Theoretically, FSR is equal to FCR in a steady state. However, in the current study, FCR 
of preβHDL and αHDL apoA-I was directly estimated from the slope of the apoA-I 
enrichment (APE) decay curve (2-14 days). Hence, the differences in the results 
between the present study and the previous study Li et al. (2012) may due to the stable 
isotope labelling method for kinetic analysis, the duration of the clinical protocol, and the 
calculation method for FCR.  
 
Table 22: Summary of data on preβHDL and αHDL apoA-I kinetic parameters 
obtained with stable isotopes in the previous studies 
 
Study FCR (pools/day) PR (mg/kg/day) 
preβHDL* αHDL preβHDL* αHDL 
Li et al. (2012) – 
Healthy subjects 
0.204 ± 0.017 
(0.124 – 0.237) 
0.170 ± 0.016 
(0.107 – 0.209) 
1.082 ± 0.048 
(0.96 – 1.27) 
7.150 ± 0.387 
(5.67 – 8.37) 
Chetiveaux et al. 
(2004) – Healthy 
subjects 
0.263 ± 0.085 
(0.142 – 0.367) 
0.112 ± 0.026 
(0.076 – 0.121) 
7.65 ± 2.75  
(5.14 - 11.12) 
396.75 ± 242.78 
(189.54 – 
844.75) 
Chetiveaux et al. 
(2006) – T2D 
subjects 
0.448 ± 0.210 
(0.286 – 0.850) 
0.249 ± 0.010 
(0.230 – 0.259) 
10.31 ± 2.65 
(5.87 – 12.62) 
446.14 ± 185.34 
(185.34 – 
684.32) 
*For Chetiveaux et al. (2004 & 2006) preβ1HDL was measured rather than preβHDL.  
T2D: Type 2 diabetes 
 
 
It has been found that preβHDL can be divided into preβ1HDL and preβ2HDL subclasses 
based on particle size (Asztalos et al., 2004). PreβHDL is present in low concentrations 
in plasma, which leads to technical difficulties in separating it and assessing its kinetics. 
Very few studies have investigated the kinetics of preβHDL, and most studies working 
on preβHDL and αHDL kinetics were reported by Chetiveaux et al. (2002, 2004, 2006). 
An infusion of [5,5,5-2H3] leucine for 14 hours was used to examine apoA-I-HDL kinetics 
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in a fasting state, and preβ1HDL and αHDL were isolated by fast protein liquid 
chromatography (FPLC). The kinetics of preβ1HDL and αHDL was investigated in both 
healthy and type II diabetes patients. Chetiveaux et al. (2004) reported that in healthy 
male subjects (n=6), the FCR of preβ1HDL and αHDL apoA-I was 0.263 ± 0.085 and 
0.112 ± 0.026 pools/day (Table 22), which is similar to the previous study by Li et al., 
(2012) but higher than the current study. The absolute production rate (APR) of 
preβ1HDL and αHDL apoA-I in the study by Chetiveaux et al. (2004) was 7.65 ± 2.75 
and 396.75 mg/kg/day, which is also higher than the current study.  
 
Only total preβHDL was separated in the current study rather than preβ1HDL, and the 
kinetic data in the study by Chetiveaux et al. (2004) was obtained from a multi-
compartmental model using computer software for simulation, analysis and modelling, 
SAAM II. Therefore, these factors may cause the difference in the results in the present 
study and in Chetiveaux’ study. Chetiveaux et al. (2002) reported that using FPLC 
method to separate preβ1HDL and αHDL could lead to the dilution of samples. Li et al. 
(2012) also suggested that compared to the two-dimensional electrophoresis technique 
which separates preβHDL and αHDL directly from plasma, using FPLC may result in 
overlap between HDL subclasses which may occur when samples were processed in the 
buffers during the isolation. These disadvantages of the FPLC method may cause errors 
in the kinetic results. Moreover, the different methods used for stable isotope labelling, 
as well as the different duration of the study may also lead to the different results. 
 
In the study by Chetiveaux et al. (2004, 2006), the APR was estimated as the product of 
FPR and pool size of apoA-I in HDL subclasses, which is similar to the calculation 
method of PR used in the current study. Furthermore, in Chetiveaux’ study, the pool size 
of preβ1HDL and αHDL apoA-I in healthy subjects (7.72 ± 2.86 and 56.13 ± 6.13 mg/kg 
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respectively) was similar to the current study (8.1 ± 1.7 and 51.3 ± 4.4 mg/kg for 
preβHDL and αHDL apoA-I respectively).  Ooi et al. (2006) reviewed 29 published 
articles which measured the kinetics of plasma total HDL apoA-I in healthy subjects 
using both radioactive and stable isotopes. They reported that the mean PR of total HDL 
apoA-I assessed by stable isotopes was 12.1 ± 0.67 mg/kg. In the study by Chetiveaux 
et al. (2004, 2006), the APR of preβ1HDL and αHDL apoA-I is much higher than PR of 
total HDL apoA-I reported by Ooi et al. (2006). The possible explanation for this huge 
difference in PR could be the calculation error. Based on the equation 3 (Chapter2, 
section 2.2.15), the PR in healthy subjects was recalculated using the data of FCR and 
apoA-I pool size reported by Chetiveaux et al. (2004), and the results are shown in Table 
23. The recalculated PR of preβ1HDL and αHDL seems to be much closer to the data 
reported by Ooi et al. (2006) and Li et al., (2012). 
 
Table 23: Recalculated results of APR of preβ1HDL and αHDL in healthy subjects 
in the study by Chetiveaux et al., 2004 
 
Subjects (n=6) preβ1HDL (mg/kg/day) αHDL (mg/kg/day) 
S1 2.51 4.98 
S2 2.71 4.32 
S3 2.65 8.88 
S4 0.88 6.49 
S5 0.77 6.09 
S6 NI 6.77 
Mean ± SEM 1.9 ± 0.99 6.25 ± 1.59 
APR: absolute production rate; NI: not identifiable 
 
In the present study, the PR of preβHDL apoA-I was lower than the PR of αHDL apoA-I, 
which was not expected since preβHDL is considered to be the precursor pool of αHDL. 
However, it has been suggested that preβHDL is a mixture of nascent HDL, recycled 
lipid-poor apoA-I and the remnants of large HDL particles (Rye and Barter, 2004; Lewis 
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and Rader, 2005; Barrans et al., 1994). Li et al. (2012) suggested that as the precursor 
of αHDL, the enrichment of preβHDL apoA-I could be diluted by the recycling of apoA-I, 
which would lead to an erroneously low production rate. 
 
It has been reported that both pre- and post-menopausal women have higher levels of 
HDL-C and apoA-I than age-matched men (Collins, 2008; Schaefer et al., 1982; Velez-
Carrasco et al., 2000), as shown in the current study. Schaefer et al. (1982) investigated 
apoA-I metabolism in young healthy men and women aged 22 ± 2 and 21 ± 2 years 
respectively, and they suggested that the higher plasma apoA-I concentration in females 
might due to the higher apoA-I synthesis rate compared to male subjects. The higher 
production rate of apoA-I in women could be due to hormonal effects. It has been found 
that estrogen administration mainly increases the levels of HDL that contain apoA-I 
without apoA-II rather than HDL particles which contained both apoA-I and apoA-II 
(Walsh et al., 1991). Another study which investigated apoA-I metabolism in older 
subjects (11 postmenopausal women and 11 men aged >50 years) also showed a 
higher secretion rate of total apoA-I in females compared with males (Tilly-Kiesi et al., 
1997). However, in the study by Velez-Carrasco et al. (2000) which examined the apoA-I 
kinetics in 14 postmenopausal women and 18 men aged >40 years, it found that the 
secretion rate of apoA-I was similar between men and women while gender differences 
was shown in apoA-I FCR. The study population and study protocol was similar in the 
study by Tilly-Kiesi et al. (1997) and by Velez-Carrasco et al. (2000), and the calculation 
method of apoA-I SR, which was as FCR (pools per day) × apolipoprotein pool size 
(mg)/body weight (kg), was the same in these two studies. However, the apoA-I FSR, 
which is equal to apoA-I FCR under the steady state, was estimated by fitting 
tracer/trace ratios to a monoexponential function using the SAAM II program in the study 
by Velez-Carrasco et al. (2000), and was calculated by dividing the rate of appearance 
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of deuterated leucine in HDL subclass apoA-I by the VLDL apoB-100 plateau enrichment 
(assuming to be the precursor pool enrichment) in the study by Tilly-Kiesi et al. (1997). 
Therefore, this difference in analysed methods of kinetic data may cause the difference 
in the results of apoA-I FCR and SR between the two studies. A study by Brinton et al. 
(1994) which involved 57 subjects with a wide range of age and HDL-C levels also found 
no difference in apoA-I secretion rate between men and women, but a lower apoA-I FCR 
in females than males.  
 
The PR of apoA-I in the studies discussed above was all expressed in terms of body 
weight. It has been known that women usually have higher levels of body fat than men, 
and apoA-I is synthesised from the intestine and liver but not from adipose tissues. 
Hence, expressing the PR of apoA-I by body weight, which includes body fat, might 
affect the accuracy of assessing the gender differences. In the present study, apoA-I PR 
was presented in both body weight and FFM to investigate the difference between the 
two genders. However, no differences were observed between males and females by 
expressing the apoA-I PR in either body weight or FFM. The non-significant difference in 
both FCR and PR of αHDL apoA-I between the two genders in the current study, which 
was also showed in the study by Li et al. (2012), might be due to the small sample size. 
 
For future work, a larger sample size is needed to assess the difference in αHDL and 
preβHDL metabolism between men and women, and also in the whole group. For the 
calculation of kinetic parameters, modelling using multi-compartmental analysis may 
improve the understanding of HDL metabolism, since it can provide not only the FCR 
and PR but also the conversion rate between the HDL subclasses. 
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4.4.2 The metabolism of HDL2 and HDL3 in healthy subjects 
 A bolus injection of 13C leucine stable isotope was used to measure the kinetics of HDL2 
and HDL3 apoA-I in the present study. Ultracentrifugation and SDS-PAGE technique 
were utilized to separate HDL2 and HDL3 fractions from plasma, and apoA-I in these two 
fractions. A previous study measured HDL2 and HDL3 kinetics in six healthy subjects 
using a constant infusion of 13C leucine stable isotope (Li, 2009), and the laboratory 
method used in this study was the same as the present study. In this previous study, the 
FCR of HDL2 and HDL3 apoA-I was 0.182 ± 0.017 and 0.155 ± 0.013 pools/day, and the 
PR of HDL2 and HDL3 apoA-I was 3.174 ± 0.688 and 3.861 ± 0.740 mg/kg/day (Table 
24). Except HDL2 apoA-I PR, which is higher than the present study, the FCR of HDL2 
and HDL3 apoA-I and PR of HDL3 apoA-I were remarkably similar between Li’s study and 
the current study. Additionally, in Li’s study, the FCR of HDL2 apoA-I was significantly 
higher than FCR of HDL3 apoA-I, and PR of HDL2 and HDL3 apoA-I was similar. However, 
in the present study, FCR of HDL2 apoA-I and FCR of HDL3 apoA-I are similar, and PR of 
HDL2 apoA-I was significantly lower than PR of HDL3 apoA-I.  
 
The study population in Li’s study was similar to the present study (aged 36 ±1.81 vs. 
37.67 ± 3.4 years, BMI 23.80 ± 1.03 vs. 23.85 ± 1.04 kg/m2), with 4 females and 2 
males. In the current study, the number of men and women was equal, and the PR of 
HDL2 apoA-I in men was much lower than that in women, which would lead to a lower 
value of mean PR of HDL2 apoA-I for the whole group. Furthermore, as mentioned in the 
previous section 4.4.1, the differences between the results in the present study and Li’s 
study (2009) may also be caused by the different method of stable isotope labelling for 
kinetic measurement, the different duration of blood sampling protocol and the different 
calculation method for FCR. 
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Table 24: Summary of data on HDL2 and HDL3 apoA-I kinetic parameters obtained 
with stable isotopes in the previous study by Li (2009) 
 
Subjects Gender FCR (pools/day) PR (mg/kg/day) 
HDL2 HDL3 HDL2 HDL3 
S1 F 0.166 0.152 5.24 2.35 
S2 F 0.164 0.141 4.91 3.28 
S3 M 0.203 0.173 2.63 3.65 
S4 F 0.116 0.101 3.51 2.08 
S5 M 0.220 0.183 1.14 6.95 
S6 F 0.223 0.183 1.63 4.86 
Female  
(Mean ± SD) 
 0.167 ± 0.043 0.144 ± 0.034* 3.820 ± 1.643 3.141 ± 1.257 
Male 
(Mean ± SD) 
 0.211 ± 0.012 0.178 ± 0.007 1.882 ± 1.051 5.301 ± 2.336 
All subjects 
(Mean ± SD) 
 0.182 ± 0.041 0.155 ± 0.032* 3.174 ± 1.686 3.861 ± 1.812 
* p < 0.05, the differences between HDL2 and HDL3 FCR in all subject or within female group 
 
Two previous studies have investigated the kinetics of HDL2 and HDL3 in healthy 
subjects, patients with type 2 diabetes and postmenopausal women (Frenais et al., 1997; 
Walsh et al., 1994). However, both of these studies showed no significant difference in 
HDL2 and HDL3 apoA-I metabolism. It is known that HDL2 and HDL3 can be 
interconverted between each other, and the similarity of HDL2 and HDL3 apoA-I kinetics 
may indicate that there is a rapid cycle of apoA-I between HDL particles or a fast 
interconversion rate between these subclasses (Frenais et al., 1997; Walsh et al., 1994). 
In the study by Frenais et al. (1997), HDL2 and HDL3 were separated by gradient 
ultracentrifugation. By using this gradient ultracentrifugation method, lipoproteins in a 
sample are separated based on different density in a single spin. Therefore, this method 
may cause difficulties in avoiding the disturbance of different fractions when removing 
them, and in identifying the density ranges for each fraction without any visible marker, 
which may lead to a mixture of HDL2 and HDL3 (Li, 2009). However, in the present study, 
the isolation of HDL2 and HDL3 fractions was achieved by sequential ultracentrifugation 
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for each fraction, and each lipoprotein fraction was removed after each 
ultracentrifugation step, which reduced the possibility of mixing of fractions. In the study 
by Walsh et al. (1994), although sequential ultracentrifugation was also used to separate 
HDL2 and HDL3, the plasma was stored at -80 °C before sequential ultracentrifugation, 
and freezing and thawing affect the integrity of HDL2 and HDL3. The differences in the 
results between the current study and previous studies may be also due to the 
differences in subject characteristics, the duration of clinical study protocol and the small 
sample size.  
 
Hasselwander et al. (1999) investigated the composition of total HDL among 10 healthy 
subjects (5 female and 5 male), and found that that HDL particles contain higher 
proportion of cholesterol (0.59 ± 0.13 mmol/g HDL protein) and lower amount of 
triglyceride (0.05 ± 0.03 mmol/g HDL protein). In terms of HDL subclasses, it has been 
shown that both HDL2 and HDL3 comprise higher percentage of cholesterol esters and 
lower percentage of triglyceride among healthy subjects (Shuhei et al., 2010). These 
results match the data in the present study. Moreover, Shuhei et al. (2010) also reported 
that the ratio of CE/TG in HDL2 and HDL3 fractions were 6.00 and 7.07 respectively, 
which is similar to the cholesterol to TG ratio in HDL2 and HDL3 fractions in the current 
study (7.00 and 7.13 respectively).  
 
According to the particle size, HDL2 can be further divided into HDL2b and HDL2a, and 
HDL3 can be divided into HDL3a, HDL3b and HDL3c (Barter, 2002). It has been suggested 
that HDL2 is a more variable subfraction and reflects the alteration in total HDL levels 
(Bakogianni et al., 2001). Schaefer et al. (1982) suggested the level of total HDL is 
significantly associated with the level of HDL2b and HDL2a. In the present study, the total 
HDL-C concentration was strongly associated with HDL2 cholesterol and HDL2 apoA-I 
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levels, which matches the findings in the previous studies. Moreover, PR of HDL2 was 
significantly higher in women than men, which could be a possible explanation of a 
higher total HDL concentration in females compared to males.  
 
Pathological conditions like CHD and type 2 diabetes have been found to be associated 
with a decreased level of HDL2 cholesterol and increased HDL3 cholesterol 
concentration (Bakogianni et al., 2001). Shuhei et al. (2010) investigated the distribution 
of HDL subclasses in 36 low-HDL-C subjects (12 of them had CHD) and 41 healthy 
subjects with normal HDL-C levels, and they found that the proportion of HDL2b was 
remarkably lower, while the amount of HDL3a and HDL3b were significantly higher in 
subjects with low HDL-C compared to the healthy subjects. Moreover, it has been 
suggested that the protective effect of total HDL against CHD is primarily performed by 
the HDL2 fraction (Bakogianni et al., 2001). However, an inconsistent finding arose in the 
study by Kontush et al. (2003). It has been known that oxidation of LDL is a key stage in 
inflammation and atherogenesis, and HDL has the effect on protecting LDL from 
oxidation. Kontush et al. (2003) examined the capacity of HDL subclasses to protect the 
oxidation of LDL, and reported that the antioxidative activity of HDL enhanced with the 
increment of the density of subclass particles: HDL2b<HDL2a<HDL3a<HDL3b<HDL3c. They 
suggested that the small and dense HDL3 particles had a higher capacity to protect LDL 
against oxidation than HDL2 particles, which implies that HDL3 has a stronger protective 
effect against CHD. 
 
A mathematical model has been used commonly to analyse the kinetic data in the 
previous lipoprotein kinetic studies. It can provide not only the FCR and PR, but also the 
interconversion rates. A mathematical model was developed using the data from the 
present HDL subclass study. However, this model was unable to fit all leucine 
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enrichment curves for αHDL, preβHDL, HDL2 and HDL3 very well, especially for the 
decaying phase of the curve. In the future, it may be possible to develop a model which 
provides a better description of the data. 
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Chapter 5: General discussion 
It is well established that HDL plays a key role in the reverse cholesterol transport (RCT) 
pathway, which transports excessive cholesterol from the peripheral tissues back to the 
liver, and there is considerable evidence that it has a protective effect against the risk of 
atherosclerotic cardiovascular disease. This thesis has focused on the effect of dietary 
sugar intake on total HDL kinetics in overweight men at risk of metabolic syndrome. It 
has also investigated the kinetics of HDL subclasses, αHDL and preβHDL, HDL2 and 
HDL3, in healthy males and females. 
 
The stable isotopic technique has been applied to investigate both total HDL and HDL 
subclass kinetics, whereas the clinical protocols were different. The administration of a 
primed constant infusion of stable isotope for a relative short study period (10 hours) was 
used to examine total HDL kinetics. A bolus injection of stable isotope was used for 
assessing the kinetics of HDL subclasses, and the study duration was longer (up to 14 
days). ApoA-I as the major apolipoprotein of HDL has a relatively slow turnover rate with 
a mean residence time of about 5 days, and the stable isotope enrichment of apoA-I was 
measured to determine the HDL kinetic parameters. Therefore, the study duration of up 
to 14 days seems to be a more appropriate protocol to measure the kinetics of HDL 
compared to the study with short duration. However, compared to a primed constant 
infusion technique, a bolus injection of stable isotope would be a less feasible clinical 
protocol for patients’ convenience when the study duration is up to two weeks. 
  
αHDL, which contains both HDL2 and HDL3, is the mature form of the HDL particle and 
should account for the major proportion of total HDL in the plasma. Therefore, the PR of 
αHDL was expected to be similar to the total PR of HDL2 and HDL3. However, the PR of 
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αHDL apoA-I in the HDL subclass study (3.94 ± 0.73 mg/kg/day) was comparatively 
lower than the total PR of HDL2 and HDL3 (1.35 ± 0.35 and 3.81 ± 0.51 mg/kg/day 
respectively). A possible explanation for the low PR of αHDL apoA-I in the HDL subclass 
study could be that there might be some other HDL subclasses beside αHDL and 
preβHDL. Asztalos et al. (2004) measured the values of HDL subspecies in plasma in 
1277 CHD-free male subjects from the Framingham Offspring Study. They separated 
HDL subclasses based on different charge by using agarose gel electrophoresis, which 
was the same technique used in the present study. However, in addition to αHDL and 
preβHDL, Asztalos et al. (2004) also isolated one more apoA-I-containing HDL subclass, 
which is pre αHDL. Even though the level of pre αHDL was much lower than αHDL, it 
was slight higher than the level of preβHDL. Moreover, Asztalos et al. (2004) found that 
the level of pre αHDL was significantly lower in subjects with CHD compared to CHD-
free subjects. 
 
The total PR of HDL2 and HDL3 (1.35 ± 0.35 and 3.81 ± 0.51 mg/kg/day respectively) in 
the subclass study was expected to be similar to total HDL PR in the diet study (7.33 ± 
0.66 and 6.05 ± 0.72 mg/kg/day for the high and low sugar diet respectively). However it 
was also lower. This may be a consequence of the different subject characteristics. 
Frenais et al. (1997) compared the HDL apoA-I FCR and PR between healthy subjects 
and subjects with type 2 diabetes (with poor metabolic control). They found that subjects 
with type 2 diabetes who had a lower plasma concentration of apoA-I and HDL-C, had a 
higher apoA-I FCR and PR than healthy subjects. The participants in the dietary 
intervention study were at metabolic risk and had a lower level of HDL apoA-I and HDL-
C compared to the healthy subjects in the HDL subclass study. 
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Numerous previous studies have examined the relationship between HDL cholesterol 
and cardiovascular risk, and a strong inverse association was found. Hence, increasing 
plasma HDL cholesterol levels via lifestyle modification or pharmacological intervention 
was considered to be a therapeutic target for reducing the risk of CVD. However, some 
recently genetic studies may challenge this concept (Haase et al., 2011; Haase et al., 
2012; Voight et al., 2012). The study by Haase et al. (2011) has examined the effect of 
mutations in apoA-I on HDL cholesterol and risk of ischemic heart disease (IHD) and 
myocardial infarction (MI). They suggested that mutation in apoA-I could predict an 
increased risk of IHD and MI in the general population independent of plasma HDL 
cholesterol levels. The other two recent genetic studies have investigated whether the 
inverse association between HDL cholesterol and the risk of IHD and MI is a causal 
relation (Haase et al., 2012; Voight et al., 2012). Both of these studies found that 
genetically reduced HDL cholesterol did not associated with an increased risk of IHD or 
MI.  
 
The findings from pharmacological intervention studies, which examined the clinical 
effects of HDL-C raising therapy, have been inconsistent. Fibrates are recommended for 
the treatment of people with low HDL-C or high triglyceride levels. In the Helsinki Heart 
Study, the Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial (VA-
HIT), and the Bezafibrate Infarction Prevention study, the administration of fibrates in 
subjects with low HDL-C or high TG and cholesterol levels, or with CHD, induced a 
moderate increase in HDL-C after a long-term follow-up, and this increase was positively 
associated with a modest to significant reduction in the incidence and/or mortality of 
CHD (Frick et al., 1987; Rubins et al., 1999; Robins et al., 2001; the BIP Study Group, 
2000). However, in some other studies, the beneficial effect of fibrates on CHD was only 
showed in patients with reduced HDL-C and increased TG but not in the subjects without 
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dyslipidaemia (Keech et al., 2005; Group et al., 2010; Scott et al., 2009). Niacin has 
been considered to be the most effective pharmacological method for raising low HDL-C 
levels (Rader, 2006). A number of previous studies have investigated the effects of 
niacin, which was used as a mono-therapy or in a combination dyslipidaemic therapy, on 
cardiovascular outcomes after a long-term follow-up (Canner et al., 1986; Carlson et al., 
1988; Brown et al., 1990; Brown et al., 1998; Brown et al., 2001). They found that niacin 
was associated with a moderate to significant reduction in CHD mortality and nonfatal 
MI. Some studies showed the increased level of HDL-C was in parallel with the reduction 
in CHD events (Brown et al., 1990; Brown et al., 1998; Brown et al., 2001). However, not 
all of the previous studies measured the HDL-C levels. Therefore, the current data may 
not be sufficient to estimate the effect of the alteration in HDL-C levels on the reduction 
of CHD after a long-term treatment. CETP inhibition has also been considered to be a 
possible therapeutic target for HDL-raising therapy. In a trial by Barter et al. (2007), 
although the CETP inhibitor torcetrapid increased HDL-C levels dramatically (about 
72%) in subjects with a high risk of CHD, it was also associated with an increased 
incidence and mortality of CHD. Barter et al. (2007) stated that the reason for this finding 
was uncertain, and they suggested that increasing the level of HDL-C might not be 
adequate for achieving a protection against CVD. 
 
 Based on these genetic and pharmacologic intervention studies, there is some doubt as 
to whether HDL cholesterol is a reasonable therapeutic target. A consensus statement 
from the National Lipids Association was published last year, which assessed the current 
status of HDL-C as a therapeutic target and evaluated the raised question regarding to 
the role of HDL-C in preventing or contributing to atherosclerotic disease (Toth et al., 
2013). They concluded that HDL cholesterol is not a therapeutic target at the present 
time even though a lot of investigations have suggested that low HDL-C is associated 
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with an increased risk of CVD and HDL may play various roles in protecting against 
atherogenesis. Toth et al. (2013), however, still emphasised that “rigorous research into 
the biology and clinical significant of low HDL-C should continue. The development of 
novel drugs designed to modulate the serum levels and functionality of HDL particles 
should also continue”. They also suggested that research exploring the therapeutic 
effect of modulating HDL structure and function needs to be continued. This consensus 
statement by Toth et al. (2013) focused on the plasma concentration of HDL-C. 
However, as discussed in this thesis HDL is a heterogeneous mix of subclasses and 
measurement of these subclasses and their functionality rather than total HDL-C may be 
a more relevant measurement. Understanding the kinetics of these HDL subclasses may 
also provide more valuable information about the role of HDL in reducing 
atherosclerosis.  
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Appendix 1: Participant information sheet for dietary intervention study 
 
 
 
 
Participant Information sheet 
 
Study Title: “The Effect of Dietary Carbohydrate on Lipids.” 
 
You are being invited to take part in a study investigating how dietary 
carbohydrate affects fat metabolism. Before you decide if you wish to participate, 
it is important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss it with your friends, relatives and anyone involved with your care. Please 
ask us if there is anything that is not clear or if you would like more information. 
 
Why have I been chosen? 
In this study we are looking for men, aged between 40-65, who are overweight 
but do not have diabetes. We want participants to be weight stable and not 
taking any other medication that may affect metabolism. 
 
Do I have to take part? 
It is up to you to decide whether to take part or not. If you decide to take part 
you will be given this information sheet to keep and asked to sign a consent form. 
If you decide to take part you are still free to withdraw at any time and without 
giving a reason.  
 
What would happen to me if I take part? 
If you are interested in taking part in this study, you would come to the Cedar 
Centre at the Royal Surrey County Hospital in the morning, without having had 
breakfast, for an initial chat about the project, when we would measure your 
height, weight, take your blood pressure and take a small blood sample to 
measure your glucose, insulin, blood chemistry and fat levels. After this you will 
be provided with a snack and drink. This is a screening visit (VISIT 1) to make 
sure you do not have diabetes or any other disorder that may affect you taking 
part in the study. We also ask you to fill in two short questionnaires about your 
general health and diet. We would normally inform you of your results within 2 
weeks of this visit. 
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If following this screening visit, you are found to fulfil the recruitment criteria and 
you are still happy to take part we will ask you to visit the Hammersmith Hospital 
in London for a second screening visit (VISIT 2) to measure the amount of fat in 
your liver. We are recruiting subjects with very low or moderate levels of liver fat.  
 
If you fulfil these criteria we will ask you to undertake a dietary intervention for a 
period of 32 weeks. This will comprise a 4 week diet based on the average UK 
diet followed by a 12 week diet with either high or low sugar foods, followed by a 
4 week diet based on the average UK diet and finally a 12 week diet with either 
high or low sugar foods (depending on which diet you followed for the first 12 
weeks). Half the men in the study will have the high sugar foods first and the low 
sugar diet second and the other half will have the low sugar diet first and the high 
sugar diet second. The nutritionist will give you guidance and advice on how to 
follow this diet at the Cedar Centre before you start, and on how to complete a 3-
day diet diary (VISIT 3). Diet diaries will be completed at the end of the run-in 
diet, and at 6 and 12 weeks during each 12 week dietary period. We will ask you 
to meet the nutritionist every 2 weeks, who will also contact you by telephone 
during the weeks you do not meet. 
 
At the end of the first 4 week diet we will ask you to visit the Cedar Centre at the 
Royal Surrey County Hospital for a blood test to measure your blood fat levels 
(VISIT 4). You will then be allocated to one of the two diets. At week 11 of the 
diet you will be asked to visit Hammersmith Hospital for another MRI scan (VISIT 
5). This visit is identical to visit 2. At the end of the first 12 week diet we will ask 
you to visit the Cedar Centre on 2 successive days for a series of tests (VISITS 6 
and 7). At the end of the second 4 week wash-out we will ask you to visit the 
Cedar Centre for a blood test to measure fat levels (VISIT 8) to start the next 
diet. At the end of the second 12 week diet at week 11 you will be asked to visit 
Hammersmith Hospital for another MRI scan (VISIT 9). This visit is identical to 
visit 2 we will ask you to visit the Cedar Centre on 2 successive days for a series 
of tests (VISITS 10 and 11).  These tests will be identical to the tests done at 
visits 6 and 7. 
 
 
VISITS 2, 4 and 7 
You will be asked to go to the Hammersmith Hospital, London after a 10 hour fast 
to have an MRI (magnetic resonance imaging) scan. MRI is a body scanning 
technique, which is used in hospitals worldwide to create images of the inside of 
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the body.  MRI has been used safely for several decades and has no known side-
effects. Each scan is directed to the specific requirements of the research study in 
which you are taking part. The MRI scan is purely for the detection of liver 
fat and is not for the purposes of a health check. 
 
You will be given an appointment for magnetic resonance scans at the Robert 
Steiner MRI unit and asked to come fasted (nothing to eat or drink for 10 hours 
before your scan) however you may drink some water and take any medication 
you would normally do.  
 
As the MRI scanner uses high magnetic field we have to make sure you do not 
have any metallic object in or on your body to ensure your safety. Before starting 
the scanning we will ask you to complete a short checklist. This will ensure that 
you do not have any magnetic implant (such as a cardiac pacemaker) which will 
stop us performing the scan. These scans are safe and do not involve any 
radioactivity or X rays.  
 
You will be in the MR scanner for up to 1 hour. None of the magnetic resonance 
imaging techniques uses ionising radiation or intravenous contrast agents and 
may be performed during a single imaging session. You lie flat in the scanner and 
are automatically moved through the scanner. Whole body anatomical MR 
scanning will be performed to determine total and regional fat volumes, and 
magnetic resonance spectroscopy (MRS) performed to measure lipid content in 
internal organs, such as liver (IHCL) and muscles (IMCL), such as soleus and 
tibialis. 
 
You may hear a knocking noise during part of the procedure, and you will 
experience no discomfort. We will give you an alarm bell to sound at any time if 
you are upset or worried during the examination and if the procedure does not 
suit you for any reason it can be stopped at any time.  
 
ANTHROPOMETRY 
Baseline anthropometric measurements including height, weight, waist and hip 
circumference, skinfold thickness, blood pressure, body-volume, and bioelectrical 
impedance analysis of percentage body fat. The bioelectrical impedance is a 
painless, safe procedure which involves either lying on a couch with sticky pads 
placed on a hand and foot, or standing on a metal platform for 1 minute so that 
the body’s electrical resistance can be measured. 
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What if anything abnormal is discovered? 
MRI is a powerful, diagnostic body scanning technique used in hospitals 
worldwide to create images of the inside of the body. MRI has been used safely 
for several decades and has no known side-effects. These scans cannot be viewed 
as a health screening procedure. However, very rarely, unexpected 
information can be detected which may warrant further investigation. In this 
event, a report will be sent to your GP, who will arrange further tests and 
coordinate your further care. The doctor involved in the research study will also 
be informed. 
 
VISIT 3 
You will be asked to come to the Royal Surrey County Hospital in the morning 
having fasted since 10 pm the previous day. At this visit we will take a blood 
sample to measure fat levels. After the sample is taken you will be provided with a 
snack and drink. You will then meet with the nutritionist who will explain about the 
12 week diet we would like you to be on. She will supply you with the food you will 
need for this period. If you do not attend by car, we can arrange for the food to be 
delivered to your home. This visit will take about 30-45 minutes. 
 
VISIT 4 
Hammersmith Hospital MRI scan. This visit is identical to visit 2. 
 
VISIT 5 
This visit will take place at the end of the 12 week diet with high or low sugar 
content. We ask you to attend the Cedar Centre at the Royal Surrey County 
Hospital. A blood sample will be taken and you will be given 2 small bottles of 
water containing labelled water and one large bottle of water containing labelled 
water. You will be asked to drink one small bottle of the labelled water at 7pm  
 
after your evening meal and the other small bottle at 10pm the same night. After 
7pm, if you need to drink we will ask you to drink only the water in the large 
bottle without any other food. This visit will take about 20 minutes. We will 
provide you with a standard ready-meal for your evening meal (of your choice) to 
take home. 
 
VISIT 6 
The next day you will be asked to come to the Cedar Centre at the Royal Surrey 
County Hospital at 7.30am having fasted since 8pm the previous day. We will 
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provide you with a standard ready-meal for your evening meal to eat at home the 
day before the study. We ask you not to undertake any vigorous activity for 2 
days before this visit and not to drink alcohol the day before.  
 
We will put 3 fine plastic tubes into your veins. Two will be placed in a vein in 
each elbow and one in a wrist vein.  The tubes are made of a flexible plastic and 
so once placed should not cause any discomfort and will not impede your arm 
movements. After taking a baseline blood sample, we will inject a labelled 
molecule of glycerol (which is a non-harmful fat that our body normally produces) 
to measure how much fat your liver is making. We will also start pumping 
(infusing) 2 solutions at a slow rate into one of the tubes in your elbow for 10 
hours.  This contains a labelled molecule of palmitic acid (another non-harmful fat 
that our body normally produces) bound to a blood protein albumin which can be 
used to measure how much fat your body is burning. This solution also contains a 
labelled amino acid which measures the number of particles of fat that your liver 
makes. At frequent time intervals during the 10 hour study blood samples will be 
taken from the vein in your elbow and the vein in your wrist. While we are taking 
blood from your wrist we will ask you to place your hand inside a “hot-box” for 20 
minutes before we take a blood sample. This box is made of Perspex and heats 
the blood in your wrist making the blood similar to blood found in arteries. It will 
make your hand hot but this is not uncomfortable. You will not feel the blood 
samples being taken.  At the end of the study we will measure the activity of 2 
enzymes which break down fat in your blood. A small amount of a substance called 
heparin will be injected which releases the enzymes then a blood sample will be 
taken 15 minutes later. The total amount of blood we will take in this test is 11 
tablespoons of blood (220mls).  
 
During the study you will be free to write/read or watch DVDs within the unit. 
Drinking water will be made available throughout the study although food will 
only be provided at the end of the study. Although you will be connected to an 
infusion pump, that pump can be moved so there will be no limit to going to the 
toilet etc. At the end of the study day you will be provided with a meal of your 
choice with tea or coffee. The whole procedure (from arrival to going home) would 
take approximately 11 hours. 
 
VISIT 7 
This is before you start your second diet and identical to visit 4. 
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VISIT 8 
Hammersmith Hospital MRI scan. This visit is identical to visit 2.  
 
VISITS 9 and 10  
These are at the end of your second diet and identical to visits 6 and 7. 
 
Expenses 
All travelling expenses will be reimbursed and there will be an inconvenience 
allowance of £200 payable upon completion of the study. 
 
What do I have to do? 
You will need to have fasted overnight (for 12 hours) for some of the visits.  This 
means having no food or drink, other than water, after your evening meal the 
day before your visit. In addition, we will ask you to eat a standard ready-meal, 
which we will provide for you to eat at home, for your evening meal the night 
before visit 6 and visit 9. We also ask you to refrain from vigorous exercise for 2 
days before these visits and to avoid alcohol.  
 
What are the possible disadvantages and risks of taking part? 
The risks of having a cannula in a vein are those associated with any blood 
sample. These are slight pain, possible bruising and, in principle, a local infection. 
We will try and avoid these problems. 
In visit 5 and 8 one of the labelled molecules is bound to albumin. As this is a 
blood protein there is a small risk of allergic reaction. Albumin is a blood protein  
 
and is purified from human blood. As such there is a very small risk of 
transmission of infectious diseases. To minimise this, the albumin is purified from 
blood donors who have been screened for pathogenic viruses and the albumin is 
heat treated to inactivate viruses.  
In visit 5 and 8 we will administer a small amount of heparin which thins the 
blood. You will be advised to avoid caffeine for 4 hours after this. You may have 
excessive bruising if you hit yourself hard within 4 hours of the procedure.  
 
What are the possible benefits of taking part? 
You will be helping medical science to understand how different types of 
carbohydrate affect fat metabolism. This will help formulate appropriate dietary 
advice for men at risk of metabolic syndrome. 
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What if something goes wrong? 
If you are harmed by taking part in this research project then you may have 
grounds for legal action. Regardless of this, if you wish to complain about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal University complaints mechanisms are available to you. 
 
Complaints 
Any complaint or concerns about any aspects of the way you have been dealt 
with during the course of the study will be addressed. Please contact Prof. Bruce 
Griffin, Principal Investigator on 01483 689724. 
 
Would my taking part in this study be kept confidential? 
All information which is collected about you during the course of this research 
would be kept strictly confidential. Any information about you which leaves the 
hospital or University would have your name and address removed so that you 
cannot be recognised from it. With your permission, your GP will be notified of 
your participation in this study. 
 
What would happen to the results of the research study? 
The results of this study will be published in the scientific press and you will not 
be identifiable in any way. It is our usual practice to send copies of any resultant 
publications to research participants. 
 
Who is organising the funding and research? 
This research is being funded by the Biotechnology and Biological Sciences 
Research Council, a government funded research body. 
 
Who reviewed this study?  
The study was reviewed by the Surrey Research Ethics Committee. 
  
Contact for further information? 
Cheryl Isherwood (01483 688642)                      c.isherwood@surrey.ac.uk 
Prof Bruce Griffin (01483 689724)                       b.griffin@surrey.ac.uk 
Dr John Wright (01483 571122 ext 4844)            john.wright@surrey.ac.uk 
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Appendix 2: Participant information sheet for pilot study 
 
 
Participant Information Sheet 
 
Study Title: 
“Development of a study design to measure HDL 
metabolism” 
 
You are being invited to take part in a study to develop an optimal study design 
to measure HDL metabolism. We want to determine an optimal blood sampling 
protocol and whether it is necessary for subjects to be fasted. Before you decide 
if you wish to participate, it is important for you to understand why the research 
is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with your friends, relatives and anyone 
involved with your care. Please ask us if there is anything that is not clear or if 
you would like more information. 
 
Why have I been chosen? 
In this study we are looking for healthy women age 18-70y. 
 
Do I have to take part? 
If you decide to take part you will be given this information sheet to keep and be 
asked to sign a consent form. You are free to withdraw at any time and without 
giving a reason. You will undertake 1 study. In this study you will need to be 
fasted on all the study visits.  
 
What would happen to me if I take part? 
Each study will involve 5-6 visits to the Cedar Centre at the Royal Surrey County 
Hospital in the morning. One visit will take up to 10.5 hours and the other visits 
will take about 15 minutes. 
 
If you are interested in taking part in this study, we will ask you to fill in a short 
questionnaire about your general health.  
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VISIT 1: CEDAR 
Measurement of HDL metabolism (approximately 10.5 hours) 
 
You are will be invited to come to the CEDAR Centre at 8am on a Monday, 
without having had breakfast for a metabolic study to measure HDL (good 
cholesterol) metabolism. Height, weight, waist and hip circumference, and body 
fat will be measured.  A fine plastic tube will be placed in a vein in the crease of 
one elbow. The tube is made of flexible plastic and should not cause any 
discomfort and will not impede your arm movement once placed. After taking a 
blood sample via this tube, we will inject a labelled molecule of an amino acid (a 
non-harmful building block of proteins that our body normally produces) into a 
vein in your other arm to measure how much good cholesterol your liver is 
making. Small blood samples (each will be approximately 2 teaspoons of blood) 
will be taken at hourly intervals for 10 hours via the plastic tube. During the 
study you will be only given water to drink. You will be able to read, watch DVDs 
or listen to music. At the end of the study the tube will be removed, we will give 
you a drink and a meal (of your choice) and you will be free to go home. 
 
VISIT 2, 3, 4, 5: CEDAR 
Continued measurement of HDL metabolism (approximately 15 min) 
 
The next morning and 4 other mornings during the next two weeks we will ask 
you to come to the CEDAR Centre in the morning, without having had breakfast 
for a single blood sample (2 teaspoons). We will give you a drink and snack 
afterwards. 
 
Expenses 
All travelling expenses will be reimbursed.  
 
What do I have to do? 
You will need to have fasted overnight (for 12 hours) for all visits.  This means 
having no food or drink, other than water, after your evening meal at 8 pm the 
day before your visit.  
 
What are the possible disadvantages and risks of taking part? 
The risks of having a cannula in a vein are those associated with any blood 
sample. These are minor discomfort, possible bruising and, in principle, a local 
infection. We will try and avoid these problems. 
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What are the possible benefits of taking part? 
You will be helping medical science. Once a study design has been optimised we 
will use this to understand more about good cholesterol metabolism. This could 
help in developing treatments which raise good cholesterol levels. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project then you may have 
grounds for legal action. Regardless of this, if you wish to complain about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal University complaints mechanisms are available to you. 
 
Complaints 
Any complaint or concerns about any aspects of the way you have been dealt 
with during the course of the study will be addressed. Please contact Prof. Margot 
Umpleby, Principal Investigator on 01483 688579. 
 
Would my taking part in this study be kept confidential? 
All information which is collected about you during the course of this research 
would be kept strictly confidential. Any information about you which leaves the 
hospital or University would have your name and address removed so that you 
cannot be recognised from it. With your permission, your GP will be notified of 
your participation in this study. 
 
What would happen to the results of the research study? 
The results of this study will be used to optimise a study design which can be 
used to understand more about good cholesterol metabolism. 
 
Who is organising the funding and research? 
This research is being funded and organised by the University of Surrey. 
 
Who reviewed this study?  
This research has been reviewed by two human ethics committees (Surrey 
Research Ethics Committee and University of Surrey Ethics Committee). 
 
Contact for further information? 
Ke Wang (01483 688639)  
k.wang@surrey.ac.uk 
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Prof Margot Umpleby (01483 688579) 
m.umpleby@surrey.ac.uk 
 
Dr Fariba Shojaee-Moradie (01483 688644) 
f.shojaee-moradie@surrey.ac.uk 
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Appendix 3: Participant screening sheet for pilot study 
 
 
 
Development of a study design to measure HDL 
metabolism 
 
Participant screening sheet  
 
GENERAL INFORMATION 
 
Name:  
Address: 
 
 
 
 
 
Contact telephone numbers:  
Best time to call / on what number?  
Email address:  
Next of kin contact name:  
Next of kin telephone number:  
GP Name:  
GP Address: 
 
 
 
 
 
Date of birth:  
Age:  
Occupation & town:  
Date informed consent obtained:  
Dates of any holidays booked   
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Would you like to be sent 
information on other studies carried 
out at The University of Surrey that 
you may be suitable for? 
             Yes             No  
        
 
VISIT 1. SCREENING VISIT             Date: 
…………………....... 
 
 
Weight: ………………     Height: …………………                   BMI: ………………. (kg/m²) 
 
 
Waist circumference …………………………….. 
 
 
Blood pressure:   R1………………..…..   R2 ………………..…….   R3…………..……      ave 
………………………. 
 
 YES NO 
Has been weight stable for the past three months (max var. 2.5 kg)   
Prior/present history of Type 1 or Type 2 diabetes; self and / or family   
Prior/present history of hormone disorders   
Prior/present history of liver disease   
Prior/present history of kidney disease   
Prior/present history of heart disease, Angina or Stroke   
Prior/present history of eating disorders, inc anorexia or bulimia 
nervosa 
  
Prior/present history of drug or alcohol abuse within the last 2 years   
Average consumption of alcoholic drinks a day?  What kind? 
 
  
Any previous surgical procedure to aid weight loss   
Any known food allergies or intolerances   
If yes please specify 
 
 
 
Medications known to alter lipid metabolism or body weight   
Beta-blockers   
Statins   
Fibrates   
Metformin   
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Non-smoker  /  Smoker:……………………………………………………… 
 
  Amount of Exercise/week ……………………………………………………… 
   
  Sedentary/non sedentary occupation……………………………………. 
 
 
 
 
 
 
 
Blood samples analyses:  
 
Haematology: 
Haemoglobin……………………………………… 
 
White blood cell count……………………… 
 
Platelet count……………………………………… 
 
Clinical chemistry:  
Triglyceride………………………………………. 
 
Total cholesterol ……………………………… 
 
Blood glucose ………………………………… 
  
Insulin …………………………………………… 
  
Suitable to participate in study: 
 
a) Yes ……………   No ……………  Maybe …………. 
 
 
Pease give further details: 
 
……………………………………………………………………………………………………………………………………
…………………. 
 
 
 
 
 
 
 
Any other medication / supplements   
If yes please specify 
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Appendix 4: Participant information sheet for HDL subclass kinetic 
study 
 
 
Participant Information Sheet 
 
Study Title: 
 “Effect of gender differences on HDL subclass kinetics” 
 
You are being invited to take part in a study to develop an optimal study design 
to measure HDL metabolism. We want to determine an optimal blood sampling 
protocol and whether it is necessary for subjects to be fasted. Before you decide 
if you wish to participate, it is important for you to understand why the research 
is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with your friends, relatives and anyone 
involved with your care. Please ask us if there is anything that is not clear or if 
you would like more information. 
 
Why have I been chosen? 
In this study we are looking for healthy women and men age 18-70y. 
 
Do I have to take part? 
If you decide to take part you will be given this information sheet to keep and be 
asked to sign a consent form. You are free to withdraw at any time and without 
giving a reason. You will undertake 1 study. In this study you will need to be 
fasted on all the study visits.  
 
What would happen to me if I take part? 
Each study will involve 8 visits to the Cedar Centre at the Royal Surrey County 
Hospital in the morning. One visit will take up to 11 hours and the other visits will 
take about 15 minutes. 
 
If you are interested in taking part in this study, we will ask you to fill in a short 
questionnaire about your general health.  
  
Visit 1: Screening (approximately 1 hour) 
If you are interested in taking part in this study, you would come to the Cedar 
Centre at the Royal Surrey County Hospital in the morning, without having had 
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breakfast. Someone from the research team will ask you some questions about 
your health. The research nurse will measure your height, weight, take your 
blood pressure and take a blood sample (3 teaspoons) to measure your blood 
glucose and check you are not anaemic. After this you will be provided with a 
snack and drink.   
This is a screening visit to make sure you do not have diabetes or any other 
disorder that may affect you taking part in the study. We would normally inform 
you of your results within 2 weeks of this visit.  
 
 
VISIT 2: CEDAR 
Measurement of HDL metabolism (approximately 11 hours) 
 
If you are healthy we will invite you to come to the CEDAR Centre at 8am on a 
Monday, without having had breakfast for a metabolic study to measure HDL 
(good cholesterol) metabolism. Height, weight, waist and hip circumference, and 
body fat will be measured.  A fine plastic tube will be placed in a vein in the 
crease of one elbow. The tube is made of flexible plastic and should not cause 
any discomfort and will not impede your arm movement once placed. After taking 
a blood sample via this tube, we will inject a labelled molecule of an amino acid 
(a non-harmful building block of proteins that our body normally produces) into a 
vein in your other arm to measure how much good cholesterol your liver is 
making. Small blood samples (each will be approximately 2 teaspoons of blood) 
will be taken at hourly intervals for 10 hours via the plastic tube. During the 
study you will be only given water to drink. You will be able to read, watch DVDs 
or listen to music. At the end of the study the tube will be removed, we will give 
you a drink and a meal (of your choice) and you will be free to go home. 
 
VISIT  3, 4, 5, 6, 7 & 8: CEDAR 
Continued measurement of HDL metabolism (approximately 15 min) 
 
The next morning and 5 other mornings during the next two weeks we will ask 
you to come to the CEDAR Centre in the morning, without having had breakfast 
for a single blood sample (2 teaspoons). We will give you a drink and snack 
afterwards. 
 
 
 194
Expenses 
All travelling expenses will be reimbursed. A payment of £200 will be made on 
completion of the last visit. 
 
What do I have to do? 
You will need to have fasted overnight (for 12 hours) for all visits.  This means 
having no food or drink, other than water, after your evening meal at 8 pm the 
day before your visit.  
 
What are the possible disadvantages and risks of taking part? 
The risks of having a cannula in a vein are those associated with any blood 
sample. These are minor discomfort, possible bruising and, in principle, a local 
infection. We will try and avoid these problems. 
 
What are the possible benefits of taking part? 
You will be helping medical science. Once a study design has been optimised we 
will use this to understand more about good cholesterol metabolism. This could 
help in developing treatments which raise good cholesterol levels. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project then you may have 
grounds for legal action. Regardless of this, if you wish to complain about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal University complaints mechanisms are available to you. 
 
Complaints 
Any complaint or concerns about any aspects of the way you have been dealt 
with during the course of the study will be addressed. Please contact Prof. Margot 
Umpleby, Principal Investigator on 01483 688579. 
 
Would my taking part in this study be kept confidential? 
All information which is collected about you during the course of this research 
would be kept strictly confidential. Any information about you which leaves the 
hospital or University would have your name and address removed so that you 
cannot be recognised from it. With your permission, your GP will be notified of 
your participation in this study. 
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What would happen to the results of the research study? 
The results of this study will be used to optimise a study design which can be 
used to understand more about good cholesterol metabolism. 
 
Who is organising the funding and research? 
This research is being funded and organised by the University of Surrey. 
 
Who reviewed this study?  
This research has been reviewed by two human ethics committees (Surrey 
Research Ethics Committee and University of Surrey Ethics Committee).List of 
visits: Design of study for HDL metabolism 
 
Visit  Approximate 
Week 
 
Test 
approx. 
time 
Fasted  Place Test 
Visit 1  Screening  1hour Required CEDAR   Visit 2 Week 1 11 hours Required CEDAR HDL metabolism study Visit  3 Week 1: 1 daysfrom Visit 2 15 min  Required CEDAR Single blood test Visit  4 Week 1: 4 days from Visit 2 15 min Required CEDAR Single blood test Visit  5 Week 2: 7 days from Visit 2  15 min Required CEDAR Single blood test Visit 6 Week 2: 9 days from Visit 2 15 mins  Required CEDAR Single blood test  Visit 7  Week 2:11 days from Visit 2 15 min Required CEDAR Single blood test Visit  8 Week 3: 14 day from Visit 2 15 min  Required CEDAR Single blood test 
 
Contact for further information? 
Ke Wang (01483 688639)  
k.wang@surrey.ac.uk 
 
Prof Margot Umpleby (01483 688579) 
m.umpleby@surrey.ac.uk 
 
Dr Fariba Shojaee-Moradie (01483 688644) 
f.shojaee-moradie@surrey.ac.uk 
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Kate McLean (01483 688642) 
k.Mclean@surrey.ac.uk 
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Appendix 5: Study consent form for HDL subclass kinetic study 
 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
Title of project: Effect of gender differences on good cholesterol 
 
 
Name of Researcher: Dr Fariba Shojaee-Moradie/ Dr. John Wright 
                                                                   
Please initial box 
 
            
        
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________             _______________         __________________ 
Name of participant                         Date                             Signature 
 
 
________________________ ________________    __________________ 
Name of Person taking consent  Date                              Signature 
(if different from researcher)   
 
 
_____________________             _______________    _________________ 
Researcher                          Date                 Signature 
 
 
! I consent to my personal data, as outlined in the accompanying information sheet, 
being used for the research project detailed in the information sheet, and agree that 
data collected may be shared with other researchers or interested parties. I 
understand that all personal data relating to volunteers is held and processed in the 
strictest confidence, and in accordance with the Data Protection Act (1998). 
•  
! I confirm that I have read and understand the Information Sheet dated January 20th 
2010 (Version 2) for the above study and have had the opportunity to ask questions.  
! I understand that my participation is voluntary and that I am free to withdraw from the 
study at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
! I agree to take part in the above study 
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Appendix 6: Participant screening sheet for HDL subclass kinetic study 
 
 
 
 
Effect of gender differences on HDL subclass 
kinetics 
 
Participant screening sheet  
 
GENERAL INFORMATION 
 
Name:  
Address: 
 
 
 
 
 
Contact telephone numbers:  
Best time to call / on what number?  
Email address:  
Next of kin contact name:  
Next of kin telephone number:  
GP Name:  
GP Address: 
 
 
 
 
 
Date of birth:  
Age:  
Occupation & town:  
Date informed consent obtained:  
Dates of any holidays booked  
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Would you like to be sent 
information on other studies carried 
out at The University of Surrey that 
you may be suitable for? 
             Yes             No  
 
VISIT 1. SCREENING VISIT             Date:……………. 
 
 
Weight: ………………     Height: …………………                   BMI: ………………. (kg/m²) 
 
 
Waist circumference …………………………….. 
 
 
Blood pressure:   R1………………..…..   R2 ………………..…….   R3…………..……      ave 
………………………. 
 
 YES NO 
Has been weight stable for the past three months (max var. 2.5 kg)   
Prior/present history of Type 1 or Type 2 diabetes; self and / or family   
Prior/present history of hormone disorders   
Prior/present history of liver disease   
Prior/present history of kidney disease   
Prior/present history of heart disease, Angina or Stroke   
Prior/present history of eating disorders, inc anorexia or bulimia 
nervosa 
  
Prior/present history of drug or alcohol abuse within the last 2 years   
Average consumption of alcoholic drinks a day?  What kind? 
 
  
Any previous surgical procedure to aid weight loss   
Any known food allergies or intolerances   
If yes please specify 
 
 
 
Medications known to alter lipid metabolism or body weight   
Beta-blockers   
Statins   
Fibrates   
Metformin   
Any other medication / supplements   
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Non-smoker  /  Smoker:……………………………………………………… 
 
  Amount of Exercise/week ……………………………………………………… 
   
  Sedentary/non sedentary occupation……………………………………. 
 
 
 
 
 
 
Blood samples analyses:  
 
Haematology: 
Haemoglobin……………………………………… 
 
White blood cell count……………………… 
 
Platelet count……………………………………… 
 
Clinical chemistry:  
Triglyceride………………………………………. 
 
Total cholesterol ……………………………… 
 
Blood glucose ………………………………… 
  
Insulin …………………………………………… 
  
Suitable to participate in study: 
 
b) Yes ……………   No ……………  Maybe …………. 
 
 
Pease give further details: 
 
…………………………………………………………………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
 
If yes please specify 
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Appendix 7: HDL subclass kinetic data for individual subject in Chapter 
4 
 
1. The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1(a): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during the first 10 hour study for subject F01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1(b): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during 14 days for subject F01 
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Figure A2(a): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during the first 10 hour study for subject F02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2(b): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during 14 days for subject F02 
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Figure A3(a): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during the first 10 hour study for subject F03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3(b): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during 14 days for subject F03 
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Figure A4(a): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during the first 10 hour study for subject M01 
 
 
 
Figure A4(b): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during 14 days for subject M01 
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Figure A5(a): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during the first 10 hour study for subject M02 
 
 
 
Figure A5(b): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during 14 days for subject M02 
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Figure A6(a): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during the first 10 hour study for subject M03 
 
 
 
Figure A6(b): The isotopic enrichment of leucine in preβHDL and αHDL apoA-I 
during 14 days for subject M03 
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2. The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7(a): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during the 
first 10 hour study for subject F01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7(b): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 14 
days for subject F01 
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Figure A8(a): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during the 
first 10 hour study for subject F02 
 
 
 
Figure A8(b): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 14 
days for subject F02 
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Figure A9(a): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during the 
first 10 hour study for subject F03 
 
 
 
Figure A9(b): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 14 
days for subject F03 
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Figure A10(a): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 
the first 10 hour study for subject M01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A10(b): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 
14 days for subject M01 
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Figure A11(a): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 
the first 10 hour study for subject M02 
 
 
 
Figure A11(b): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 
14 days for subject M02 
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Figure A12(a): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 
the first 10 hour study for subject M03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A12(b): The isotopic enrichment of leucine in HDL2 and HDL3 apoA-I during 
14 days for subject M03 
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